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ABSTRACT 
Title: An Investigation of a Neuro-Inflammatory Profile of HIV-Associated 
Neurocognitive Disorders 
Background 
HIV-associated neurocognitive disorder (HAND) is the consequence of the effects of 
HIV-1 within the central nervous system (CNS). HIV-associated neurocognitive 
impairment differs in severity with milder forms presenting in 50% of people living 
with HIV (PLWH), regardless of treatment status. Chronic immune dysregulation has 
been associated with HAND; in particular, it has been noted that inflammation 
persists despite the successful treatment with antiretroviral therapy (ART). However, 
the nature to which (neuro)inflammation influences cognitive performance and 
brain integrity remain unclear. Further, it is not clear how sequence variation in 
neurotoxic viral proteins, including Tat, affects inflammation in PLWH. This study 
aimed to 1) perform a systematic review of the existing literature to identify changes 
in peripheral immune markers that are associated with HAND in ART-experienced 
PLWH, 2) determine the association of blood peripheral immune markers with 
domain-based neurocognitive performance and structural brain changes in South 
African PLWH, and 3) lastly, to evaluate the possible influence of Tat sequence 
variation on a dysregulated immune profile in HIV-1C infection (i.e. Tat-C). 
Methods 
A systematic review of the published literature was performed to identify the most 
common markers associated with HAND in the ART-era. A panel of markers was 
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measured in a treatment naïve South African cohort by enzyme-linked 
immunosorbent assays (ELISA). Cognitive performance was established using a 
battery of tests sensitive to HIV-associated neurocognitive impairment, with domain-
based scores utilized in analysis. Thickness and surface area of all cortical regions 
were derived using automated parcellation of T1-weighted images acquired at 3T. 
Markers were correlated with neurocognitive performance and cortical thickness 
and surface area. Further, a prospective review of the literature was performed to 
determine the association between Tat sequence variation and underlying 
mechanisms (and inflammation) of HAND. The HIV-1 was genotyped and the 
influence of Tat sequence variation on immune marker levels was evaluated in a 
subset of South African participants. 
 
Results 
A systematic review of the existing literature suggested that peripheral immune 
markers of monocyte activation (sCD14 and sCD163) and inflammation (IL-18 and IP-
10) were associated with HAND in the majority of studies. Evaluation of blood 
immune markers in a treatment naïve South African cohort showed that thymidine 
phosphorylase (TYMP) and neutrophil gelatinase-associated lipocalin (NGAL) levels 
were significantly higher, while matrix metalloproteinase (MMP)9 levels were 
significantly lower in PLWH. The results further showed that in PLWH, worse 
psychomotor processing speed was associated with higher TYMP and NGAL levels 
and worse motor function was associated with higher NGAL levels. Further, in 
imaging analysis, it was reported that higher NGAL levels were associated with the 
reduced thickness of the bilateral orbitofrontal cortex. The association of NGAL with 
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worse motor function was mediated by the cortical thickness of the bilateral 
orbitofrontal cortex. The associations between higher NGAL and TYMP levels with 
cortical thickness were largely found in the regions of the frontal cortex. A review of 
the literature suggests that key protein signatures (C31S and R57S) present in the Tat 
protein from HIV-1 subtype C (Tat-C) infection may contribute to the lowered 
inflammation. Supporting this hypothesis, the results from this thesis showed that 
HIV-1C participants with the R57S mutation had lower peripheral TYMP levels. 
 
Conclusions 
Current literature supports the premise that chronic inflammation may be an 
important contributor to the development of the milder forms of HAND. For patients 
on ART, other strategies are required to address the ongoing peripheral 
inflammation, in addition to simply suppressing the viral load. In a South African 
context, TYMP and NGAL may be promising markers for their involvement in HAND. 
Patients were largely treatment-naïve; therefore, these markers may represent HIV-
related effects without the potential confounding effects of ART. Therefore, these 
findings may represent long-standing effects which might persist in treatment-
experienced participants. In HIV-1C infection, the level of certain inflammatory 
markers may be influenced by the R57S Tat protein signature. To our best knowledge, 
this is the first thesis to report the association of these markers with HAND. These 
immune markers need to be investigated for their potential role in the underlying 
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The bars indicate mean protein concentrations in the different study groups and are 
expressed as mean±standard error of the mean (SEM). ........................................... 288 
Figure 2: Differences in peripheral immune marker levels between Tat-C R57 and R57S. 
The bars indicate mean protein concentrations in the different study groups and are 
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1.1. Context  
 
HIV-associated neurocognitive disorder (HAND) is the consequence of the effects of 
HIV-1 within the central nervous system (CNS) (González-Scarano and Martín-García, 
2005). Approximately 50% of people living with HIV (PLWH) may develop milder 
forms of HAND despite viral suppression (Heaton et al., 2010). The onset and 
severity of HAND are affected by HIV subtype differences (Tyor et al., 2013), with 
HIV-1 subtype-B (HIV-1B) and HIV-1 subtype-C (HIV-1C) having different effects 
(Santerre et al., 2019). HIV-1B is present in America, Western Europe, and 
Australasia and represents about 12% of all HIV infections (Taylor et al., 2008). In 
contrast, the more prevalent HIV-1C is present in countries of Southern Africa and 
India and represents about 50% of the world’s HIV infected population (Geretti, 
2006). 
 
The neuropathogenesis of HIV-1 is multifactorial and not clearly understood. Our 
current understanding of the HIV-1 neuropathogenesis is largely derived from 
studies of HIV-1B infection (Taylor et al., 2008). There is a need for further 
investigation of the underlying neuropathology of HIV-1C infection. This is important 
as HIV-1C is responsible for the highest number of HIV-1 infections globally (Geretti, 
2006). 
 
With the neuro-invasion of HIV-1 into the CNS, a sequel of neuropathology 
influences the current phenotype of HAND (González-Scarano and Martín-García, 
2005). Amongst several underlying mechanisms of HAND, there has been a great 
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interest in understanding the role of (neuro)inflammation and its dysregulation in 
HIV-1 infection. Several studies have reported associations of peripheral immune 
markers with HAND (Cohen et al., 2011; Correia et al., 2013; Falasca et al., 2017) and 
brain volume alterations (Gongvatana et al., 2014; Ragin et al., 2010). Multiple 
immune markers have been studied; however, none were shown to consistently and 
robustly correlate with HIV neuropathology and clinical neurocognitive impairment. 
Furthermore, there are inconsistencies in the direction of the reported associations 
between immune markers and HAND (Cohen et al., 2011; Falasca et al., 2017). The 
associations of peripheral immune markers with cortical thickness and surface area 
were not previously assessed in HIV-1 infection. This is important as cortical 
structures may be indirectly affected via several (inflammatory) mechanisms and 
observed as changes in cortical thickness, surface area and cognitive status. Further, 
there are currently no established/proven adjunctive treatments for HAND. 
Therefore, there is a need to identify new markers that are associated with HAND 
and brain structural changes. These markers may improve our understanding of the 
mechanisms involved in the neuropathophysiology of HAND. The identified markers 
may be surrogate endpoints during trials of HAND treatments. Further investigation 
would be required to determine their potential as prognostic, diagnostic and 
therapeutic targets.  
 
Inflammation may be influenced by the activity of the HIV-1 viral proteins. HIV-1 viral 
proteins; including glycoprotein 120, transactivator of transcription (Tat) protein and 
Viral protein r (Vpr) (Jones et al., 2007; Rao et al., 2014) are important in the 
neuropathogenesis of HIV-1, however, there is a strong research interest in Tat 
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because it remains present despite the introduction of ART (Johnson et al., 2013; 
Mediouni et al., 2012). Sequence polymorphisms in the Tat protein influences the 
neurovirulence of HIV-1. Pre-clinical studies have identified that the C30S and R57S 
mutations of Tat are major contributors to the reduced immune activity and 
neurovirulence of HIV-1C infection (Campbell et al., 2007; Rao et al., 2013; Ruiz et 
al., 2019; Wong et al., 2010). However, it is not clear which Tat protein signatures 
influence differential inflammation in PLWH. 
 
Therefore, this thesis will attempt to address the gaps in the research of HAND 
within South African participants, which are primarily HIV-1C infected. These gaps 
will be addressed by (1) investigating the association of peripheral immune markers 
with neurocognitive performance and structural brain integrity in a South African 
cohort and (2) evaluating the influence of Tat sequence variation on immune marker 
levels. Findings from this thesis may help with the understanding of the underlying 
mechanisms of HAND and provide targets for the development of improved 
therapies.  
 
1.2. Research aims 
 
The overall aim of this thesis is to determine the association of peripheral immune 
markers with HIV-associated neurocognitive impairments, based on their putative 
neurobiological function. In particular, we aimed to 1) perform a systematic review 
of the existing literature to identify changes in peripheral immune markers that are 
associated with HAND in ART-experienced PLWH (Chapter 2), 2) determine the 
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association of blood peripheral immune markers with domain-based neurocognitive 
performance (Chapter 3) and structural brain changes (Chapter 4) in South African 
PLWH, and 3) lastly, to evaluate the possible influence of Tat sequence variation on a 
dysregulated immune profile in HIV-1C infection (i.e. Tat from HIV-1C) (Chapter 5 
and Chapter 6) (Figure 1).  
 
1.3. Coherence of the thesis  
 
This thesis has a common underlying theme, which includes the investigation of a 
dysregulated immune profile of HIV-associated neurocognitive impairments in the 
South African (HIV-1C) context. This thesis resulted in a series of manuscripts, of 
which four have been published to date.  
 
For this thesis, I have included two review papers (chapters 2 and chapters 5). The 
first, which has been published, is a systematic review which summarized findings 
from clinical studies and identified 1) peripheral immune markers that are altered in 
ART experienced PLWH compared to HIV-negative controls and 2) peripheral 
immune markers that are associated with HAND. Findings from this systematic 
review strengthen the evidence that a pro-inflammatory environment is associated 
with HAND. However, inconsistencies in the associations of peripheral immune 
markers with HIV-associated neurocognitive impairment suggest the need for 
further investigations to identify new markers for HAND. In addition to the markers 
related to inflammation/monocyte activation reported in this chapter, I selected 
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immune markers based on their putative neurobiological relation to pathways of 
HAND for investigation in Chapter 3. 
 
The second review, which has been published, explored studies presenting data on 
the differential effects of Tat sequence variation on the underlying mechanisms 
(inflammation) of HAND. This paper highlighted the key protein signatures in Tat 
from HIV-1C (predominant in South Africa) which may influence lower immune 
responses. The identified protein signatures as reviewed (Chapter 5) were used to 
investigate the current South African cohort (Chapter 6). 
 
This thesis also includes three original empirical papers (Chapters 3, 4, and 6). The 
first of which has been published (Chapter 3), shows the associations of several 
immune markers with domain-based neurocognitive impairment in a South African 
cohort. Several new immune markers were identified in this chapter. Chapter 4, 
which has been published, reported the associations of immune markers with 
cortical thickness and surface area in South African PLWH. In the final empirical 
paper, chapter 6, I investigated the influence of Tat sequence variation on immune 
marker levels in a subset of South African HIV-1C participants. The empirical papers 
(Chapters 3, 4, and 6) investigated PLWH that were largely treatment naïve. Firstly, 
this population represents participants with a higher risk of developing dementia 
and therefore this investigation may provide an opportunity to investigate the 
immune response in these individuals. Secondly, this allowed me to investigate the 
nature of inflammation without the possible confounding effects of ART-related 
neurotoxicity. Thirdly, recent statistics for South Africa indicated that by 2018, only 
 33 
62% of the HIV population were on antiretroviral (ARV) treatment and 54% of the 
HIV population were virally suppressed (UNAIDS, 2019). Considering these statistics, 
the need to understand the underlying mechanisms of treatment-naïve HAND are 
emphasized. Lastly, inflammation may persist regardless of treatment status, 
therefore, findings presented in this thesis may be relevant for future investigations 
of treatment-experienced participants.  
 
 
Figure 1: Description of thesis aims. The overall aim is to determine the relationship 
between inflammation and HIV-associated neurocognitive impairment (relationship 
1) and the relationship between Tat sequence variation and inflammation 
(relationship 2). Relationship 1 investigated the association of peripheral immune 
markers with neurocognitive performance and brain integrity. Relationship 2 
investigated the influence of Tat protein signatures (at position 31 and 57) on 
peripheral immune marker levels.   
 
NOTE: Minor adjustments to the format and structure of the original manuscripts 
have been made in order to maintain consistency, connectedness and clarity 




à Tat protein signature





Relationship 1 Relationship 2
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Human immunodeficiency virus-associated neurocognitive disorder (HAND) remains 
problematic despite the effective use of antiretroviral therapy (ART) and viral 
suppression. A dysregulated immune response contributes to the development of 
HAND but findings on the association between peripheral blood immune markers 
and HAND have been inconsistent. We therefore conducted a systematic review of 
studies of the association of peripheral blood immune markers with neurocognitive 
performance in ART experienced people living with HIV (PLWH). Thirty-seven studies 
were eligible, including 12 longitudinal studies and 25 cross-sectional studies. 
Findings consistently show that PLWH have altered immune marker levels, including 
elevated markers of monocyte activation (neopterin, sCD14, sCD163) and 
inflammation (CCL2, IL-8, IL-18, IP-10, IFN-α, sTNFR-II and TNF-α). These elevated 
levels persist in PLWH despite ART. The majority of studies found associations of HIV-
associated neurocognitive impairment with immune markers, including markers 
linked to monocyte activation (sCD14 and sCD163) and inflammation (IL-18 and IP-
10). Despite the heterogeneity of studies reviewed, due to the presence of raised 
peripheral markers, our narrative review provides evidence of chronic inflammation 
despite ART. The raised levels of these markers may suggest certain mechanisms are 






2.1.  Introduction 
 
The human immunodeficiency virus (HIV) has complex interactions among the brain 
and the immune system and is responsible for the development of a spectrum of  
HIV-associated neurocognitive disorders (HAND) (Hong and Banks, 2015). HIV-
associated neurocognitive impairment differs in impairment severity and remains 
problematic for people living with HIV (PLWH) regardless of treatment status. 
Approximately 50% of PLWH may develop milder forms of HAND (Heaton et al., 
2010). The neuroinvasion of HIV-1 into the central nervous system (CNS) is explained 
by the “trojan horse” hypothesis which states that HIV finds passage into the CNS 
through infected monocytes (González-Scarano and Martín-García, 2005). Here, 
infected monocytes that subsequently differentiate into macrophages are able to 
elicit an immune response. Immune activation or more specifically, 
monocyte/macrophage activation, is an important step in the normal immune 
response to pathogens and other relevant stimuli (Ivanova and Orekhov, 2016). 
Depending on the stimulus, macrophages acquire either a pro- or anti-inflammatory 
phenotype which are characterized by the secretion of cytokines and signaling 
molecules (Ivanova and Orekhov, 2016). As with HIV, the disturbance of these 
processes by immunopathologies results in abnormal monocyte activation and 
immune regulation. 
 
The persistence of HAND in the ART era is hypothesized to be due to the continued 
immune activation and low-grade inflammation experienced by PLWH (Harezlak et 
al., 2011). Immune activation is characterized by monocyte activation (Imp et al., 
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2017; Ivanova and Orekhov, 2016) and inflammation (Krebs et al., 2016; Rubin et al., 
2018). PLWH experience a dysregulated immune response within both the CNS 
(Yuan et al., 2013) and the periphery (Lyons et al., 2011). An aberrant regulation of 
immune markers within the periphery demonstrates an association with 
neurocognitive impairment as shown in several empirical studies (Burdo et al., 2013; 
Lyons et al., 2011; Xing et al., 2017; Yuan et al., 2015). This immune dysregulation is 
also present in the human brain as indicated by increased monocyte/macrophage 
activation (Tavazzi et al., 2014) and increased levels of pro-inflammatory markers 
(Shapshak et al., 2004) in post mortem brain tissue of cognitively impaired PLWH. 
Thus, immune-related processes as shown in both the CNS and periphery may 
contribute to neuronal dysfunction and consequent neurocognitive impairment in 
PLWH (Harezlak et al., 2011). 
 
Even though CSF markers may be a more accurate representation of 
neuroinflammation and pathways that are associated with or lead to HAND, the ease 
and limited invasiveness of obtaining peripheral blood create an attractive 
opportunity to investigate peripheral immune markers that are associated with 
HAND. To a certain extent, peripheral inflammation may present the state of 
inflammation within the CNS (Capuron and Miller, 2011). Therefore, the 
identification of peripheral markers with the potential for predicting or stratifying 
the risk of HAND may contribute to strategies in the early identification of HAND and 
assessing the efficacy of therapeutic interventions. Further, this line of research 
could advance our understanding of the underlying mechanisms involved in HAND. 
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Several studies have investigated the associations between immune peripheral 
blood markers (monocyte activation and inflammation) and cognitive impairments in 
HIV. Based on significant associations with HAND, evidence suggests that the most 
important and promising peripheral immune markers are those related to monocyte 
activation (e.g. soluble cluster of differentiation (sCD)14, sCD163) (Imp et al., 2017; 
Lyons et al., 2011; Xing et al., 2017) and inflammation (e.g. tumor necrosis factor 
(TNF)-α and interleukins) (Ancuta et al., 2008; Cohen et al., 2011; Falasca et al., 
2017). However, there are inconsistencies in the association between peripheral 
immune markers and HAND.  
 
These inconsistencies are seen with both pro- and anti-inflammatory immune 
markers. Some studies have found that tumor necrosis factor (TNF)-α (Falasca et al., 
2017) and interleukin (IL)-10 (Correia et al., 2013) are higher in PLWH and have an 
association with HAND. However, an inverse association has also been found, with 
lower TNF-α and IL-10 in PLWH and the lower levels were associated with HAND 
(Cohen et al., 2011). The differences in these findings may be due to the measures of 
cognitive functioning in PLWH that vary between studies and disparate study designs 
which include the number of study participants, type of measurement assays (Breen 
et al., 2011), ART regimen and CNS penetration (Nightingale et al., 2016; Valcour et 
al., 2015), presence of comorbidities (Keating et al., 2017), age (De Oliveira et al., 
2015), sex (Krebs et al., 2016; Mathad et al., 2016) and viral clade (Rao et al., 2013). 
Therefore, a clearer understanding of the association of peripheral monocyte 
activation and inflammatory markers with HAND is important as these findings may 
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suggest an involvement of peripheral immune markers in the neuropathophysiology 
of HAND.  
 
Therefore, this systematic review aimed to summarize findings from clinical studies 
to identify 1) immune markers that may be altered in ART experienced PLWH 
compared to HIV-negative controls and 2) immune markers that may be associated 
with HAND. These findings may delineate a set of immune markers for future studies 
in this research area and provide insights into the neuropathophysiology of HAND.   
 
2.2. Methodology  
 
2.2.1.  Study Design 
 
This is a descriptive and narrative systematic review aimed at summarizing the 
extant literature of the association between the peripheral blood immune markers 
and neurocognitive performance in ART experienced PLWH.  
 
2.2.2. Eligibility criteria 
 
Eligible studies were those which included 1) HIV seropositive clinical samples from 
adults with relevant neuropsychological and medical assessments, 2) a relevant 
control group to the respective study (e.g. HIV-negative, normal cognition or 
baseline ART status in longitudinal studies), 3) cohorts on a regimen of ART. All 
medication types were included, and no cut-off was applied for treatment duration, 
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as this was not declared in all studies and 4) marker measurement done from 
plasma/serum using enzyme-linked immunosorbent assay (ELISA) or 
Multiplex/Milliplex analysis for cytokines, chemokines and monocyte-associated 
immune markers.  
 
Pre-clinical (animal and cell culture models) studies and reviews were excluded. Also, 
studies investigating only cerebrospinal fluid (CSF) markers were excluded, as these 
were considered outside the scope of this study. 
 
2.2.3. Data Sources  
 
We electronically searched for publications in PubMed, Scopus and Web of Science 
databases based on all studies published until 11/03/2020. Eligible studies included 
published studies in English only. The search strategy was executed without 
publication date limitations. The full search criteria for each database is included in 
the supplementary file. The following search terms were applied to PubMed: (HIV 
[mh] OR HIV [tw] OR Acquired Immunodeficiency Syndrome [mh] OR "Acquired 
Immunodeficiency Syndrome" [tw] OR AIDS [tw]) AND (HIV associated 
neurocognitive disorders [mh] OR HAND [tw] OR neurocognitive [tw] OR cogniti* 
[tw] OR Executive Function [mh] OR executive [tw] OR Memory [mh] OR memory 
[tw] OR Attention [mh] OR attention [tw] OR Neuropsychological Tests [mh]) AND 
(Cytokines [mh] OR cytokin* [tw] OR Chemokines [mh] OR chemokine [tw] OR 
Inflammation [mh] OR inflammation [tw] OR Neurogenic Inflammation [mh] OR 
neuroinflammation [tw] OR TNF [tw] OR Interleukins [mh] OR interleukins [tw]) AND 
 45 
(Microglia [mh] OR microglia [tw] OR Monocytes [mh] OR monocyte* [tw] OR 
sCD163 [tw] OR sCD14 [tw] OR sCD40 [tw]) AND (Anti-HIV Agents [mh] OR 
Antiretroviral Therapy, Highly Active [mh] OR combination antiretroviral therapy [tw] 
OR cART [tw] OR HAART [tw] OR ART [tw]). 
 
In addition, we also 1) reviewed reference sections of eligible articles and manually 
searched for relevant publications, 2) consulted with the contact authors of the 
included studies and 3), contacted experts in the field for any further papers. This 
search strategy and the retrieved articles are shown in Figure 1. 
 
 
Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) flow diagram for results of search strategy 
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2.2.4. Data selection 
 
All articles were retrieved and loaded onto a single database using the reference 
manager computer program. Two authors, MEW and PJWN independently identified 
studies meeting the inclusion criteria. Where there was a discrepancy in article 
inclusion/exclusion, this was discussed amongst all authors, and a decision was made 
regarding its suitability. Using this criterion, 1304 abstracts and titles were screened. 
Full-text articles assessed for eligibility were done for 61 studies which further 
identified 37 research papers for data extraction and analysis (Figure 1).   
 
The quality of the included studies was assessed using a validated and published 
Likert scale (Likert 1932) for the following areas: (1) Did the study report on potential 
confounders such as substance misuse, comorbid conditions (e.g. Hepatitis C (HCV)), 
neurological conditions and psychiatric disorders and were these controlled for upon 
statistical analysis? (2) Did the study utilize a test battery of at least 5 domains of 
function commonly affected by HIV? (3) Did the study report on the current regimen 
of ART and the duration of treatment before the assays were done for cross-
sectional studies? For longitudinal studies, did the study report on the current 
regimen of ART and the duration of treatment between each time point? Each 
question was rated for 0=no, 1=partly and 2=yes. Studies that addressed all of the 
quality questions and had a total rating of 6 were classified as high quality. Studies 
with a rating between 3 and 5 were considered as intermediate quality and less than 
3 as low quality. 
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2.3. Results  
 
2.3.1. Study characteristics 
The search strategy yielded 1780 research studies as described in Figure 1. 
Duplicates were removed resulting in 1304 research studies. Thereafter, abstracts 
and titles were screened. A total of 1243 studies were excluded. Majority of the 
excluded studies were review articles (n = 434) and pre-clinical investigations (n = 
516). Studies which have not investigated immune markers in general (n = 114), and 
studies which have only investigated CSF markers (n = 26) were excluded. Studies 
which have not done any neuropsychological evaluation of participants were 
excluded (n = 15). Immune marker measurements not done by ELISA/multiplex (n = 
3) were excluded. Treatment naïve participants (n = 14) and studies including 
participants under the age of 18 were excluded (n = 10). Studies investigating 
neuroimaging data on ly (n = 47) were excluded. Studies not reporting statistical 
analysis for immune marker levels and neurocognitive performance were excluded 
(n = 8). Lastly, studies not published in English were excluded (n = 21).  
 
The full-text analysis was done for 61 studies, and 24 studies were excluded based 
on the inclusion criteria. A total of 37 studies were eligible for inclusion. A total 
sample size of n = 3852 participants (HIV-positive and HIV-negative) were included in 
the eligible studies. This included 3105 PLWH with an age ranging between 18-71 
years. Approximately two-thirds of the eligible studies employed a cross-section 
design (25; 68%), with the remainder employing longitudinal study designs (12; 
32%). Investigations were conducted using plasma, serum and CSF. For this study, we 
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only included results obtained from that analyses of plasma and serum, as CSF 
immune markers were outside the scope of this review. For all cross-sectional 
studies and the majority of longitudinal studies, participants were on a regimen of 
ART (exact regimen not stated in all studies). Several longitudinal studies recruited 
participants that were treatment naïve and initiated ART as part of the study (long 
term treatment studies). For longitudinal studies that recruited treatment naïve 
patients at baseline, only follow-up results were considered as participants had to be 
ART experienced to be included. The minimum ART duration across all studies were 
12 weeks. However, no restriction was applied for the minimum required duration of 
ART exposure. Only 14/37 studies reported on treatment duration (range of 3-274 
months) before analysis. For the measurements of immune markers, ELISA, 
multiplex, or a combination of the two, were utilized.  
 
Several peripheral blood immune markers were investigated across all studies. To 
provide clinical practicality, these markers were clustered into (1) monocyte 
activation and (2) inflammation. The formal classification of these markers remains 
controversial as many have an overlapping function (i.e. both inflammation and 
monocyte activation) (Table 1). A description of all investigated markers is described 







Table 1: Immune markers investigated across all reviewed studies 
Monocyte activation Inflammation 
Neopterin Chemokine ligand 
(CCL)2/MCP-1 
IL-17  
sCD14 CCL5/RANTES IL-18  
sCD163 Chemokine (C-X-C motif) 
ligand (CXCL)9/MIG 
IL-1β  
sCD40 ligand C-reactive protein (CRP) Macrophage colony-stimulating factor 
(M-CSF)  
 Cystatin-C Macrophage inflammatory protein 
(MIP)-1α  
 Eotaxin MIP-1β  
 Erythropoietin (EPO) Matrix metalloproteinases (MMP)-1 
 Interferon (IFN)-α2 MMP-2  
 IFN-γ MMP-7  
 IFN- gamma-induced protein 
(IP)-10 
MMP-9  
 IL-2 MMP-10  
 IL-4  Osteopontin  
 IL-5  Progranulin (PGRN)  
 IL-6  Soluble tumour necrosis factor (TNF) 
receptor (sTNFR)-I 
 IL-7  sTNFR-II  
 IL-8  Stromal cell-derived factor (SDF)-1α 
 IL-10 Transforming growth factor (TGF)-β1  
 IL-12  TGF-β2  
 IL-13  TNF-related apoptosis-inducing ligand 
(TRAIL)  
 IL-16  TNF-α 
 
2.3.2. Neuropsychological evaluation 
 
Global neurocognitive impairment was evaluated in the included studies using a 
range of criteria, as set out by the Memorial Sloan Kettering (MSK) (n = 4), American 
Academy of Neurology (AAN) (n = 6) and Frascati (n = 7). Furthermore, n = 18 studies 
utilized test batteries which measured seven domains commonly affected by HIV. 
Two studies investigated <7 domains (2). The term “HAND” was used when the 
neuropsychological evaluation diagnosed HAND according to a relevant criterion 
(e.g. Frascati, AAN or MSK). The term “HIV-associated neurocognitive impairment” 
was used when the neuropsychological evaluation did not formally diagnose HAND 
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according to a relevant criterion and instead, utilized domain-based scores in 
analysis. This has been applied throughout the thesis. Across all studies, domain 
measurements included action and verbal (i.e., animal) fluency, attention, working 
memory, psychomotor speed, visuospatial reasoning, executive function, learning 
and memory, and motor function. In the case of HAND, significant deficits were 
observed in memory, psychomotor speed, motor skills, executive function, 
processing speed, attention and learning. This is aligned with previous findings for 
domains commonly affected by HIV (Woods et al., 2009). 
 
2.3.3.  Quality assessment of the included studies  
 
A majority of the included studies were rated as intermediate quality (n=28), with six 
considered as high quality and three as low quality. Even though according to this 
criterion a large number of studies are of intermediate quality, not all of these 
studies met the quality criteria. Specifically, only n = 6 studies received a rating of 2 
for each of the quality questions and a total score of 6 for the overall quality criteria. 
As an inclusion criterion, all study participants had to be treated with ART (or initiate 
treatment in longitudinal studies), however, only n = 17 studies reported on the 
duration of therapy before assays. In addition, only n = 15 studies reported the exact 
ART regimen used (Supplementary Table 2). Lastly, only n = 13 studies reported on 
both the duration of treatment before the relevant assays as well as the exact 
treatment regimen (Supplementary Table 2). 
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The reporting and adjustment of potential confounders upon statistical analysis were 
done in 78% (n=29) of all studies included. The majority of the studies included in 
this review evaluated multiple immune markers, and 37% (n=14) of all studies 
controlled for multiple comparisons by utilizing either Benjamini-Hochberg, 
Bonferroni corrections or Dunn's multiple comparisons  
 
 
2.3.4.  Immune marker levels and HAND  
 
Irrespective of neurocognitive status, findings show that PLWH had altered levels of 
several blood immune markers compared to seronegative controls (Table 2). Studies 
show that PLWH had higher levels of cystatin-c, IL-6, IL-8, IL-10, IL-18, IP-10, IFN-α, 
CCL2, MIP-1β, MMP-2, MMP-9, neopterin, sCD14, sCD163, sTNFR-I, sTNFR-II, TIMP-1, 
TIMP-2 and TNF-α. Several studies consistently reported higher blood marker levels 
of IL-8, IL-18, IP-10, sCD14, sCD163, sTNFR-II (all p < 0.05) in PLWH (Table 2).  
 
PLWH may also have lower blood levels of IL-1β, IFN-γ and SDF-1α (all p < .025) 
(Table 2). Contradictory findings for several markers were also reported, with PLWH 
also having lower levels of IL-6, CCL2, MMP-2 and TNF-α (Table 2).   
 
Findings from longitudinal treatment studies showed that PLWH had a dysregulated 
immune response over various time points despite treatment status. Studies indicate 
that immune markers remain elevated at subsequent times compared to HIV-
negative participants (Table 2). These included the markers IL-8, IL-18, IP-10, IFN-α, 
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CCL2, neopterin, sCD14, sCD163, sTNFR-II and TNF-α. Across all studies, a consistent 
direction in findings were reported for the elevated blood levels of IP-10, CCL2, 
neopterin, sCD14, sTNFR-II, TNF-α (all p < 0.05) at subsequent time points. 
Longitudinal studies did not report any marker to be significantly lower in PLWH. 
Two studies similarly reported that IP-10 and neopterin were decreased over time, 
however, levels remained consistently and significantly higher than controls (Krebs 
et al., 2016; Valcour et al., 2015). Similarly, in chronic HIV infection, sCD163 
decreased over time but remained significantly higher than controls (p < .0001) 
(D’Antoni et al., 2018a). One study also showed that plasma sTNFR-II and TNF-α 
increased significantly between time points (Marcotte et al., 2013). Several markers 
were shown to be increased in PLWH and have an association with HAND.  
 
Table 2: Immune marker levels in PLWH 
Markers higher in 
PLWH 
P-value (Effect size) Reference  
Cystatin-c p < .001 (d = .79) (Sakoda et al., 2017) 
IL-6  p < .001 (N/A) (Ancuta et al., 2008) 
p < .0001 (Kamat et al., 2012) 
IL-8  p = .003 (N/A) (Correia et al., 2013) 
p < .001 (N/A) *(Krebs et al., 2016) 
IL-10 p = .0046 (N/A) *(Krebs et al., 2016) 
IL-18 p = .002 (N/A) (Correia et al., 2013) 
p = .05 (N/A) *(Rubin et al., 2018)   
IP-10 
 
p = .001 (Partial η2 = .162) (Cohen et al., 2011) 
p < .001 (N/A) (Correia et al., 2013) 
p < .001 (N/A) *(Krebs et al., 2016) 
p = .05 (N/A) *(Rubin et al., 2018) 
p = .007 (N/A) *(Valcour et al., 2015) 




p < .001 (N/A) (Ancuta et al., 2008) 
p = .01 (N/A) (Kamat et al., 2012) 
p = .007 (N/A) *(Krebs et al., 2016) 
P < .001 (r = .37) (Montoya et al., 2019) 
p < .05 (N/A) *(Rubin et al., 2018) 
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p = .02 (d = .51) (Yu et al., 2017) 
MIP-1β  p = .034 (Partial η2 = .073) (Cohen et al., 2011) 
MMP-2  p < .01 (N/A) (Xing et al., 2017) 
MMP-9 p < .01 (N/A) (Xing et al., 2017) 
Neopterin p < .001 (N/A) *(Krebs et al., 2016) 
p < .001 (N/A) *(Valcour et al., 2015) 
sCD14 
   
p < .001 (N/A) (Ancuta et al., 2008) 
p = .03 (N/A) *(Burdo et al., 2013) 
p < .0001 (N/A) (Kamat et al., 2012) 
p = .002 (N/A) *(Krebs et al., 2016) 
p = .007 (r = .2) (Montoya et al., 2019) 
p = .001 (N/A) (Muñoz-Nevárez et al., 2019) 
p < .01 (N/A) (Ryan et al., 2001) 
p < .001 (N/A) (Sakoda et al., 2017) 
p = .007 (N/A) (Sun et al., 2010) 
p = .01 (N/A) (Xing et al., 2017) 
sCD163 p = .01 (N/A) *(Burdo et al., 2013) 
p < .01 (N/A) (Xing et al., 2017) 
sTNFR-I p < .01 (N/A) (Ryan et al., 2001) 
sTNFR-II p < .001 (N/A) *(Krebs et al., 2016) 
p = .03 (N/A) *(Marcotte et al., 2013) 
p < .05 (N/A) *(Rubin et al., 2018) 
p < .01 (N/A) (Ryan et al., 2001) 
TIMP-1 p < .001 (N/A) (Xing et al., 2017) 




p < .001 (N/A) *(Krebs et al., 2016) 
p = .017 (N/A) *(Marcotte et al., 2013) 
p = .003 (r = .22) (Montoya et al., 2019) 
p < .05 (N/A) *(Rubin et al., 2018) 
p < .01 (N/A) (Ryan et al., 2001) 
Markers lower in PLWH 
IL-1β  p = .004 (Partial η2 = .129) (Cohen et al., 2011) 
IL-6  p = .003 (Partial η2 = .134) (Cohen et al., 2011) 
P < .05 (N/A) (Rubin et al., 2018) 
IFN-γ  p = .002 (Partial η2 = .143) (Cohen et al., 2011) 
CCL2  p = .04 (Partial η2 = .066) (Cohen et al., 2011) 
MMP-2  p < .001 (N/A) (Li et al., 2013) 
SDF-1α p = .025 (N/A) (Correia et al., 2013) 
TNF-α  p = .003 (Partial η2 = .136) (Cohen et al., 2011) 
*Longitudinal studies, N/A: Not Available.  
 
Dysregulated levels (higher and lower levels) of blood immune markers were 
associated with both global and domain-based HIV-associated neurocognitive 
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impairment (Table 3). Across all studies and all markers investigated (Table 1), 
several markers including CRP, IL-6, IL-10, IL-16, IL-18, IL-1β, IP-10, IFN-γ, MMP-1, 
MMP-2, MMP-7, MMP-9, MMP-10, CCL2, MIP-1β, neopterin, sCD40L, sCD14, 
sCD163, sTNFR-II, TIMP-1, TIMP-2, TNF-α and TRAIL were associated with HAND 
(Table 3). From these markers, several cross-sectional and longitudinal studies 
reported consistent associations of increased IL-18, IP-10, sCD14 and sCD163 with 
HIV-associated neurocognitive impairment.  
 
Mixed findings were reported for the blood levels of CCL2 and TNF-α and its 
association with HAND. Compared to the relevant controls, both higher (Ancuta et 
al., 2008; Woods et al., 2006) and lower CCL2 blood levels (Cohen et al., 2011) were 
respectively associated with HAND. Similar findings were reported for TNF-α where 
both higher (Falasca et al., 2017; Sevigny et al., 2004) and lower (Cohen et al., 2011) 
levels were respectively associated with HAND when compared to controls. The 
contradictory findings for both CCL2 and TNF-α were found by a study which 
included HIV patients co-infected with HCV (Cohen et al., 2011).  
 
Long term treatment studies reported associations of immune markers with HAND 
(Table 3). Compared to the relevant controls, increased levels of neopterin (Krebs et 
al., 2016), sTNFR-II (Krebs et al., 2016), sCD14 (Burdo et al., 2013; Monnig et al., 
2017) and sCD163 (Burdo et al., 2013) were associated with global HIV-associated 
neurocognitive impairment at follow-up analysis (all p < .0082) (Table 2). 
Furthermore, in a cohort of seventy-two PLWH (36 with HAND) the change of CRP 
levels at subsequent visits was negatively associated with global HAND (Rubin et al., 
 55 
2018). The change of CRP levels at subsequent time points may be associated with 
worse executive function, attention/working memory, and psychomotor speed in 
HIV-positive women (Rubin et al., 2018). Higher levels of sCD14 may be associated 
with worse processing speed in HIV-positive men (Monnig et al., 2017) and higher 
sCD163 may be associated with impaired learning and executive function when 
compared to PLWH with normal cognition (NC) (Burdo et al., 2013) (Table 5). 
Therefore, based on their consistent findings across several studies, monocyte 
activation and inflammatory markers are promising targets for future investigations. 
These will be described in the latter part of the review 
 









Impaired domain Reference 
CRP p = .04 (N/A) Global *(Rubin et al., 2018) 
p = .01 (Rs = -.30) Executive function *(Rubin et al., 2018) 
p = .004 (Rs = -.34) Psychomotor speed *(Rubin et al., 2018) 
p = .01 (Rs = -.24) Attention/working memory *(Rubin et al., 2018) 
IL-6  p = .027 (N/A) Global (Ancuta et al., 2008) 
p = .023 (β = -.348) Attention/working memory (Falasca et al., 2017) 
p = .003 (rho = .18) Global (Sattler et al., 2015) 
IL-10  p = .04 (β = .26) Processing speed/flexibility (Cohen et al., 2011) 
p = .001 (β = .42) Processing speed (Cohen et al., 2011) 
p = .003 (β = .38) Attention/working memory 
performance 
(Cohen et al., 2011) 
p = .036 (β = -1.194)  Memory performance (Correia et al., 2013) 
IL-16 p = .0007 (β = -.06) Processing speed/flexibility (Cohen et al., 2011) 
p < .0001 (β = -.14) Processing speed (Cohen et al., 2011) 
p = .01 (β = -.08)  Predictor of Motor skills (Cohen et al., 2011) 
IL-18 p = .008 (β = .07) Processing speed/flexibility (Cohen et al., 2011) 
p < .001 (β = .09) Attention/executive 
function 
(Cohen et al., 2011) 
p = .050 (β = -3.314) Memory  (Correia et al., 2013) 
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p = .015 (β = .283)  Psychomotor processing 
speed 
(Falasca et al., 2017) 
p = .049 (β = -.298) Attention/working memory  (Falasca et al., 2017) 
IL-1β p = .04 (β = 2.34) Processing speed/flexibility (Cohen et al., 2011) 
1P-10 p = .02 (β = -.003) Processing speed/flexibility (Cohen et al., 2011) 
p = .003 (β = -.006) Processing speed (Cohen et al., 2011) 
p = .02 (β = -.004) Predictor of processing 
speed 
(Cohen et al., 2011) 
p = .0377 (N/A)  Global (Yuan et al., 2015) 
IFN-γ  p = .02 (β = -1.82) Processing speed/flexibility (Cohen et al., 2011) 
MMP-1 p = .019 (R = -.283) Verbal memory  (Li et al., 2013) 
p = .003 (R = .350) Frontal executive 
performance  
(Li et al., 2013) 
MMP-2  p < .001 (N/A) Global (Xing et al., 2017) 
MMP-7 p = .03 (R = .359) Motor speed  (Li et al., 2013) 
MMP-9  p < .01 (N/A) Global (Xing et al., 2017) 
MMP-10 p = .035 (R = .254) Frontal executive 
performance   
(Li et al., 2013) 
CCL2  p < .01 (N/A) Global (Ancuta et al., 2008) 
p = .007 (β = .02) Attention/executive 
function  
(Cohen et al., 2011) 
p = .01 (R = -.49)  Prospective memory (Woods et al., 2006) 
MIP-1β p = .044 (β = -.03) Attention/executive 
function 
(Cohen et al., 2011) 
Neopterin p = .0455 (N/A) Global *(Krebs et al., 2016) 
sCD40L  p < .01 (N/A) Global (Sui et al., 2007) 
sCD14 p = .03 (N/A) Global (Ancuta et al., 2008) 
p = .029 (N/A) Executive function *(Burdo et al., 2013) 
p < .05 (β = -.20) Executive function (Imp et al., 2017) 
p = .02 (N/A) Global (Kamat et al., 2012) 
p = .03 (N/A) Learning (Lyons et al., 2011) 
p = .015 (N/A) Attention (Lyons et al., 2011) 
p = .007 (N/A)  Global (Lyons et al., 2011) 
p < .008 (β = -.003) Processing speed  *(Monnig et al., 2017) 
p = .037 (r = -.14) Global (Muñoz-Nevárez et 
al., 2019) 
p < .01 (N/A) Global  (Ryan et al., 2001) 
p < .001 (N/A) Global (Xing et al., 2017) 
sCD163 p = .028 (N/A) Global *(Burdo et al., 2013) 
p = .005 (N/A) Learning  *(Burdo et al., 2013) 
p = .029 (N/A) Executive function *(Burdo et al., 2013) 
p < .001 (β = -.30) Global (Imp et al., 2017) 
p < .05 (β = -.33) Verbal memory (Imp et al., 2017) 
p < .05 (β = -.24) Psychomotor speed  (Imp et al., 2017) 
p < .05 (β = -.21) Fine motor skills (Imp et al., 2017) 
p < .01 (N/A) Global (Xing et al., 2017) 
sTNFR-II, p = .0082 (N/A) Global *(Krebs et al., 2016) 
TIMP-1  p < .001 (N/A) Global (Xing et al., 2017), 
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TIMP-2  p < .001 (N/A) Global (Xing et al., 2017),  
TNF-α p = .003 (β = 2.02) Attention/executive 
function  
(Cohen et al., 2011) 
p = .024 (β = -.282) Worse executive function (Falasca et al., 2017) 
p = .03 (N/A) Global *(Sevigny et al., 2004) 
TRAIL p = .05 (β = .23) Predictor of Processing 
speed 
(Cohen et al., 2011) 
p = .02 (β = .23) Predictor of 
Attention/working memory  
(Cohen et al., 2011) 
*Longitudinal studies, N/A: Not Available.   
 
Not all included studies have reported on treatment durations before analysis as this 
may have affected immune reconstitution and potentially the peripheral immune 
marker levels. To account for immune status (CD4+ count) and its potential effect on 
immune marker levels, studies were stratified according to their CD4+ count. We 
subdivided studies into two categories, specifically having a current (or follow-up for 
longitudinal studies) mean/median CD4+ count of <200 cells/μl or >200 cells/μl. 
These included 8 studies with <200cells/μl and 24 studies with >200 cells/μl 
(Supplementary Table 3). Five studies did not provide sufficient information to 
stratify according to CD4+ count (i.e. did not include follow up CD4 counts (D’Antoni 
et al., 2018a; Monnig et al., 2017; Robertson et al., 2019; Sevigny et al., 2004) or did 
not report statistical associations (Valcour et al., 2015). From the 8 studies 
(<200cells/μl), the majority investigated immune markers that had an association 
with HIV-associated neurocognitive impairment. However, in studies with cohorts 
having >200cells/μl, half of the studies investigated markers with an association with 
HIV-associated neurocognitive impairment (Supplementary Table 3). When stratified 
by CD4 count, study cohorts with >200 cells/μl consistently report associations of 
immune markers with HAND. Therefore, despite cross-sectional and longitudinal 
studies investigating patients with varying CD4 counts (both higher and lower than 
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200cells/μl), peripheral blood immune markers continue having a reported 
association with HIV-associated neurocognitive impairment. A similar trend is noted 
in cognitively impaired PLWH regardless of viral suppression.  
 
For this review, participants were considered as being virally suppressed with <1000 
copies/ml. Studies were stratified according to mean/median viral suppression 
(<1000 copies/ml) and non-viral suppression (>1000 copies/ml) (Supplementary 
Table 4). Across all studies, viral load was reported as a mean (SD), median (range) or 
percentage distribution. Thirty-three studies provided sufficient information to be 
stratified according to viral load. From the 33 studies, 20 studies investigated 
patients that were largely virally suppressed, and 50% of these studies reported an 
association with immune markers. The remaining 13/33 studies investigated non-
virally suppressed participants, and 69% of these studies reported markers with an 
association with HAND. This suggests that despite plasma viral suppression, a 
dysregulated peripheral immune response present in PLWH has an association with 
HIV-associated neurocognitive impairment. This potentially represents unchecked 
monocyte activation and inflammation, and this might be a trigger for ongoing 
neuroinflammation and cognitive impairment 
 
2.3.5. Monocyte activation and neuroinflammation in HAND 
 
Studies included in this review indicate that monocyte activation markers sCD14 
(Ancuta et al., 2008; Burdo et al., 2013; Kamat et al., 2012; Krebs et al., 2016; 
Montoya et al., 2019; Muñoz-Nevárez et al., 2019; Ryan et al., 2001; Sakoda et al., 
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2017; Sun et al., 2010; Xing et al., 2017) and sCD163 (Burdo et al., 2013; Xing et al., 
2017) are consistently elevated in PLWH compared to controls. The higher blood 
levels of monocyte activation markers have a reported association with HIV-
associated neurocognitive impairment. 
 
Studies collectively show that the increased sCD14 blood levels have an association 
with both global and domain-based HIV-associated neurocognitive impairments. 
sCD14 has been implicated in global HAND (Ancuta et al., 2008; Kamat et al., 2012; 
Lyons et al., 2011; Muñoz-Nevárez et al., 2019; Ryan et al., 2001; Xing et al., 2017) as 
well as impairment in domains of executive function (Burdo et al., 2013; Imp et al., 
2017), attention and learning (Lyons et al., 2011) and processing speed (Monnig et 
al., 2017). sCD163 has been associated with global HAND (Burdo et al., 2013; Imp et 
al., 2017; Xing et al., 2017) and impairment in verbal memory, psychomotor speed, 
fine motor skills (Imp et al., 2017), learning and executive function (Burdo et al., 
2013) (Table 2). Similarly, in long term treatment investigations, sCD14 (Burdo et al., 
2013; Monnig et al., 2017) and sCD163 (Burdo et al., 2013) were associated with 
HAND at multiple time points.   
 
Various inflammatory cytokines and chemokines were investigated across studies. 
However, only some markers were consistently higher in PLWH. These included a 
combination between pro- and anti-inflammatory blood markers; IL-8, IL-18, IP-10 
and sTNFR-II. From these markers, several studies reported that the consistently 
increased blood levels of IL-18 (Cohen et al., 2011; Correia et al., 2013; Falasca et al., 
2017) and IP-10 (Cohen et al., 2011; Yuan et al., 2015) were associated with HAND.  
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Inconsistent findings were found for the inflammatory cytokines/chemokines IL-6, 
CCL2 and TNF-α. Studies reported higher IL-6 levels in PLWH (Ancuta et al., 2008; 
Kamat et al., 2012). However, IL-6 has also been shown to be lower in PLWH (Cohen 
et al., 2011; Rubin et al., 2018). The higher IL-6 levels were associated with global 
HAND (Ancuta et al., 2008) and impairment in attention/working memory (Falasca et 
al., 2017). 
 
Several studies reported higher levels of the monocyte recruitment chemokine, CCL2 
in PLWH (Ancuta et al., 2008; Krebs et al., 2016; Montoya et al., 2019; Rubin et al., 
2018; Yu et al., 2017). Another study, on the contrary, showed lower levels of CCL2 
in PLWH (Cohen et al., 2011). Two studies showed that higher CCL2 levels in PLWH 
were associated with HAND (Ancuta et al., 2008; Woods et al., 2006), whereas an 
inverse direction of this association was also reported (Cohen et al., 2011). Higher 
CCL2 was found to be associated with global HAND (Ancuta et al., 2008), worse 
attention/executive function (Cohen et al., 2011) and prospective memory 
performance (Woods et al., 2006) (Table 4 and Table 5).   
 
Conflicting results were also reported for TNF-α levels, with studies showing higher 
levels (Krebs et al., 2016; Marcotte et al., 2013; Montoya et al., 2019; Rubin et al., 
2018; Ryan et al., 2001) and opposing lower levels (Cohen et al., 2011) in PLWH 
when compared to controls. Higher (Falasca et al., 2017; Sevigny et al., 2004) and 
lower (Cohen et al., 2011) levels of TNF-α were found to be associated with HAND. 
Despite the varying associations of TNF-α levels with HAND, the dysregulated TNF-α 
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levels were shown to have an association with attention and executive function 
(Cohen et al., 2011; Falasca et al., 2017). A full description of all studies investigated 
in this review is described in Table 4 and Table 5.
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Table 4: Cross-sectional studies reporting the association of peripheral blood immune markers with cognitive performance in HIV-ART cohorts 
References  Type of 
Study  
Treatment  Sampling  
technique  
Cohort  Neuro 
test 





HAART ELISA and 
LAL 
HIV+: n= 119 
HIV+ NCI: n=73 
NCI (other causes): n= 20,  
HIV+ NC: n=32 and HIV-: 
n=25 
 
Female: 20% (n=30) 
Age: 45 (±8) 
 
CD4 count: 110 cells/μl  
(±197) 
 





N/A sCD14, IL-6 
and CCL2  
1. CCL2 (p < .001), IL-6 (p 
< .001) and sCD14 (p 
< .001) were significantly 
higher in AIDS participants 
compared to negative 
controls. 
2. NCI participants had 
higher plasma levels of 
CCL2 (p = .01), IL-6 (p 
= .027) and sCD14 (p = .03) 





HAART ELISA HIV+ NCI: n=81 





Age: 42.2 (±6.12) 
 
CD4 count: 127.2 cells/ml 
(±21.8) 
 
MSK N/A Osteopontin 1. No significant differences 
in plasma Osteopontin 
levels between NCI HIV+ 
and NC HIV+ participants. 
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Viral load: range between 
39811-199526 copies/ml 
(Cohen et 
al., 2011)*    
Cross-
sectional 




Female: 42% (n=27) 
Age: 44.8 (±9.06) 
 
Current CD4 count: 463.9 
cells/μl (± 284.56) 
Nadir CD4 count: 168.6 
cells/μl  (±130.76) 
 



















8, IL-10, IL-16, 
IL-18, IFN-γ, 
IP-10, MIP-1β, 
CCL2, SDF-1 α, 
TRAIL and 
TNF- α  
 
 
1. Plasma IP-10 (p = .001 
partial η2=0.162) and MIP-
1β (p = .034, partial 
η2=0.073) were higher in 
HIV+ participants whereas 
IL-1β (p = .004, partial 
η2=0.129), IL-6 (p = .003, 
partial η2=0.134), IFN-γ (p 
= .002, partial η2=0.143), 
CCL2 (p = .04, partial 
η2=0.066), and TNF-α (p 
= .003, partial η2 = 0.066) 
were lower in HIV+ 
participants. 
2. Higher plasma IL-16 (p 
= .0007, β = -0.06), IP-10 (p 
= .02, β = -.003), IFN-γ (p 
= .02, β = -1.82) and Lower 
IL-1β (p = .04, β = 2.34), IL-
10 (p = .04, β = 0.26), and 
IL-18 (p = .008, β = 0.07) 




3. Higher plasma IL-16 (p 
< .0001, β = -.14) and IP-10 
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(p = .003, β = -.006) and 
lower IL-10 (p = .001, β 
= .42) was associated with 
worse processing speed 
performance.  
4. Higher plasma MIP-1β (p 
= .044, β = -.03) and lower 
IL-18 (p < .001, β = .09), 
CCL2 (p = .007, β = .02), 
and TNF-α (p = .003, (β = 
2.02) was associated with 
worse attention/executive 
function performance.  
5. Higher plasma IP-10 (p 
= .02, β = -.004) and lower 
TRAIL (p = .05, β = .23) 
were significant predictors 
of processing speed. 
6. Lower plasma IL-10 (p 
= .003, β = .38) and TRAIL 
(p = .02, β = .23) were 
significant predictors of 
attention/working 
memory performance. 
7. Higher plasma IL-16 (p 
= .01, β = -.08) was a 
significant predictor of 
motor skills.  
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(Correia et 
al., 2013)*   
Cross-
sectional 
cART Multiplex  HIV+: n=74  
HIV-: n=50 
 
Female: 37% (n=46) 
Age: 46.22 (±11.65) 
 
Current CD4 count: 
528.83 cells/μl (±254.69) 
Nadir CD4 count: 187.15 
cells/μl (±166.88) 
 






Revised   







1. HIV+ participants had 
higher levels of IL-8 (p 
= .003), IL-18 (p = .002) 
and IP-10 (p < .001) 
compared to HIV- controls.  
2. HIV+ participants had 
significantly lower SDF-1α 
(p = .025) compared to 
HIV- controls. 
3. Higher plasma levels of IL-
8 (p = .027), and IFN-γ (p 
= .005) were associated 
with better performance 
on memory measures. In 
contrast, higher IL-10 (p 
= .036, β = -10.194) and IL-
18 levels (p = .050, β = -














HIV + (Younger group 20-
46): n=18 
HIV+ (Older :50-71): n=26 
HIV-: n=86 
 
Female: 16% (n=21) 
Age: 32 (22-40) and 
57(50-71) 
 










IL-8, IL-6 and 
TNF-α 
1. Older HIV+ participants 
demonstrated higher 
levels of IL-6 (p = .03) and 
CCL2 (p = .03) compared to 
younger individuals. 
2. None of the inflammatory 
markers were associated 
with NCI. 
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Current CD4 count: 726 
cells/μl  (603-1051) 
Nadir CD4 count: 374 
cells/μl (287-505) 
 




age group  
(Falasca et 
al., 2017)*   
Cross-
sectional 
ART ELISA HIV+: n=40  
HIV+ NCI: 40 
 
Female: 12.5% (n=5) 
Age: 47.8 (N/A) 
 
CD4 count: 646 cells/μl  
(523-964) 












IL-6, IL-8, IL-18 
and TNF-α 
1. Overall serum cytokine 
levels were significantly 
associated with 
performances on many 
neurocognitive measures.  
2. Lower IL-8 were associated 
with better executive 
function (p = .008).  
3. Higher IL-6 was associated 
with better executive 
function (p = .032).  
4. Higher levels of TNF-α 
were associated with 
worse executive function 
(p = .024, β = -.282).  
5. IL-18 serum levels were 
associated with worse 
psychomotor processing (p 
= .015, β = .283) and worse 
attention/working 
memory (p = .049, β = 
-.298). 
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(Imp et al., 
2017)*   
Cross-
sectional 
cART ELISA HIV+: n=186  
HIV-: n=67 
 
Female: 0% (n=0) 
Age: 
HIV+ 48.29 (±8.63) 
HIV- 44.15 (±10.27) 
 
Nadir CD4 count: 261 
cells/μl (±210) 
 
>500cells/μl : n=101 
200-500cells/μl : n=63 
<200 cells/μl : n=22  
 
Viral load: 
50% <500 copies/ml 
37% <10000 copies/ml 

























and IL-6  
 
1. Marker levels between 
HIV+ and HIV- participants 
were not reported. 
2. Serum IL-6 levels were not 
associated with overall 
cognitive performance or 
with any specific cognitive 
domain. 
3. Higher serum CRP levels 
were associated with 
better verbal memory in 
aviremic women (p = .04). 
4. Higher sCD163 was 
associated with overall 
performance (β = -.30), 
verbal memory (β = -.33), 
psychomotor speed (β = 
-.24), and fine motor skills 
(β = -.21) (all p < .05) in the 
overall samples. 
5. Higher sCD14 remained 
associated with worse 
executive function (p < .05, 
β = -.20). 
6. In aviremic participants, 
sCD163 was significantly 
associated with global NCI 
(β = −.24, p = .04), verbal 
memory (β = −.36, p 
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= .003), psychomotor 
speed (β = −.28, p = .01), 
and fine motor skills (β = 
−.34, p = .004).  
7. In aviremic participants, 
sCD14 was associated with 
executive function (β = 
−.25, p = .02), and a trend 
for significance was noted 
for psychomotor speed (β 





cART ELISA and 
multiplex 
HIV+ NCI: n=45,  
HIV+ NC: n=19, HIV+ 
Unknown: n=3 
 
Female: 17% (n=23) 
Age: 46 (32–69) 
 
Nadir CD4 count: 75 
cells/μl (±93) 
 
CD4 count: 155 (±162) 
 
Viral load:  
31% <400 copies/ml 
67% >400 copies/ml 









2, IL-4, IL-5, IL-
6, IL-7, IL-8, IL-
10, IL-12, IL-
13, IL-17, IFN-





1. sCD14 (p < .0001), CCL2 (p 
= .01) and IL-6 (p < .0001) 
were significantly higher in 
HIV+ participants. 
2. Plasma sCD14 (p = .02), 
was higher in HIV+ 
participants with NCI 







ART ELISA HIV+ NCI: n=31  
HIV+ NC: n=30 
 
Female: 0% (n=0) 
Age: 48 (27–63) 
 
CD4 count: 589 (407-776) 
 
Viral load:  
95% undetectable HIV 
RNA 
Frascati Age  sCD14 1. sCD14 plasma levels were 








HIV+ NCI: n= 30  
HIV+ NC: n= 73 
HIV-: n=10 
Female:  N/A 
Age: 43 (38-50) 
 
Nadir CD4 count: 227 (76-
350) cells/μl 
 
CD4 count: 495 (358-747) 
cells/μl  
 
Viral load:  
65% undetectable viral 
load 








4, IL-5, IL-6, IL-
7, IL-8, IL-9, IL-
10, IL-13, IL-






1. No significant differences 
in immune marker levels 
between HIV+ NCI and NC 
groups.  
(Li et al., 
2013)*   
Cross-
sectional 






1. HIV+ participants had 
lower plasma MMP-2 
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Female: 15% (n=11) 
Age: 33.2 (±9.9) 
 
CD4 count: 548 cells/μl 
(±252)  
 
Viral load: 1291 (±16.5) 





levels compared to the 
HIV- control group (p 
< .001).  
2. MMP-9 levels were 
significantly higher in the 
ARV-initiated than ARV-
naïve subgroup (p = .016).  
3. MMP-1 was correlated 
with verbal memory (p 
= .019, R = -.283) and 
frontal executive 
performance (p = .003, R 
= .350).  
4. MMP-7 was correlated 
with motor speed (p 
= .003, R = .359). 
5. MMP-10 was correlated 
with frontal executive 
performance (p = .035, R 





cART ELISA HIV+ NCI: n=47 
HIV+ NC: n=20 
HIV+ Unknown: n=5  
HIV+ NCI (other causes): 
n= 25 
 
Female: 23% (n=23) 
Age: 47.1 (± 8.0) 
 
AAN N/A sCD14 and 
CCL2 
1. CCL2 was not associated 
with a significant 
difference in global T-
scores. 
2. Higher sCD14 was 
associated with global NCI 
(p = .007) and impaired 
attention (p = .015) and 
learning (p = .03). 
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Nadir CD4 count: 63 (±65) 
CD4 count: 138 (±139) 
 
Viral load:  
36% <400 copies/mL 
61% >400 copies/mL  








HIV+: n=90  
HIV-: n=94 
 
Female: 48% (n=90) 
Age: 36-45 
 
Nadir CD4 count: 160 (74-
407) 
CD4 count: 627 (398-884) 
 





























TNF- α .  
1. CCL2 (r = .37), sCD14 (r = 
.2), and TNF- α (r = .22) 
were higher in the HIV+ 
group (all p < .05), 
2. Higher inflammation 
composite score was 
associated with cognitive 
impairment; however, no 
individual marker was 







cART ELISA HIV+: n=290 
HIV-: n=104 
 
Female: 55% (n=220) 
Age:  
HIV+: 41 (19-68) 
HIV-: 39 (19-69) 
 
Nadir CD4 count: 247 
(258) 
CD4 count: 402 (232) 
 














1. Plasma sCD14 was 
significantly higher in HIV+ 
compared HIV- 
participants (p = .001).  
2. Higher plasma sCD14 
levels were associated 
with lower global scores in 
both HIV+ and HIV- 
participants (r = .0001, p 
= .037). 
3. Plasma sCD163 (p =.938) 
and neopterin were not 
associated with lower 
global scores in  the 
overall sample or any sub-





HAART ELISA HIV+ NCI: n=20  
HIV+ NC: n=8 
HIV-: n=6 
 
Female: 10% (n=3) 
Age: 28 (29-61) 
 
CD4 count: 237 cells/μl 
(±41) 
 






N/A sCD14, TNF-α, 
sTNFR-I and 
sTNFR-II. 
1. TNF-α, sTNFR-I and sTNFR-
II were significantly higher 
in HIV+ participants (p 
< .01). 
2. There was no significant 
association for TNF-α, 
sTNFR-I and sTNFR-II with 
NCI in HIV+ participants. 
3. Higher sCD14 was 
associated with NCI (p 






ART ELISA HIV+: n=77  
HIV-: n= 47 
Female: 25% (n=31) 
Age: 58.26 (6.06) 
 
Nadir CD4 count: 185 
cells/μl (±192)  
 
CD4 count: 646 cells/μl 
(±341)  
 





































1. Plasma cystatin-c (p < .001, 
d = 0.79) and sCD14 (p 
< .001) levels were 
significantly higher in HIV+ 
than in HIV− participants.  
2. Cystatin-c levels tended to 
be higher in those with 
global NCI compared to 











ART ELISA and 
multiplex 
HIV+: 152 
Female: 15% (n=23) 
Age: 49 (22-69) 
 



















1. Only higher IL-6 was 
associated with lower GDS 
(rho = .18, p = .003), 
however, this was limited 
to participants with a waist 
circumference of > 99cm. 




cART ELISA and 
multiplex 
HIV+ NCI: n=58  
HIV+ NC: n=49 
 
Female: 13% (n=14) 
Age: 43,7 (±8.7) 
 
CD4 count: 396 cells/μl 
(190-582)  
 



















1. Plasma PGRN levels (p 
= .003) were significantly 
higher in viremic 
compared to aviremic 
participants. 
2. Plasma PGRN was not 
associated with NCI. 
 
(Sui et al., 
2007)*   
Cross-
sectional 
HAART ELISA HIV+ NCI: n=16 
HIV+ NC: n=9 
Female: 24% (n=6) 
Age: 41 (±11) 
MSK N/A CD40L and 
TNF-α 
1. Plasma sCD40L was 
significantly higher in 
participants with NCI, 
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CD4 count NCI: 266 
cells/μl (±182)  
CD4 count NC: 257 
cells/μl (±69)  
 
Viral load:  
NCI: 1287 copies/ml 
(±33,28) 
NC: 3234 copies/ml 
(±16,93) 
when compared with NC 
HIV+ controls (p < .01).  




HAART ELISA HIV+ NCI: n=17 
HIV+ NC: n=38 
HIV-: n=11 
 
Female: 0% (n=0) 
Age: 50.9 (± 7.4) 
 
CD4 count: 493.3 cells/μl 
(±410)  
 











sCD14 1. sCD14 was higher in HIV+ 
participants (p = .007). 
2. Higher sCD14 levels were 
associated with better 
information-processing 
speed (p = .047). 
 
(Woods et 
al., 2006)*    
Cross-
sectional 
HAART ELISA HIV+: n=35  
Normal for ProM: n=28 
















1. Higher plasma CCL2 was 
associated with 
prospective memory 
(ProM) (p < .05, R = -.49). 
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Severe ProM impairment: 
n=2 
 
Female: 22% (n=8)  
Age: 43.1 (±7.8) 
 
CD4 count: 510.5 cells/μl 
(288-622.2) 
 
Viral load:  

















ART ELISA HIV+ NCI: n=44  
HIV+ NC: n=30 
 
Female: 40% (n=30) 
Age: 45.1 (±9.0) 
 
Nadir CD4 count: 217.5 
cells/μl (46.5-360.3) 




Undetectable in 60.8%  









CCL2, EPO and 
IP-10 
1. There was no correlation 
between any of the 
plasma markers and 
action/noun fluency in 
HIV+ participants. 




cART ELISA and 
multiplex 
HIV+ NCI: n=19 
HIV+ NC: n=9 
HIV-: n=9 
 





1. MMP-2 (p < .01), MMP-9 
(p < .01), TIMP-1 (p 
< .001), TIMP-2 (p < .01), 
sCD14 (p = .01) and 
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Female: 17% (n=5) 
Age: 
HIV+ CI: 45 (±2) 
HIV+ NC: 48 (±2) 
 
CD4 count: 
HIV+ NCI: 150 cells/μl 
(±34) 




NCI: 10000 copies/ml (±2) 
NC: 2512 copies/ml (±3) 
sCD14 and 
sCD163 
sCD163 (p < .01) were 
higher in HIV+ participants 
compared to controls. 
1. HIV+ NCI participants had 
higher MMP-2 (p < .001), 
MMP-9 (p < .01), TIMP-1 
(p < .001) and TIMP-2 (p 
< .001), sCD14 (p < .001) 
and sCD163 (p < .01) 





HAART Milliplex  HIV+ NCI: n=52,  
HIV+ NC: n=33,  
 
Female: 30% (n=26) 
Age: 38 (31–76) 
 
CD4 count:  
HIV+ NCI: 41 cells/μl (21-
120)  
HIV+ NC: 69 cells/μl (21-
120)  
 
Viral load:  
NCI: 796347 copies/ml 
(2541-12500000) 




1. HIV + participants with NCI 
had higher levels of 
plasma IP-10 (p = .0377) 
compared to HIV+ NC 
controls. 
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NC: 7943 copies/ml (501-
158489) 




ART ELISA HIV+: 41   
HIV-: 42  
(Total sample  
NCI: 25 and NC: 58) 
 
Female: 15% (n=15) 
Age: 42.6 (±8.9) 
 
CD4 count: 422.6 cells/μl 
(±192.5) 
















age, sex, or 
ethnicity 
CCL2 1. Plasma CCL2 levels were 
increased in HIV+ 
participants compared to 
HIV− controls (p = .02) but 




Neurocognitive test of 7 domains: attention; working memory; psychomotor speed; visuospatial reasoning; executive function; learning and memory, and gross motor. Age: 
mean (Range/Standard deviation), CD4 count: mean (IQR/standard deviation) and viral load: mean (SD), median (range) or percentage distribution. Inflammatory: 
participants with inflammatory conditions (multiple sclerosis (MS), relapsing-remitting MS, secondary progressive MS, meningitis, and brachial neuritis). Non-inflammatory: 
participants with non-inflammatory conditions (Intracranial hypertension, pseudotumor cerebri, hydrocephalus, headaches, and migraine).  
 
* = Studies reporting a mean/median CD4 count >200cells/μl and an association with HIV-associated neurocognitive impairment 
 
Abbreviations: AAN: American Academy of Neurology, cART: combination antiretroviral therapy, CCL2: Chemokine (C-C motif) ligand 2, ELISA: Enzyme-linked 
immunosorbent assay, GDS: Global deficit score, HAART: Highly active antiretroviral therapy, HCV: Hepatitis C, HNRC: HIV neurobehavioral research center, IFN: Interferon, 
IL: Interleukin, IP-10: interferon gamma-induced protein, LAL: Limulus amebocyte lysate, CCL2: Monocyte chemotactic protein 1, MIP: Macrophage Inflammatory Protein, 
MMP: Matrix metalloproteinases, MSK: Memorial Sloan Kettering, N/A: Not Available, NC: Normal cognition, NCI: Neurocognitive impairment, PGRN: Progranulin, RANTES, 
CD: cluster of differentiation, SDF: stromal cell-derived factor, (sTNFR)-I: soluble TNF receptor, TIMP: tissue inhibitors of metalloproteinases, TNF: tumour necrosis factor and 
TRAIL: TNF-related apoptosis-inducing ligand  
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Table 5: Longitudinal studies reporting the association of peripheral blood immune markers with cognitive performance in HIV-ART cohorts 
References Type of Study  Treatment  Sampling  
technique  
Cohort  Neuro test Covariates  Markers 
Investigated 





ART ELISA HIV+ NCI: n=6  
HIV+NC: n=6  
HIV-: n=0 
 
Female: 16% (n=2) 
Age: 40 (25-59) 
 
Baseline CD4 count:  
HIV+ NCI: 42 cells/μl (42-
74)  
HIV+ NC: 88 cells/μl (44-
98) 
 
Follow-up CD4 count:  
HIV+ NCI: 188 cell/μl 
(178–205) 
HIV+ NC: 175 cell/μl 
(123–394) 
 





Follow up:  
200 copies/ml 
Frascati N/A IL-6, IL- 10, INF-
γ, TNF-α, TGF-
β1, TGF-β2, MIP- 
1α, MIP-1β and 
CCL2  
1. No significant 
differences for marker 
levels between NCI 
and NC HIV+ 
participants after 12 







ART ELISA HIV+ NCI: n=15 
HIV+ NC: n=19 
HIV-: n=34 
 
Female: 4% (n=3) 
Age: HIV+ NCI: 42.8 (8.8)  
HIV+ NC: 44.0 (±12.2) 
 
Baseline CD4 count:  
HIV+NCI: 240 cells/μl 
(197–356) 
HIV+ NC: 215 cells/μl 
(180–300)  
Follow up: 
HIV+NCI: 658 cells/μl 
(442–876)  
HIV+ NC: 628 cells/μl 
(462–796)  








1. Higher plasma 
sCD163 (p = .01) and 
sCD14 (p = .03) in 
HIV+ participants 
compared to HIV- 
participants at visit 
A. 
2. sCD163 decreased 
significantly at visit B 
(p = .01) whereas 
sCD14 had no 
significant difference 
at visit B. 
3. sCD163 was higher in 
NCI HIV+ participants 
(p = .028). 
4. Higher sCD163 was 
associated with 
impaired learning (p 
= .005) and executive 









N/A sCD163 and 
neopterin  




HIV+ Fiebig I/II: 5% (n=1) 
HIV+ Fiebig III: 9% (n=3) 
HIV-: 50% (n=9) 
Age: 
HIV+ Fiebig I/II: 31 (26-
39) 
HIV+ Fiebig III: 28 (23-29) 
HIV-: 33 (28-39) 
 
Baseline CD4 count:  
HIV+ Fiebig I/II: 447 (307-
567) 
HIV+ Fiebig III: 370 (293-
470) 
 





HIV+ Fiebig I/II: 1000000 
(19953-316228) 








increased by week 24 
(p = .034), and by 
week 48 decreased 
matching pre-cART 
levels (p < .0001).   
2. Fiebig III: After cART 
initiation, at week 48, 
plasma sCD163 levels 
decreased matching 
uninfected controls (p 
< .0001).   
3. Chronic infection: 
After cART, plasma 
sCD163 decreased but 
remained higher than 
controls (p < .0001). 
4. Before cART, higher 
plasma sCD163 were 
associated with better 
psychomotor 
performance (p 
= .044), however, no 
associations were 







(24 weeks)  
ART ELISA HIV+: n=17 
 
Female: 5% (n=1) 
Age: 55 (47–58) 
Baseline Nadir CD4 
count: 200 cells/μl (90-
280) 
CD4 count: 545 cells/μl 
(404-731) 
 
Follow-up analysis: 732 
cells/μl (397-900) 
 
Viral load:  









defined.   




1. Plasma neopterin (p 
< .01), sCD163 (p 
= .001) and sCD14 (p 
= .003) levels 
decreased 
significantly at 
subsequent visits (24 
weeks). 
2. Neopterin and sCD163 
were not associated 
with cognitive 
performance at any 
time point. 
3. At baseline, higher 
sCD14 was associated 
with worse 
psychomotor speed (p 
= .064). 
4. With the reduction in 
all markers after 2 
weeks, no association 
with NCI was found at 
subsequent visits.  
(Krebs et al., 
2016)* 
Longitudinal 
(96 weeks)  
cART ELISA HIV+: n=60  
HIV-: n=18 
Female: 44% (n=35) 
Age: 35 (22-47) 
 
Baseline CD4 count:  
Frascati HIV-1 viral load, 







1β, IL-4, IL-5, IL-
6, IL-8, IL-10, IL-
15, CCL2, t-Tau, 
1. In HIV+ females, 
plasma neopterin (p 
< .001), IP-10 (p 
< .001), TNF-α (p 
< .001), TNF-RII (p 
< .001), IFN-α (p 
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Males: 239 (29-532) 
Female: 230 (23-553)  
 
Follow up CD4 count:  
Increased significantly 




Female: 40503 copies/ml 
(1585-639659) 




Viral load decreased 
significantly p < .0001. 
Majority of participants 
were aviremic.   
addition, sex was 




IFNα and sCD14 
= .0439), CCL2 (p 
= .007), IL-8 (p 
< .001),IL-10 (p 
= .0046) and sCD14 (p 
= .002) levels were 
decreased after 48 
weeks but remained 
elevated compared to 
uninfected controls. 
2. HIV+ females with NCI 
reported higher 
neopterin levels (p 
= .0114) at baseline as 
well as after 48 weeks 
of treatment (p 
= .0445) compared to 
NC HIV+ females.  
3. HIV+ females with NCI 
reported significantly 
higher sTNFR-II (p 
= .0082) compared to 
HIV+ females with NC 
after 48 weeks. 
(Lentz et al., 
2010) 
Longitudinal 
(40 weeks)  
cART ELISA HIV+ NCI: n=30  
HIV+ NC: n=24 
Female: 31% (n=17) 
Age:  
HIV+ NCI: 41.4 (±7.6)  
HIV+ NC: 40.2 (±5.9) 
MSK N/A M-CSF 1. Plasma M-CSF were 
significantly 
decreased after 10 




CD4 count:  
Baseline: 184 cells/μl 
(±164) 
 
Follow up: 256 cells/μl (± 








2. Plasma M-CSF had no 
significant 
relationship to 
cognitive measures at 
any time point or be 










HIV+: n=98  
Cognition stably Normal 
(SN): n=25  
Worsened (Wo): n=25 
Stably Impaired (SI): 
n=25 
Cognition Improved (Im): 
n=23 
 
Female: 34% (n=34)  












Age, sex, education 
and ethnicity 
CCL2, IL-6, TNF-
α, IP-10, SDF-1α, 
sTNFRII and 
sCD14 
1. Plasma sTNFRII (p 
= .03) and TNF-α (p 
= .017) increased 
significantly between 
visits.  
2. No significant 
associations between 




SN: 462 cells/μl (321-
667), Wo: 335 cells/μl 
(194-481), SI: 463 cells/μl 
(304-642) and Im: 260 
cells/μl (102-540) 
 
Follow up: Groups who 
remained 
neurocognitively stable 
had higher CD4 counts at 
the first visit (p < .01) 
 
Viral load: 







(12 weeks)  
ART ELISA HIV+: n=21 
 
Female: 0% 
Age: 46.7 (26-63) 
 
CD4 count:  












sCD14 1. Higher sCD14 was 
associated with worse 
processing speed (p 
< .008, β = -.003). 
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100% <75 copies/ml 
(Robertson 













CD4 count:  










Frascati Age, education, 









1. No associations were 
found between NCI 
and immune markers 
at week 48. 
(Rubin et al., 
2018) * 
Longitudinal 
(288 weeks)  
HAART Multiplex, 
milliport 
and ELISA  
HIV+ NCI: n=36 
HIV+ NC: n=36 
HIV− NCI: n=29 
HIV− NC: n=29 
 
Female: 100% (n=130) 








Viral load, current 
and nadir CD4 
count, and 
CD4/CD8 ratio 
IL-10, IL-1β, IL-6, 
IP-10, CCL2, MIP-
1β, TNF-α, IL-16, 
TRAIL, sTNFR-I, 
sTNFR-II, MMP-
9, CRP and IL-18 
1. HIV+ women reported 
higher serum levels of 
IL-18, sTNFR-II, CCL2, 
IP-10, TNF-α, and 
lower levels of IL-6 (p 
values < .05) 
compared to controls. 
2. Greater CRP variability 
predicted decreased 
executive function (Rs 
= -.30), 
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HIV+ NCI: 641 cells/μl 
(379-799) 






NCI: 86% <80 copies/ml 
 
NC: 72% <80 copies/ml 
attention/working 
memory (Rs = -.24), 
and psychomotor 
speed (Rs = -.34) in 





(84 weeks)  
ART ELISA HIV+ NCI: n=74  
HIV+ NC: n=129  
 
Female: 26% (n=54) 
Age: 42 (±7.2) 
 
CD4 count: 







11500 (270-66,000)  
 
Follow-up: NA 
AAN Age, sex, years of 
education, duration 




score, and presence 
of minor cognitive 
motor disorder  
CCL2, TNF- α, M-
CSF and MMP-2 
1. Plasma TNF-α (p = .03) 
tended to be 








(24 weeks)  
cART ELISA HIV+ cART: n=30,  
HIV+ cART+ integrase 
inhibitor + CCR5 
antagonist: n=32  
HIV-: n=29 
 
Female: 18% (n=17) 
Age: 27 (18-47) 
 
CD4 count: 
Baseline HIV+ cART: 369 
cells/μl (±277) 




No significant difference 
in CD4 counts 
 
Viral load  
Baseline 




cART: 53 copies/ml (50–
102) 
cART+: 234 copies/ml 
(50–5596)  
 AAN Age, gender and 
mean educational 
level. 
IL-6, IP-10, CCL2 
and neopterin 
1. Plasma neopterin (p 
< .001) and IP-10 (p 
= .007) levels were 
decreased in HIV+ 
participants however, 
it remained higher 
compared to controls.  
2. The associations 
between immune 
markers and cognitive 
performance were not 
reported.  
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Neurocognitive test of 7 domains: attention; working memory; psychomotor speed; visuospatial reasoning; executive function; learning and memory, and gross motor. Age: 
mean (Range/Standard deviation), CD4 count: mean (IQR/standard deviation) and viral load: mean (SD), median (range) or percentage distribution. 
 
*= Studies reporting a mean/median CD4 count >200cells/μl and an association with HIV-associated neurocognitive impairment 
 
Abbreviations: AAN: American Academy of Neurology, cART: combination antiretroviral therapy, CRP: C-reactive protein, CCL2: Chemokine (C-C motif) ligand 2, CCR: C-C 
chemokine receptor type, ELISA: Enzyme-linked immunosorbent assay, HAART: Highly active antiretroviral therapy, HCV: Hepatitis C, HNRC: HIV neurobehavioral research 
center, IFN: Interferon, IL: Interleukin, IP-10: interferon gamma-induced protein, LAL: Limulus amebocyte lysate, M-CSF: Macrophage colony-stimulating factor MIP: 
Macrophage  inflammatory Protein, MMP: Matrix metalloproteinases, MSK: Memorial Sloan Kettering, N/A: Not Available, NC: Normal cognition, NCI: Neurocognitive 
impairment, PGRN: Progranulin, RANTES, CD: cluster of differentiation, SDF: stromal cell-derived factor, sTNFRI: soluble TNF receptor, TIMP: tissue inhibitors of 




2.4. Discussion  
 
The main findings from studies reviewed here show that 1) immune markers were 
altered in ART experienced PLWH compared to HIV-negative controls, and 2) an 
alteration of immune markers linked to key pathways of monocyte activation (sCD14 
and sCD163) and inflammation (IL-18 and IP-10) were was associated with HIV-
associated neurocognitive impairment. With consistent evidence across several 
studies reviewed here, immune markers linked to key pathways of monocyte 
activation (sCD14 and sCD163) and inflammation (IL-18 and IP-10) may be important 
markers in the neuropathophysiology of HAND. Even with ART and studies including 
patients with varying CD4+ counts/reconstituted immune systems and viral 
suppression, there is a continued association of monocyte activation and 
inflammation immune markers with HAND.  
 
Our findings suggest that certain monocyte activation markers may be promising 
markers in the neuropathophysiology of HAND, due to their consistent findings 
across the majority of studies. sCD14 is a marker of monocyte activation and 
represents a state of activated immune cells. Due to the higher levels of sCD14 in 
PLWH and its association with HAND, sCD14 may have a functional role in the 
neuropathology of HIV. sCD14 is significantly increased in PLWH with cerebral 
atrophy compared to PLWH without cerebral atrophy (Ryan et al., 2001). sCD163 is a 
complex scavenger receptor which is cleaved and shed from activated 
monocytes/macrophages. Similar to sCD14, sCD163 represents an activated immune 
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system, which is a crucial step in the neuropathogenesis of HAND (Burdo et al., 
2013).  
 
In addition to chronic immune activation, a dysregulated inflammatory profile in HIV-
associated neurocognitive impairment is reported in this review (Table 2). Promising 
inflammatory markers included the pro-inflammatory cytokines, IL-18 (Cohen et al., 
2011; Correia et al., 2013; Falasca et al., 2017) and anti-inflammatory cytokine, IP-10 
(Cohen et al., 2011; Yuan et al., 2015). IL-18 is a key inflammatory cytokine in HIV 
infection and may be an important cytokine in activating microglia during stress 
(Sugama et al., 2007). IP-10, also known as C-X-C motif chemokine 10 (CXCL10), is an 
anti-inflammatory cytokine that is increased in both the periphery (Cohen et al., 
2011) and the CNS (Yuan et al., 2013) of PLWH. IP-10 can exacerbate the neurotoxic 
effects of HIV-1 and mediates pro-inflammatory cytokine production (Williams et al., 
2009). Due to the higher levels of IP-10 and IL-18, this may suggest active 
mechanisms, potentially those involved in the neuropathophysiology of HIV-
associated neurocognitive impairment. Higher plasma IL-18 and IP-10 levels were 
associated with lower volumes of the putamen, pallidum, thalamus, hippocampus, 
amygdala, gray and white matter, as well as higher ventricular volumes in PLWH 
(Gongvatana et al., 2014). IL-18 and IP-10 may, therefore, be involved in mechanisms 
involved in HIV-associated CNS abnormalities. 
 
As shown in this review, the direction of the associations of CCL2 and TNF-α with 
HAND are inconsistent. This is an interesting finding, as this may suggest that the 
dysregulation of these markers beyond homeostatic immunological levels (higher or 
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lower), may contribute to the neuropathophysiology of HIV-associated 
neurocognitive disorders. However, this warrants further investigation as these 
studies differed in study design, cohort size, treatment duration and regimen and 
relevant statistical analysis. All of which may have affected these findings. The 
contradictory findings presented in this review were largely reported by a study by 
(Cohen et al., 2011), which included participants co-infected with HCV. It may be that 
the presence of HCV may affect inflammatory markers in treated HIV patients (Taye 
and Lakew, 2013), and this may be a plausible reason for the inconsistent findings 
presented by these studies (Cohen et al., 2011; Rubin et al., 2018).  
 
This systematic review supports the hypothesis of continuous low-grade 
(neuro)inflammation despite treatment status. Long term treatment studies showed 
that inflammatory levels remained elevated or unchanged at subsequent visits on 
various treatment regimens. This continuous inflammatory profile may be 
responsible for the development of milder forms of HAND despite the introduction 
of ART (Gannon et al., 2011) 
 
Furthermore, two longitudinal studies recruited treatment-naive patients. These 
studies suggest that CD4+ counts are significantly increased at subsequent time 
points. Inflammatory marker levels were decreased at follow up analysis, however 
marker levels remained significantly higher than levels found in HIV-negative 
controls. This further supports previous findings that in the era of ART, immune 
marker levels may decrease but not to levels matching HIV- controls.  
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Even though CD4+ counts may increase with ART, using CD4+ count as predictors of 
cognitive impairment need further consideration (Ellis et al., 2011; Sacktor et al., 
2001). To extend on this area, studies were stratified according to their CD4+ count 
and viral suppression. Regardless of CD4+ count/reconstituted immune system and 
viral suppression, peripheral cytokines still had an association with HAND, further 
supporting the argument that other mechanisms may contribute and trigger chronic 
immune activation and inflammation. Not all studies accounted for the effect of 
CD4+ count in their analyses, which may have affected findings.  
Several studies have reported an association between viral load and HAND 
(Marcotte et al., 2003; Mccombe et al., 2013). With the effective roll-out of ART, 
current viral load is no longer strongly associated with HAND and the dominant 
hypothesis for ongoing brain dysfunction has been linked to persistent inflammation 
(Clifford and Ances, 2013). ART may significantly reduce the viral load and systemic 
inflammation, but not with resolution to normal levels (Clifford and Ances, 2013). As 
reviewed here, studies including participants with higher viral load, more commonly 
reported associations between peripheral immune markers and HIV-associated 
neurocognitive impairment (69%) compared to studies including virally suppressed 
participants (50%). Therefore, with the effective use of ART, there may be a decrease 
in the level of inflammation and the development of HAND, but not to levels 
matching HIV-negative controls. Further, in a recent 24-month longitudinal 
treatment study, volume decline of the basal ganglia was reported in young adults 
despite the initiation of ART within the first 4 weeks of infection (Kallianpur et al., 
2019). This further indicates that ART alone may not completely eradicate HIV from 
the CNS, resulting in the continued expression of HIV viral DNA and this, in turn, may 
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trigger ongoing chronic inflammation which may be partly responsible for the 
development of milder forms of HAND.  
 
It is well reported that demographics including sex (Krebs et al., 2016; Mathad et al., 
2016) and age (De Oliveira et al., 2015) may affect inflammatory marker levels, and 
this may have affected the interpretation of findings from the studies included in this 
review. Only one study stratified according to age (De Oliveira et al., 2015) and one 
according to sex (Krebs et al., 2016). The majority of studies included sex and age 
(60%) as covariates in the statistical analysis, however, studies which have reported 
findings for the associations between age/sex and immune marker levels have found 
inconsistent results (n = 5). Three studies reported significant associations between 
immune marker levels and sex. Plasma IFN-y (p = .017, R = .447) was associated with 
sex in HIV-positive participants (Cohen et al., 2011). Plasma neopterin (p = .0445) 
and TNFRII (p = .0082) were higher in HIV-positive cognitively impaired females when 
compared to normal cognition, whereas males did not display elevated levels 
between groups (Krebs et al., 2016). Further, a higher composite inflammation 
burden score (number of elevated immune markers in a panel) was associated with 
female sex in HIV-positive participants (p < .05, hedge’s g = .45) (Montoya et al., 
2019). The remaining two studies reported no significant associations between 
immune marker levels and sex (Sevigny et al., 2004; Suh et al., 2014) 
 
For the associations between immune marker levels and age (n = 6), one study 
reported significant associations between the peripheral immune markers CCL2 (p = 
.01) and IL-6 (p = .03) with increased age (De Oliveira et al., 2015). Increased plasma 
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sCD163 was associated with increased age after controlling for estimated duration of 
infection (p = .03) (De Oliveira et al., 2015). The remaining five studies found no 
associations with age (Brown et al., 2011; Correia et al., 2013; Falasca et al., 2017; 
Montoya et al., 2019; Suh et al., 2014). Studies reporting findings for associations 
between immune marker levels and sex/age were limited, therefore no significant 
conclusions could be made. 
 
Despite the heterogeneity of studies included here, the present study does suggest 
markers that may be commonly associated with HAND. Furthermore, the consistent 
evidence found for several markers may suggest a functional role in the 
neuropathogenesis of HAND. Therefore, these markers may also potentially be 




The literature included in this review has several limitations and deserve emphasis. 
First, the heterogeneity and shortcomings of the included studies should be noted. 
Many studies in this review had a low number of participants and therefore lacked 
statistical power. Further, studies did not declare socioeconomic status and mode of 
HIV transmission of the included HIV populations. The majority of studies where 
from the United States of America, with two studies from Italy and one study each 
from France, Thailand and China. Therefore, the majority of studies reported were 
from high-income countries and these may have influenced the interpretation of the 
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findings reported in this review. Despite the inclusion criteria of this review, 
heterogeneity was evident in study design and characteristics of included study 
participants. This made the interpretation of findings reported from the studies 
much more challenging. Furthermore, <1000 copies/ml was considered as “viral 
suppression” as this has been benchmarked by several other studies (Chouraya et 
al., 2019; Jordan et al., 2009; Lokpo et al., 2020; McMahon et al., 2013). We do 
acknowledge that studies also consider undetectable viral loads as viral suppression, 
however, this may have been punitive with respect to the threshold for classifying 
studies within the review. A meta-analysis was not conducted due to the 
heterogeneity of the studies pooled for review. Heterogeneity was evident in study 
design. Varying cognitive measures and inflammatory markers were analysed in the 
studies pooled for investigation. For studies that reported an association of immune 
markers with HAND, more than half failed in reporting of effect sizes.  
 
Second, several confounders may have been present, including ART-related 
inflammation and toxicity, ART regimen and CNS penetration, presence of 
comorbidities, age, sex and viral subtype. A large percentage (58%) of studies 
included in this review did not report on treatment durations before the relevant 
testing assays. The extended use of ART as recorded in long term investigations may 
indicate lower levels of plasma viral load, which may affect peripheral immune 
markers (Hattab et al., 2015). Further, it may also be related to the CNS/plasma 
discordance, whereby HIV-1 can be detected at higher levels in the CSF than in 
blood. CNS/plasma discordance coincides with the effective penetration of ART into 
the CNS (Nightingale et al., 2016; Valcour et al., 2015). The exact ART regimens have 
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not been declared for every study and were therefore not included in this systematic 
review. The brain may act as a HIV-1 reservoir which enables HIV an escape from the 
full effect of ART within the CNS (Schrager and D’Souza, 1998) and different ART 
regimens report different scores of CNS penetration (Decloedt et al., 2015; Eisfeld et 
al., 2013). This may also affect the levels of peripheral markers and subsequently the 
observed associations with cognitive performance (Nightingale et al., 2016; Valcour 
et al., 2015). This may also suggest that viral products within the CNS may more 
sensitively represent occurrences within the brain. A systematic comparison and 
investigation of the association of CSF peripheral markers with cognitive 
performance in HIV may be required to address the above. 
 
Third, the included studies also utilized various criteria for measures of cognitive 
function. Cognitive diagnostic criteria differ in stringency when categorizing 
impairment severities. It is estimated that 20% of cognitively normal PLWH is 
classified as suffering from HAND (De Francesco et al., 2016; Gisslén et al., 2011). 
This may also have affected the reported findings of this review.   
 
Fourth, critical factors influencing marker levels may include age and sex. Even 
though majority of studies included age and sex as covariates in the statistical 
analysis, majority of studies has not stratified participants according to age/sex. 
From the limited studies reporting on these associations, the findings were mixed, 
and no conclusion could be drawn. Therefore, future studies should include analysis 
for the effect of sex and age on immune markers.   
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Fifth, HIV viral subtype has not been taken into consideration for this systematic 
review. The majority of the included studies have not declared subtype status. It is 
assumed that HIV-1 subtype B is the universal strain responsible for the 
development of HAND. This may be because the majority of our understanding of 
the neuropathogenesis of HAND is derived from studies of HIV-1 subtype B (Taylor et 
al., 2008) and this may explain the lack in reporting of HIV-1 subtypes. Even though 
HIV viral subtype reportedly affects the prevalence of HAND (Rao et al., 2013), 
limited studies exist for its effect on inflammatory levels. One study conducted by de 
Almeida and colleagues showed that HIV-1 positive patients had increased 
inflammatory markers but no significant differences between Subtype-B and 
Subtype-C (de Almeida et al., 2016). However, this study had a small number of 
participants and therefore limited statistical power. Thus, the effect of HIV subtypes 
on the association of inflammatory markers with cognitive impairments cannot be 
neglected and needs further investigation.  
 
Sixth, seven studies did not report and statistically adjust for confounders. Several 
covariates including; sex (Krebs et al., 2016; Mathad et al., 2016), age (De Oliveira et 
al., 2015), comorbidities (Keating et al., 2017) and substance abuse (Cadet and 
Krasnova, 2007; Liu et al., 2012) may similarly affect marker levels. In the studies 
that did not report on the above, a trend is noted that these studies attempted to 
create stricter inclusion criteria. Even though a stricter inclusion criterion may be 
used, the lack of adjustment and reporting of confounders may still affect findings 
presented in these studies and ultimately the interpretation thereof. Only 40% (n = 
14) of studies controlled for multiple comparisons by utilizing either Benjamini-
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Hochberg, Bonferroni corrections or Dunn's multiple comparisons. Controlling for 
multiple comparisons provide support for the findings presented in each study, and 
the lack to control for this may affect the interpretation of the findings.   
 
Several markers were investigated more often than others across studies. Here we 
reviewed the most common markers found. Other exploratory studies may have 
identified immune marker candidates which were not highlighted here. Thus, the 
need for further investigation into the identification of candidate immune markers 
for HAND is required.   
 
Lastly, there are also significant variations across assays used to measure blood 
immune markers, and these variations may lead to inconsistent associations 
observed in the reported studies. It was shown that in a multisite investigation of 
HIV positive serum/plasma samples, current multiplex assays vary significantly in 
their ability to measure serum and/or plasma concentrations of cytokines. 
Therefore, findings may not be reproducible for repeated determinations over a 
long-term study or in multiple laboratories. However, it may be useful for 
longitudinal studies in which relative, rather than absolute, changes in cytokines are 
important (Breen et al., 2011). This further emphasizes the need for uniformity of 




2.6. Recommendations  
 
Monocyte activation and inflammatory markers, in particular, peripheral sCD14, 
sCD163, IL-18 and IP-10 are promising immune markers, given their consistent 
findings for their correlation with HAND. These markers, therefore, may potentially 
be investigated as crucial markers in the neuropathophysiology of HAND. Studies 
pooled for investigation differed in ART regimen, treatment duration (CNS 
penetration), viral subtype and statistical protocols, and this may have affected the 
interpretation of the findings. Greater uniformity in all studies investigating general 
markers and cognitive performance will allow for improved comparability. 
Specifically, investigations of cognitive severities and patterns in PLWH will allow the 
teasing out of which markers may be related to HAND and not to the presence of 
HIV-1 in general. Finally, future studies should investigate the association of a 
combination of immune markers with HAND. This approach may be more beneficial 
than investigating the association of individual markers with HAND. It was recently 
shown that using a composite score for a combination of inflammation markers were 
associated with neurocognitive impairment in PLWH, whereas, no association was 




Despite the heterogeneity of study conditions and patient populations, this study 
reports that PLWH with HAND experiences a chronic inflammatory regulation that 
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may persist regardless of ART. Results show that chronic inflammation is associated 
with HIV-associated neurocognitive impairment, particularly monocyte activation 
markers; sCD14 and sCD163 and inflammatory markers; IL-18 and IP-10. Based on 
these associations there is a possibility that these markers may be involved in the 
neurobiological mechanisms that manifest into HAND. Future studies in cell cultures 
and animal models are needed to determine specific neurobiological and molecular 
signaling pathways that can contribute to the neuropathophysiology of 
neurocognitive impairment in PLWH.  
 
The findings presented in this review may contribute to this line of research.  
Firstly, this review addressed the inconsistency for the association between 
peripheral immune markers and HIV-associated neurocognitive impairment and 
suggests a panel of markers which were most commonly associated with HIV-
associated neurocognitive impairment. Secondly, based on the consistent findings, 
the suggested peripheral immune markers may be important contributors to the 
underlying neuropathophysiology of HIV-associated neurocognitive impairment and 
may be fundamental for future research. We believe that this review presents 
researchers with a panel of markers which may be the basis for future research, 
without the need to scour the extensive literature of the field. Lastly, monocyte 
activation and inflammation may persist despite successful ART. Therefore, in 
addition to simply suppressing the viral load, other strategies are required to address 
the ongoing peripheral inflammation in PLWH. 
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The majority of studies investigating the association of peripheral immune markers 
with HAND were done in HIV-1B infection. Limited investigations exist in HIV-1C 
infected participants. Associations between immune markers of monocyte activation 
and inflammation with HAND were the most consistent outcome between the 
majority of the studies. However, I highlighted the inconsistency in the direction of 
the association of these peripheral immune markers with HAND. Therefore, in the 
next chapter, I investigated a new combination of markers for their potential 
association with HIV-associated neurocognitive impairments. This was in the aim of 
identifying additional markers that are potentially associated with HIV-associated 
neurocognitive impairments. It is also of interest to investigate the nature of 
inflammation without the possible confounding effects of ART-related neurotoxicity. 
Therefore, in Chapter 3 and Chapter 4, I investigated treatment-naïve populations. 
These populations represent participants with a higher risk of developing dementia 
and therefore these investigations may provide an opportunity to investigate the 
immune response in these individuals without the possible confounding effects of 
ART.  
 
I expect immune marker levels to be higher in treatment naïve PLWH. However, as 
reported in the current review, although ART may reduce immune marker levels, it 
does not return to levels matching HIV-negative controls. Further, despite elevated 
CD4 counts and viral suppression, immune marker levels are associated with HIV-
associated neurocognitive impairment. This is suggestive of ongoing inflammation in 
the modern ART-era. I therefore hypothesize that the findings of treatment-naïve 
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2.9. Supplementary: Chapter 2 
 
Search terms  
PubMed 
 (HIV [mh] OR HIV [tw] OR Acquired Immunodeficiency Syndrome [mh] OR "Acquired 
Immunodeficiency Syndrome" [tw] OR AIDS [tw]) AND (HIV associated neurocognitive disorders [mh] 
OR HAND [tw] OR neurocognitive [tw] OR cogniti* [tw] OR Executive Function [mh] OR executive [tw] 
OR Memory [mh] OR memory [tw] OR Attention [mh] OR attention [tw] OR Neuropsychological Tests 
[mh]) AND (Cytokines [mh] OR cytokin* [tw] OR Chemokines [mh] OR chemokine [tw] OR 
Inflammation [mh] OR inflammation [tw] OR Neurogenic Inflammation [mh] OR neuroinflammation 
[tw] OR TNF [tw] OR Interleukins [mh] OR interleukins [tw]) AND (Microglia [mh] OR microglia [tw] OR 
Monocytes [mh] OR monocyte* [tw] OR sCD163 [tw] OR sCD14 [tw] OR sCD40 [tw]) AND (Anti-HIV 
Agents [mh] OR Antiretroviral Therapy, Highly Active [mh] OR combination antiretroviral therapy [tw] 
OR cART [tw] OR HAART [tw] OR ART [tw]). 
Scopus  
(HIV OR acquired immunodeficiency syndrome OR “acquired immunodeficiency syndrome” OR aids) 
AND (hiv associated neurocognitive disorders OR hand OR  neurocognitive OR cogniti* OR executive 
function OR executive OR memory OR attention OR neuropsychological tests) AND (cytokines OR 
cytokin* OR chemokines OR inflammation OR neurogenic inflammation OR neuroinflammation OR tnf 
OR interleukins) AND (microglia  OR monocytes OR  monocyte* OR scd163 OR scd14 OR scd40)  
Web of Science  
TS=(HIV OR Acquired Immunodeficiency Syndrome OR "Acquired Immunodeficiency Syndrome" OR 
AIDS) ANDTS=(HIV associated neurocognitive disorders OR HAND OR neurocognitive OR cogniti* OR 
Executive Function OR executive OR Memory OR memory OR Attention OR attention OR 
Neuropsychological Tests) AND TS=(Cytokines OR cytokin* OR Chemokines OR chemokine OR 
Inflammation OR inflammation OR Neurogenic Inflammation OR neuroinflammation OR TNF OR 
Interleukins OR interleukins) AND TS=(Microglia OR microglia OR Monocytes OR monocyte* OR sCD163 
OR sCD14 OR sCD40)
 120 




Marker Function Marker Function 
Neopterin Neopterin is a CNS immune activation 
marker (Hagberg et al., 2010), and its 
dysregulated levels in blood (Krebs et al., 
2016) and CSF (Burdo et al., 2013; 
Ceccarelli et al., 2017) have been 
associated with HAND. 
Chemokine ligand 
(CCL)2/MCP-1 
CCL2 is an important immune marker within the neuropathogenesis of HAND, with 
both neuro-toxic (Yang et al., 2011) and neuro-protective properties (Eugenin et al., 
2007, 2003). CCL2 is a major component for the transmigration of CD14+CD16+  
monocytes across the blood-brain barrier (Buckner et al., 2011). Elevated CSF (Yuan et 
al., 2013) and blood (Marcotte et al., 2013) levels have been associated with 
structural brain changes (Ragin et al., 2006) and neurocognitive impairment in PLWH. 
sCD14 sCD14 is an immune marker which is shed 
from activated monocytes/macrophages 
and represents an activated immune 
system (Burdo et al., 2013). sCD14 blood 
(Ryan et al., 2001) and CSF (Kamat et al., 
2012a) levels were associated with HAND. 
CCL5/RANTES CCL5 is a chemotactic cytokine encoded by the CCL5 gene. CCL5 is increased in the 
CNS after HIV-1 infection and in HIV-associated dementia (HAD) (Kelder et al., 1998). 
CCL5 has also reported neuroprotective properties in vitro (Kaul and Lipton, 1999; 
Meucci et al., 2000, 1998) 
sCD163 CD163 is cleaved from the surface of 
macrophages and shed as sCD163 
following activation and differentiation of 
monocyte and macrophages (Møller, 
2012). Elevated blood (Burdo et al., 2013) 
and CSF (De Oliveira et al., 2015) levels 




CXCL9 is a chemokine which plays a role in chemotaxis and immune activation in HIV-
1 infection (Kamat et al., 2012b). Limited studies have investigated CXCL9 for its role 




CD40L is a type II membrane glycoprotein 
that is predominantly expressed by 
activated cells (Van Kooten and 
Banchereau, 2000) and is associated with 
neurocognitive impairment in people living 
with HIV (PLWH) (Sui et al., 2007). 
C-reactive protein 
(CRP) 
CRP is a homopentameric acute-phase inflammatory protein and a marker indicative 
of inflammation. Further, CRP levels have been associated with HIV-1 infection 
(Neuhaus et al., 2010) and HAND (Rubin et al., 2018). 
Cystatin-C Cystatin-c is a low-molecular-weight protein that is produced by nucleated cells. 
Cystatin- c has been associated with neurocognitive impairment in selected 
neurodegenerative populations (Chen et al., 2015; Yaffe et al., 2008) including people 
with HAND (Sakoda et al., 2017). 
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Eotaxin/ CCL11 Eotaxin is an eosinophil-specific chemokine that is associated with the recruitment of 
eosinophils into sites of inflammation (Teixeira et al., 2018). Despite many studies 
investigating Eotaxin in HAND, significant findings remain limited at this stage. 
Erythropoietin (EPO) EPO is a glycoprotein cytokine and has been characterized as a potent anti-
inflammatory cytokine in various diseases (Nairz et al., 2012). EPO was found to be 
neuroprotective in a murine model of HAND (Kang et al., 2010). 
Interferon (IFN)-α2 IFN-α2 is a type I Interferon cytokine involved in activation of the immune system. 
IFN- α is suggested to be involved in HIV neuropathology, as higher CSF levels were 
associated with neurocognitive impairment in PLWH (Anderson et al., 2017; Fritz-
French and Tyor, 2012; Sas et al., 2009).  
IFN-γ IFN-γ is a cytokine critical to both innate and adaptive immunity, and functions as the 
primary activator of macrophages. IFN-γ levels are elevated in PLWH and are 
associated with HAND (Schrier et al., 2015). Further, IFN-γ has recently been reported 
to contribute to BBB (Jansson et al., 2016). 
IFN- gamma-induced 
protein (IP)-10 
CXCL10 is an anti-inflammatory marker that exacerbates neurotoxicity and 
inflammation in PLWH (Williams et al., 2009). CXCL10 has chemoattractant properties 
that mediate neuronal injury (Williams et al., 2009). Higher peripheral CXCL10 levels 
were also associated with lower brain volumes in PLWH (Gongvatana et al., 2014). 
Interleukin (IL)-2 IL- 2 promotes inflammatory responses through the generation of Th1 and Th2 
effector cells (Hoyer et al., 2008). CSF IL-2 levels were significantly higher in PLWH 
with a CD4+ count of <200 cells/μL (Abassi et al., 2017). Significant findings for the 
association of IL-2 with HAND remain limited.  
IL-4  IL-4 is a cytokine that functions as a potent regulator of immunity secreted primarily 
by mast cells, Th2 cells, eosinophils and basophils (Gadani, Sachin P; Cronk, 2013). 
Studies of the association of IL-4 and HAND remains limited, however, one study 
found no significant difference in CSF levels between women living with HIV with and 
without HAND (Gerena et al., 2019). 
IL-5  IL-5 is an eosinophil-specific regulatory cytokine involved in the differentiation, 
activation, and survival of eosinophils (Kouro and Takatsu, 2009). Despite many 
reports, significant findings for the association of IL-5 with HAND remain limited. 
IL-6  IL-6 is a mediator of the acute phase response and can be produced by astrocytes 
exposed to HIV (Nitkiewicz et al., 2017). Studies show that IL-6 is increased in the CSF 
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(Airoldi et al., 2012) as well as blood (Ancuta et al., 2008; Kamat et al., 2012a) of 
neurocognitively impaired PLWH.  
IL-7  IL-7 is a non-redundant cytokine in T-cell development and function (Elkassar and 
Gress, 2010). Higher blood IL-7 levels in mothers with HIV were associated with lower 
composite scores for language in HIV exposed uninfected children (24-28 months) 
(Sevenoaks et al., 2020). 
IL-8  IL-8 is the primary cytokine involved in neutrophil chemotaxis (Bickel, 1993). IL-8 may 
be increased by astrocytes in a gp120 mediated pathway  (Shah and Kumar, 2010). IL-
8 CSF levels were significantly higher in PLWH and HAND (Yuan et al., 2013). 
IL-10 IL-10 is an anti-inflammatory cytokine and maintains the balance of the immune 
response, allowing the clearance of infection while minimizing damage to the host 
(Iyer and Cheng, 2012). In brain-derived macrophages infected with HIV-1 and treated 
with raltegravir, IL-10 was one of the cytokines that remained detectable in samples 
(Tatro et al., 2014). Blood IL-10 levels were significantly associated with several 
domains of neurocognitive function (Cohen et al., 2011; Krebs et al., 2016). 
IL-12  IL-12 is a heterodimeric pro-inflammatory cytokine that regulates T-cell and natural 
killer-cell responses. Further, it induces the production of IFN-γ, favours the 
differentiation of TH1 cells and is an important link between innate resistance and 
adaptive immunity (Liu et al., 2005). CSF IL-12 levels were significantly higher in PLWH 
with a CD4+ count of <200 cells/μL (Abassi et al., 2017), however, significant findings 
for its association with HAND remain limited.  
IL-13  IL-13 is an immunoregulatory cytokine (Khurana Hershey, 2003). It regulates the 
function of human B cells and monocytes (McKenzie et al., 1993). At this stage, 
significant associations of IL-13 and HAND remains limited. 
IL-16  IL-16 is a pleiotropic cytokine acting as a chemoattractive and modulating factor of T 
cell activation (Hermann et al., 1999). Serum concentrations of IL-16 were significantly 
associated with slower processing speed, independently of body mass index (Okafor 
et al., 2017). 
IL-17  IL-17 is a key proinflammatory cytokine that links T cell activation to neutrophil 
mobilization and activation (Zenobia and Hajishengallis, 2015). In a recent study, no 
associations were found between IL-17 levels from peripheral blood mononuclear 
cells and HIV-associated neurocognitive impairment (Swanta et al., 2020). 
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IL-18  IL-18 is a pro-inflammatory cytokine and an important simulator of antigen-activated 
Th1 cells (Dinarello, 2000). Higher IL-18 levels were related to HIV-associated 
neurocognitive impairment (Correia et al., 2013). 
IL-1β  IL-1β is a potent pro-inflammatory cytokine that is responsible for host defense and 
responses. IL-1β is increased by HIV infection and aging (Kreuzer et al., 1997; Scully et 
al., 2016; Wiercińska-Drapalo et al., 2004). A more recent study by Festa and 
colleagues convincingly suggest that IL-1β functions as a key neuroinflammatory 
constituent in the pathogenesis of HIV-associated neurocognitive impairment (Festa 




M-CSF is a hematopoietic growth factor controlling survival, proliferation, and 
differentiation as well as other functions of cells of the monocyte/macrophage 
lineage (Rappaport and Volsky, 2015). Several studies have now investigated the 
association of M-CSF and HAND, however, majority of the studies have not reported 




MIP-1α is a chemotactic chemokine secreted by macrophages and functions in the 
recruitment of cells and inflammation(Bhavsar et al., 2015). In conjunction with HIV 
Tat, MIP is involved in the pathogenesis of HAND (Bonwetsch et al., 1999). 
MIP-1β (CCL4) MIP-1β/CCL4 is chemotactic for monocytes, T cells, and Natural Killer cells (Maurer 
and Von Stebut, 2004). Evidence supports the neuroprotective properties of MIP-1β 





Matrix metalloproteinases (MMPs) have found to regulate neuroinflammation, blood-
brain barrier (BBB) damage and cell migration(Rempe et al., 2016). MMP-1 levels 
were associated with HIV-associated neurocognitive impairment (Li et al., 2013), 
microstructural brain alterations and the degree of atrophy in PLWH (Li et al., 2013; 
Ragin et al., 2009).  
MMP-2  MMP-2 is a type IV collagenase which is elevated in the CSF of PLWH and HAD 
(Conant et al., 1999).  
MMP-7  MMP-7 is associated with breakdown of the BBB and leukocyte infiltration of the CNS 
(Anthony et al., 1998). 
MMP-9  MMP-9 is responsible for remodeling of processes involved in inflammation, degrades 
extracellular matrix proteins and activates cytokines and chemokines (Yabluchanskiy 
et al., 2013). MMP9 is increased in HIV infection via pro-inflammatory pathways 
 124 
(Missé et al., 2001). It is directly involved in BBB disruption (Takata et al., 2011) and 
increased levels in serum (Barr et al., 2010) can be used as an indication of BBB 
damage (Niebroj-Dobosz et al., 2010). 
MMP-10  MMP-10 is expressed by macrophages in numerous tissues after injury. Further, it 
moderates inflammation by controlling macrophage activation (McMahan et al., 
2016) and has been associated with HIV-associated neurocognitive impairment and 
structural brain changes in PLWH (Li et al., 2013). 
Osteopontin (OPN) OPN is a cytokine-like phosphoprotein that is increased in the brain, CSF and blood of 
people with neurodegenerative disorders including Parkinson’s (Maetzler et al., 
2007), Alzheimer’s (Wung et al., 2007), Multiple Sclerosis (Comabella et al., 2005) and 
HAND (Brown, 2012).  
Progranulin (PGRN)  PGRN is a soluble factor that regulates cell proliferation, motility and inflammation 
(Suh et al., 2014). PGRN has a potential role in HIV-associated CNS pathologies and 
neurocognitive impairment (Suh et al., 2014). 
Soluble tumour 
necrosis factor (TNF) 
receptor (sTNFR)-I 
sTNFR’s are the cleaved-off extracellular domains of transmembrane TNF receptors. 
Blood sTNFR-I is higher in neurocognitively impaired PLWH (Ryan et al., 2001). 
sTNFR-II  sTNFR-II is an inflammatory cytokine that is elevated in blood and CSF of PLWH. 
Further, its levels are associated with HIV-associated neurocognitive impairment 




SDF-1α is a chemokine which belongs to the subfamily of CXC-chemokines. It was 
shown that SDF-1α is present in the HIV brain and offers neuroprotective properties 
(Langford et al., 2002) 
Transforming growth 
factor (TGF)-β1  
TGF-β1is a potent modulator of immune and glial cells. TGF-β1 exerts anti-
inflammatory effects in the HIV-positive brain and play a neuroprotective function 
(Dhar et al., 2006). An inverse correlation between TGF-β1 and dementia in HIV has 
been reported (Perrella et al., 2001). 
TGF-β2  TGF-β2 is part of the TGF-β family of cytokines which regulates cell proliferation, 
differentiation, recognition, and death via serine/threonine kinase activity receptors 
(Zhang et al., 2017). Thus far, the studies investigating the association of TGF-β2 with 





ligand (TRAIL)  
TRAIL is a type II transmembrane protein belonging to the TNF superfamily (Thorburn 
et al., 2008). TRAIL is expressed on the surface of natural killer and T cells, 
macrophages, and dendritic cells (Thorburn, 2007). TRAIL levels were also considered 
to be specific predictors of cognitive impairment in HIV positive women (Rubin et al., 
2018). 
TNF-α TNF-α is an inflammatory cytokine produced by macrophages/monocytes during 
acute inflammation and is responsible for a diverse range of signalling events within 
cells, leading to necrosis or apoptosis (Idriss and Naismith, 2000). TNF has been 
extensively studied for its role in HAND, with higher levels detected in the brain, CSF 





BBB: Blood-brain barrier, CCL: Chemokine ligand, CNS: Central nervous system, CRP: C-reactive protein, CSF: Cerebrospinal fluid, CXCL: Chemokine (C-X-C motif) ligand, 
EPO: Erythropoietin, HAD: HIV-associated dementia, HAND: HIV-associated neurocognitive disorders, IFN: Interferon, IL: Interleukin, IP-10: IFN- gamma-induced protein 10, 
M-CSF: Macrophage colony-stimulating factor, MIP: Macrophage inflammatory protein, MMP: Matrix metalloproteinases (MMP), OPN: Osteopontin, PGRN: Progranulin, 
PLWH: People living with HIV, RANTES: Regulated upon Activation Normal T Cell Expressed and Presumably Secreted, sCD: Soluble cluster of differentiation, SDF: Stromal 









Table 2: Quality assessment of studies 
 
Reference Question 1 Question 2  Question 3 Rating  
*(Airoldi et al., 2012) 1 2 2 Intermediate 
(Ancuta et al., 2008) 1 2 2 Intermediate  
(Brown et al., 2011) 2 2 1 Intermediate 
*(Burdo et al., 2013) 2 2 1 Intermediate 
(Cohen et al., 2011) 2 2 1 Intermediate 
(Correia et al., 2013) 2 0 1 Low  
*(D’Antoni et al., 2018) 2 2 2 High 
(De Oliveira et al., 
2015) 
2 2 2 High 
(Falasca et al., 2017) 2 2 2 High 
(Imp et al., 2017) 2 2 1 Intermediate 
(Kamat et al., 2012) 2 2 1 Intermediate  
*(Krebs et al., 2016) 2 2 2 High 
(Gougeon et al., 2017) 2 2 1 Intermediate  
*(Lentz et al., 2010) 1 2 2 Intermediate 
(Li et al., 2013) 1 2 1 Intermediate 
(Lyons et al., 2011) 2 2 1 Intermediate 
*(Marcotte et al., 2013) 2 2 1 Intermediate 
*(Monnig et al., 2017) 2 2 1 Intermediate 
(Montoya et al., 2019) 2 2 2 High 
*(Rubin et al., 2018) 2 2 1 Intermediate 
(Ryan et al., 2001) 0 2 1 Low  
(Sakoda et al., 2017) 2 2 1 Intermediate 
*(Sevigny et al., 2004) 2 2 2 High 
(Suh et al., 2014) 2 2 1 Intermediate  
(Sui et al., 2007) 0 2 1 Low 
(Sun et al., 2010) 2 2 1 Intermediate  
*(Valcour et al., 2015) 2 1 2 Intermediate 
(Woods et al., 2006) 2 1 1 Intermediate 
(Woods et al., 2010) 2 2 1 Intermediate 
(Xing et al., 2017) 2 2 1 Intermediate 
(Yuan et al., 2015) 1 2 1 Intermediate 
(Yu et al., 2017) 2 2 1 Intermediate 
*Longitudinal studies. Questions 1-3 were classified as follows: (1) Did the study report on potential 
confounders such as substance misuse, comorbid conditions (e.g. Hepatitis C (HCV)), neurological 
conditions and psychiatric disorders and were these controlled for upon statistical analysis? (2) Did 
the study utilize a test battery of at least 5 domains of function commonly affected by HIV? (3) Did the 
study report on the current regimen of ART and the duration of treatment before the assays were 
done for cross-sectional studies? For longitudinal studies, did the study report on the current regimen 
of ART and the duration of treatment between each time point? Each question was rated for 0=no, 
1=partly and 2=yes. Studies that addressed all of the quality questions and had a total rating of 6 were 
classified as high quality. Studies with a rating between 3 and 5 were considered as intermediate 




Table 3: Studies reporting a relationship with HIV-associated neurocognitive performance when 
stratified according to CD4 count 
Reference <200 cells/μl >200 cells/μl Association with HAND 
Yes No 
(Ancuta et al., 2008) ✓  ✓  
*(Airoldi et al., 2012) ✓   ✓ 
(Brown et al., 2011) ✓   ✓ 
*(Burdo et al., 2013)  ✓ ✓  
(Cohen et al., 2011)  ✓ ✓  
(S. Correia et al., 2013)  ✓ ✓  
*(Michelle L D’Antoni 
et al., 2018) 
 ✓  ✓ 
(De Oliveira et al., 
2015) 
 ✓  ✓ 
(Falasca et al., 2017)  ✓ ✓  
(Kamat et al., 2012) ✓  ✓  
*(Krebs et al., 2016)  ✓ ✓  
(Gougeon et al., 2017)  ✓  ✓ 
*(Lentz et al., 2010)  ✓  ✓ 
(Li et al., 2013)  ✓ ✓  
(Lyons et al., 2011) ✓  ✓  
 (Montoya et al., 2019)  ✓  ✓ 
*(Rubin et al., 2018)  ✓ ✓  
(Ryan et al., 2001) ✓  ✓  
(Sakoda et al., 2017)  ✓  ✓ 
(Suh et al., 2014)  ✓  ✓ 
(Sui et al., 2007)  ✓ ✓  
(Sun et al., 2010)  ✓  ✓ 
(Woods et al., 2006)  ✓ ✓  
(Xing et al., 2017) ✓  ✓  
(Yuan et al., 2015) ✓  ✓  
(Yu et al., 2017)  ✓  ✓ 










Table 4: Studies reporting a relationship with HIV-associated neurocognitive performance when 
stratified according to viral suppression  
Reference Virally suppressed  Non-virally 
suppressed 
Association with HAND 
Yes No 
(Ancuta et al., 2008)  ✓ ✓  
*(Airoldi et al., 2012) ✓   ✓ 
(Brown et al., 2011)  ✓  ✓ 
*(Burdo et al., 2013) ✓  ✓  
(Cohen et al., 2011) ✓  ✓  
(S. Correia et al., 2013) ✓  ✓  
*(Michelle L D’Antoni 
et al., 2018) 
✓   ✓ 
(De Oliveira et al., 
2015) 
✓   ✓ 
(Falasca et al., 2017) ✓  ✓  
(Imp et al., 2017)  ✓  ✓  
(Kamat et al., 2012)  ✓ ✓  
*(Krebs et al., 2016)  ✓ ✓  
(Gougeon et al., 2017) ✓   ✓ 
*(Lentz et al., 2010)  ✓  ✓ 
(Li et al., 2013)  ✓ ✓  
(Lyons et al., 2011)  ✓ ✓  
*(Marcotte et al., 
2013) 
✓   ✓ 
*(Monnig et al., 2017) ✓  ✓  
 (Montoya et al., 2019) ✓   ✓ 
*(Rubin et al., 2018) ✓  ✓  
(Ryan et al., 2001)  ✓ ✓  
(Sakoda et al., 2017) ✓   ✓ 
(Suh et al., 2014)  ✓  ✓ 
(Sui et al., 2007)  ✓ ✓  
(Sun et al., 2010)  ✓  ✓ 
(Woods et al., 2006) ✓  ✓  
(Woods et al., 2010) ✓   ✓ 
(Xing et al., 2017)  ✓ ✓  
(Yuan et al., 2015)  ✓ ✓  
(Yu et al., 2017) ✓   ✓ 
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Dysregulated expression of neuro-immune markers has previously been linked to 
HIV-associated neurocognitive impairment. We undertook an exploratory approach 
in a South African cohort, investigating the association between eight immune 
markers and neurocognitive performance in 99 people living with HIV (PLWH) and 51 
HIV-negative participants. Markers were selected on preliminary and putative 
evidence of their link to key neuro-immune functions. Cognitive performance was 
established using a battery of tests sensitive to HIV-associated neurocognitive 
impairment, with domain-based scores utilized in analysis. The markers thymidine 
phosphorylase (TYMP) and neutrophil gelatinase-associated lipocalin (NGAL) were 
significantly higher while matrix metalloproteinase (MMP)9 was significantly lower in 
PLWH. Our results further showed that in PLWH, worse psychomotor processing 
speed was associated with higher TYMP and NGAL levels and worse motor function 
was associated with higher NGAL levels. Future studies should explore the 















HIV-associated neurocognitive impairment occurs in up to 50% of the HIV-infected 
population (Heaton et al., 2010). HIV-1 invades the brain through a “Trojan Horse” 
method by crossing the blood-brain barrier (BBB) through infected monocytes that 
later differentiate into macrophages (González-Scarano and Martín-García, 2005). 
This triggers an inflammatory response, which is considered to be a crucial 
contributor to the neuropathogenesis of HIV-associated neurocognitive impairment 
(Beck et al., 2015; Jones et al., 2016). In human studies, associations of increased 
pro-inflammatory markers in peripheral blood with cognitive impairments in HIV 
further support the involvement of a dysregulated immune system in cognitive 
impairment in HIV (Cohen et al., 2011; Correia et al., 2013; Yuan et al., 2013)  
 
Damage to the BBB is another common hallmark of HIV-associated neurocognitive 
impairments (Banks et al., 2006). BBB damage allows for the further recruitment of 
infected cells into the brain (Banks et al., 2006). Differential expression of BBB 
integrity markers in blood and CSF (e.g. MMP9 and s100-β) correlated with 
neurocognitive impairment in HIV participants (Abassi et al., 2017; Li et al., 2013; 
Xing et al., 2017). Therefore, a dysregulated expression of immune markers may 
contribute to the development of HIV-associated neurocognitive impairments. 
Efforts in elucidating the neuro-immune response of HIV-associated neurocognitive 
impairment have to date largely been centered on investigation of monocyte 
activation markers (Burdo et al., 2013; Imp et al., 2017; Kamat et al., 2012; Lyons et 
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al., 2011; McGuire et al., 2015) and pro-inflammatory markers (e.g. TNF-α) (Brabers 
and Nottet, 2006; Wesselingh et al., 1997). 
 
The systematic review (Chapter 2) suggests that an aberrant immune regulation is a 
key characteristic of HAND. However, low to moderate effect sizes in their 
associations with HAND and inconsistencies between studies (Cohen et al., 2011; 
Kamat et al., 2012; Marcotte et al., 2013; Montoya et al., 2019; Rubin et al., 2018; 
Ryan et al., 2001) suggest that further investigations on new immune markers are 
warranted. Here, we aimed to explore the associations between several immune 
markers and neurocognitive performance in HIV (subtype C) participants that were 
treatment naïve or had only recently started combination antiretroviral therapy 
(cART) (< 1 month) to elucidate the inflammatory profile without the confounding 
effects of cART on neuronal health. Specifically, to investigate the association 
between these markers and neurocognitive domains commonly affected by HIV 
(Butters et al., 1990). Furthermore, a systematic review and meta-analysis indicate 
that globally, a large percentage of patients do not adhere to treatment (Uthman et 
al., 2014), making this population interesting for further investigation. Majority of 
longitudinal studies also report that with the introduction of cART, the first neuro-
immune responses are noted at durations greater than 3 months (Hattab et al., 
2014; Krebs et al., 2016; Richert et al., 2017). This population represents participants 
with a higher risk of developing dementia and therefore this study may provide an 
opportunity to investigate the immune response in these individuals.  
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The markers monocyte chemoattractant protein-1/C-C motif ligand 2 (MCP-1/CCL2), 
transforming growth factor (TGF)-β, matrix metalloproteinase (MMP)9, vascular 
endothelial growth factor (VEGF), thymidine phosphorylase (TYMP) and neutrophil 
gelatinase-associated lipocalin (NGAL) were selected for investigation based on their 
potential involvement in the pathophysiology of neurocognitive impairments in HIV, 
as identified from the scientific literature. As shown in other neurodegenerative 
disorders and HIV preclinical studies, these markers are involved in pathways of 1) 
inflammatory induced neuronal dysfunction and 2) BBB damage (Supplementary 
Table 1). Similarly, these markers may have a functional role in pathways related to 
the development of HIV-associated neurocognitive impairments. A literature 
summary of the potential neurobiological function of these markers are presented in 
Supplementary Table 1  
 
3.2. Methods 
3.2.1. Study participants:  
This study included n = 99 HIV-positive and n = 51 HIV-negative participants, which 
were pooled from two independent studies. Cohort 1 (Joska et al. 2011) included 56 
HIV-positive participants from a study which characterized HAND among South 
African PLWH. Cohort 2 included 43 HIV-positive participants from an ongoing study 
that is investigating the effects of heavy drinking on HIV-associated neurocognitive 
impairments. PLWH included in this study were previously recruited from primary 
health care clinics in Cape Town and the Western Cape region of South Africa. PLWH 
completed at least one study visit, which included a detailed sociodemographic, 
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medical and neuropsychological assessment as well as the relevant laboratory 
measures (including viral load and CD4 count). HIV serostatus was confirmed by two 
independent rapid tests and confirmed via ELISA analysis. In addition, 51 HIV-
negative control participants recruited from local voluntary counseling and testing 
clinics as part of the ongoing study were included in this study for comparison 
purposes. Participants included in this study ranged from 18 through 65 years in age 
with at least 7 years of formal education, across both cohorts. PLWH were treatment 
naïve or had only recently started cART (< 1 month) prior to neurocognitive 
measurements and blood collection. Cases were excluded from this study if they had 
1) severe psychiatric disorder or presented any other neurological disorder, 2) 
substance abuse (other than alcohol) and 3) moderate to severe head injury.  
 
Participation was voluntary, and individuals were informed that they could withdraw 
from the study at any time. Written informed consent was obtained following a 
thorough explanation of the study procedures. This study was approved by the 
Human Research Ethics Committee of the Faculty of Health Sciences (University of 
Cape Town) (Sub-study HREC 213/2018 linked to primary studies: 003/2015, 
023/2008 and 263/2007). Individuals received financial compensation for their time. 
Bloods were obtained at the same visit when measures for neurocognitive 





3.2.2. Neurocognitive measures:  
 
The presence of HIV-associated neurocognitive impairment was assessed with a 
detailed battery. All participants were tested in their home language and all 
instruments had their instructions and content translated into isiXhosa and 
Afrikaans. Instructions were also back-translated for fidelity. The test battery 
represents measures of domains typically affected by HIV (Butters et al., 1990) and 
encompassed several domains of cognitive function. The specific scores used for 
each domain were acquired from the following neuropsychological measures: 
Processing speed (WAIS-III Digit symbol, WAIS-III Symbol search, Colour trails I 
Stroop Colour) (Golden, 1975), verbal (Animal Fluency) (Acevedo et al., 2000), 
learning (the Hopkins Verbal Learning, Brief Visuospatial Memory Test) (Benedict et 
al., 1998), memory (HVLT Delayed recall, BVMT Delayed recall), motor functioning 
(Groove peg board Dominant, Groove peg board Non-dominant) (Klove 1963) and 
executive functioning (Colour trails II) (D’Elia et al., 1996). The raw 
neuropsychological test scores were standardized using data from the HIV-negative 
control participants to calculate z-scores. Z-scores were then averaged to create 6 






3.2.3. Laboratory assessment of blood 
 
Blood samples for all study participants were collected into tubes via venipuncture. 
Serum tubes were kept at room temperature for 30 minutes to allow for clotting. 
Plasma EDTA tubes were kept on ice for 30 min until centrifugation. Serum and EDTA 
tubes were subsequently centrifuged at 2,500 × g. Serum and plasma were then 
aliquoted into cryo vials and immediately stored at -80 °C until analyses. HIV viral 
load was determined by the CAP/Roche Cobas Ampliprep (sampled post-2015) and 
the Abbott M2000SP and M2000RT (sampled prior to 2015) methods. The CD4 count 
was determined by PanLeucogate (PLG) (Beckman Coulter FC500MPL) method. 
 
All immune markers were measured using Enzyme-linked Immunosorbent Assays 
(ELISA) (R&D systems, DuoSet ELISA) according to the manufactures instructions. 
CCL2, VEGF and TYMP were measured in serum. TGF-β1, IL-1β, IFN-γ, MMP9 were 
measured in plasma. Samples were diluted as follows MCP-1/CCL2: 1:2, TGF-β1: 
1:30, IL-1β: no dilution, IFN-γ: no dilution, MMP9: 1:150, VEGF: no dilution, TYMP: 
1:10 and NGAL: 1:100. All samples were assayed in duplicate. The intra- and inter-
assay coefficients of variation for all tests were within acceptable ranges of < 8% and 





3.2.4. Other potential covariates 
 
Years of completed formal education and age were included as covariates in models 
of the association of immune system markers and cognitive function. In addition, 
given the presence of heavy drinkers in cohort 2, and the observation that chronic 
excessive alcohol consumption may affect both the immune system and cognitive 
function in people with HIV (Meyerhoff, 2001), problematic drinking was also 
included as a covariate. Hazardous drinking was operationalised as more than 5 
standard drinks per occasion over a 2-week period for 3 months prior to the marker 
assays, as assessed using the timeline follow-back calendar questionnaire. A further 
description of the cohort is described in the supplementary file (Table 2).  
 
3.2.5. Statistical analyses:  
 
All analyses were conducted using SPSS (version 25, IBM, USA). P - values were 
considered statistically significant for all analyses at a value of less than .05. Data 
distribution for markers NGAL, CCL2 and TGF- β1 were found to be skewed, 
therefore the data was log transformed prior to statistical analyses. MMP9, TYMP 
and VEGF demonstrated normal data distribution with acceptable skewness and 
kurtosis. IL-1β and INF-γ were below the detectable ranges in serum for all samples 
and omitted from further analyses. Unpaired t-test analyses were performed to 
investigate differences in the levels of plasma/serum markers between PLWH and 
HIV-negative study participants. Analyses of covariance (ANCOVA) with levels of 
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immune markers as dependent variables were subsequently performed to analyze 
the levels of the immune markers PLWH and HIV-negative study participants, 
adjusted for age, sex, education, cohort and alcohol use. Exploratory analyses were 
done with Pearson correlations to investigate associations between the immune 
markers with the cognitive domains in PLWH and HIV-negative respectively. A 
Bonferroni correction was accounted for the number of cognitive domains tested 
(α/n = .05/6 = .008). Subsequently, separate regression models were conducted to 
examine the associations between cognitive functions and marker concentrations, 
after adjusting for the following covariates individually: demographics (age, sex and 
education), cohort (cohort, heavy drinkers) and HIV-positive disease parameters 
(nadir CD4 count, and viral load). 
 
3.3. Results 
3.3.1. Sample characteristics:  
 
The study population included a total of n=150 participants which comprised of n = 
99 PLWH and n = 51 HIV-negative controls. PLWH had a mean age of 33.88 years and 
36% were female. The HIV-positive group had a median nadir CD4 count of 305 (159 
- 414.5) cells/μl and viral load of 3.91 (2.853 - 4.69) log copies/ml. From the PLWH, n 
= 19 had been on treatment for less than one month upon sample collection, with 
the remainder cART naïve. The two cohorts differed with respect to mean age, 
gender composition and current CD4 count. Differences between mean age and 
gender were controlled for upon statistical analysis. Sample characteristics are 
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summarized in Table 1. Information on the sample characteristic of the separate 
cohorts is presented in the supplementary file (Table 2). The effect of drinking habits 
on cognitive performance in either HIV-negative controls or PLWH in the second 
cohort was evaluated. No significant differences between the heavy drinkers vs. 
non/light drinkers in either the HIV-negative control group or the PLWH were found 
for any of the cognitive domains tested (all p-values were greater than .1) (results 
not shown).   
 
Table 1. Characteristics of HIV-negative and HIV-positive study participants.   





Age years mean (SD) 37.51 (9.07) 33.88 (6.91) .01 
Sex, female N (%) 27 (52.9) 36 (36.4) .051 
Education, years (SD) 10.28 (1.55) 10.50 (1.30) .38 
CD4 + nadir, median (IQR) - 305 (159 -414.5) - 
Viral load log copies/mL 
median (IQR) 
- 3.91 (2.853 - 4.69) - 
Heavy drinkers, N (%) 26 (51.0) 18 (18.2) < .001 
Abbreviations: Interquartile range (IQR), Standard deviation (SD) 
 
3.3.2. Immune markers in HIV-positive versus HIV-negative participants.   
 
Bivariate analyses revealed that TYMP (p < .001) and CCL2 (p = .027) were 
significantly higher whereas MMP9 (p = .007) was lower in PLWH relative to controls 
(Figure 1). TYMP remained significantly higher (p < .015) and MMP9 significantly 
lower (p = .005) in PLWH after controlling for age, sex, education and alcohol use 
with ANCOVA. CCL2 was no longer significantly higher (p = .78) in PLWH after 
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controlling for these covariates. After controlling for these variables, the difference 
in NGAL level was statistically significant between the two groups (p = .046). 
 
 
Figure 1. Concentrations of immune markers between HIV-negative and HIV-positive 
study participants. NGAL, CCL2 and TGF- β1 were ln-transformed and for 
interpretation purposes presented means were back-transformed. Bars indicate the 
mean protein concentrations in the different study groups and are expressed as 





3.3.3. Association of immune marker levels and cognitive performance in HIV-
negative participants.  
 
After applying Bonferroni corrections of p = .05/6, higher levels of TGF-B1 were 
associated with better performance in processing speed in HIV-negative participants 
(p = .008) (Table 2) (unadjusted). Linear regression analyses with covariates; 1) 
alcohol use and 2) demographics (age, sex and education) were controlled for. After 
controlling for 1) alcohol use only (B = .367, SE = .149, β =.391, p = .019) and 2) 
demographics (B =.172, SE =.148, β = .171, p = .25) the association was attenuated.  
 
Table 2. Pearson correlations between immune markers and composite cognitive 
domain scores (through averaging Z scores of specific within-domain tests) in HIV-
negative participants  
 TYMP VEGF MMP9 CCL2 NGAL TGF-Β1 
Cognitive domain       
Processing speed -.118 .053 .101 .047 -.189 .425a 
Verbal  -.086 -.250 -.154 .041 -.159 -.007 
Learning -.211 -.048 -.027 .002 -.163 .021 
Memory  -.122 -.072 .123 -.142 -.167 .166 
Motor Functioning .187 .119 .085 .210 .117 -.227 
Executive function .098 -.061 .028 .042 .061 -.078 
a p = .008.  
 
3.3.4. Association of immune marker levels and cognitive performance in PLWH 
 
After applying Bonferroni corrections of p = .05/6, higher TYMP (p = .001) and NGAL 
(p = .007) levels were associated with worse processing speed and higher NGAL 
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levels with worse motor functioning (p = .002) in PLWH (Table 3). Further analyses 
were performed for these markers after adjusting for the covariates, age, sex, 
education, alcohol use, nadir CD4 count, cohort and HIV viral load (Table 4). The 
association between TYMP and NGAL with neurocognitive performance remained 
after correcting for demographics, cohort, alcohol use and HIV disease parameters 
(Table 4).  
 
Table 3. Pearson correlations between immune markers and composite cognitive 
domain scores (through averaging Z scores of specific within-domain tests) in PLWH 
 TYMP VEGF MMP9 CCL2 NGAL TGF-Β1 
Cognitive domain       
Processing speed -.340a -.136 -.025 -.101 -.285b .049 
Verbal  -.100 -.101 -.046 -.134 -.061 -.034 
Learning -.012 -.257c .208d .176 -.049 -.012 
Memory  .014 -.186 .025 .120 -.016 -.015 
Motor Functioning .178 .061 .007 .130 .329e -.026 
Executive function .132 .180 .106 .091 .146 .089 
ap = .001, bp = .007, cp = .011, dp = .043, ep = .002. 
 
Table 4. Association of TYMP and NGAL with cognitive performance, including 
covariates in PLWH. 
 TYMP and Processing speed NGAL and Processing 
speed 
NGAL and motor functioning 
 B (SE) β p B (SE) β p B (SE) β p 
Unadjusted -.013 (.004) -.34 .001 -.37 (.134) -.285 .007 .602 (.182) .329 .002 
Model 1 -.014 (.004) -.37 .001 -.463 (.128) -.358 .001 .611 (.180) .350 .001 
Model 2 -.013 (.004) -.33 .003 -.362 (.142) -.279 .012 .690 (.190) .377 <.001 
Model 3 -.014 (.005) -.319 .010 -.533 (.172) -.375 .003 .615 (.269) .279 .025 
Model 1: adjusted for demographics; age, sex and education. 
Model 2: adjusted for cohort; cohort, heavy drinkers. 
Model 3: adjusted for HIV-positive disease parameters; nadir CD4 count, and viral load 
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3.4. Discussion  
 
In this exploratory study, we investigated the serum and plasma levels of several 
immune markers and their associations with domain-based neurocognitive 
performance. We found significantly higher levels of TYMP and NGAL, and 
significantly lower levels of MMP9 in PLWH compared to HIV- controls, after 
controlling for age, sex, education, and alcohol use. Furthermore, in PLWH, we found 
that after controlling for age, sex, education, alcohol use, CD4 count, cohort and viral 
load, higher TYMP levels were associated with worse processing speed and higher 
NGAL levels were associated with worse processing speed and motor functioning.  
 
The current study is the first to our best knowledge to investigate peripheral 
circulating TYMP levels in PLWH. Changes to the neuroimmmunity in PLWH may 
contribute to the higher serum levels of TYMP demonstrated in this study. A 
microarray study of gene expression of TYMP across tissues reported that its 
expression is particularly high in CD14+ monocytes (Su et al., 2002). The TYMP gene 
expression was reported to be increased in primary monocytes of HIV patients with 
viremia (Wu et al., 2013). Moreover, CD14+ monocytes are increased in PLWH 
(Bowers et al., 2014) regardless of treatment status (Bowers et al., 2014; Mendez-
Lagares et al., 2013). CD14+ monocytes may account for the higher TYMP levels in 
patients with HIV.    
 
Evidence from basic science research may provide insights into the association of 
TYMP with neurocognitive performance, specifically in the domains of processing 
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speed. Generally, in a treatment naïve cohort, HIV replication is not controlled and a 
typical sub-cortical pattern of pathology is seen, with resulting impairment of 
processing speed and executive functions (Bell, 2004; Moore et al., 2006). A study on 
post mortem brain tissues from patients with HIV/ Tuberculosis Meningitis (TBM) 
demonstrated that the TYMP protein expression was further increased when HIV 
was present in patients with TBM (Kumar et al., 2012). It was further reported that 
TYMP co-localized with microglia (Kumar et al., 2012), indicating that activated 
microglia may produce TYMP in the HIV brain. In a study conducted by Chapouly and 
colleagues, it was demonstrated that TYMP was an important contributor to BBB 
disruption in brain cell cultures and in an experimental autoimmune encephalitis 
mouse model (Chapouly et al., 2015). Further studies are needed to elucidate the 
potential involvement of TYMP in BBB dysregulation in HIV. This is of interest since 
BBB damage may play an important function in the pathophysiology of 
neurocognitive impairment in HIV (Banks et al., 2006; Maubert et al., 2017).   
 
Higher plasma NGAL levels in PLWH have recently been reported in a clinical 
investigation (Morieri et al., 2018) and is supported by the significantly higher levels 
in PLWH reported in our study. Elevated serum and plasma NGAL has been 
associated with neurocognitive impairment in patients with mild cognitive 
impairment in Alzheimer disease (Choi et al., 2011) as well as in patients with acute 
ischemic cerebrovascular diseases (Elneihoum et al., 1996). This study further 
contributes to literature indicating that NGAL is an inflammatory marker that is 
associated with cognitive impairment (Choi et al., 2011). Our findings show that 
higher NGAL levels are associated with worse processing speed. In this regard, it was 
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previously demonstrated that higher plasma NGAL levels were associated with 
impaired verbal memory and processing speed in females with late-life depression 
(Naudé et al., 2014). Mounting evidence from investigations in cell cultures and 
animal models suggest that NGAL may contribute to neurobiological mechanisms 
that are involved in the neuropathology of neurocognitive impairments. NGAL may 
act on neuronal health by in inhibiting remyelination (Al Nimer et al., 2016) and 
neuronal survival (Bi et al., 2013). Demyelination or change in myelin structure, in 
turn, could contribute towards oligodendrocyte damage, resulting in desynchronized 
neural circuits and impaired information processing speed (Pajevic et al., 2014), 
which are common pathologies in HIV (Liu et al., 2016). NGAL may also be involved 
in motor functioning. Animal studies suggest that increased levels of NGAL may 
interfere with motor functioning (Jang et al., 2013) and BBB integrity (Egashira et al., 
2016). However, the neurobiological mechanisms of NGAL in HIV requires further 
investigation.  
Contradictory to previous findings (Lorenzl et al., 2008), here MMP9 was significantly 
lower in PLWH. This may be due to clinical studies largely investigated MMP9 in 
extended-duration treatment cohorts and cART may contribute to increased 
inflammatory levels. A HIV cART treatment cohort demonstrated higher MMP9 
levels compared to that of the treatment naïve cohort (Li et al., 2013). In addition, 
the study by Li and colleagues also found that MMP9 expression levels were very 
similar for HIV-negative participants (33,385pg/ml ± 16,230) and treatment naïve 
PLWH (35,073pg.ml ± 43,245) (Li et al., 2013). This may suggest that MMP9 levels 
may be affected by the extended use of cART.   
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In addition to the above, Southern Africa is largely a HIV subtype-C population 
(Wainberg, 2004), which has been linked to lower levels of neurotoxicity (Rao et al., 
2013). MMP9 investigations were largely done in subtype-B HIV cohorts (Kim et al., 
2014; Li et al., 2013; Sporer et al., 1998), which has been linked to increased 
prevalence of neurocognitive impairments (Langford et al., 2003) and increased 
neuroinflammatory levels (Gandhi et al., 2009; Wong et al., 2010). This has been 
largely attributed to the presence of a dicysteine motif in that Tat protein of 
subtype-B cohorts, which potentiates increased monocyte chemotaxis and increased 
neurotoxicity (Rao et al., 2013). It is, therefore, possible that MMP9 levels are 
affected by subtype differences as well as extended use of cART, potentially 
explaining the lower MMP9 levels in the PLWH from which our sample was drawn.   
A limitation of the present study is its relatively small sample size, which warrants 
replication in a larger sample size. The cohorts pooled for investigation in this study 
may have influenced the results. Participants were excluded if they presented with 
clinical signs of any other co-infections on history and clinical examination. However, 
potential confounding factors that were not screened out from this study, may in 
part, explain the outcomes reported in this study. Considering that a subset of 
participants were heavy drinkers, we performed a sub-analysis to determine the 
effects of heavy drinking on inflammatory profiles in our HIV-positive population. We 
demonstrated that there were no significant differences in inflammatory profiles for 
the HIV-positive non/light drinkers vs. HIV-positive heavy drinkers (Supplementary 
file, Table 3). Participants included in this study were either treatment naïve or only 
recently initiated treatment (<30 days). cART is also a contributor to dysregulated 
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inflammatory levels in PLWH(Shah et al., 2016). However, long-term treatment 
studies reported that in most cases, the first neuro-immune responses are noted at 
durations greater than 3 months (Hattab et al., 2014; Krebs et al., 2016; Richert et 
al., 2017). Serum IL-1β and IFN-γ were below the detectable ranges of the assays 
used in this study and therefore excluded from further statistical analyses. A number 
of the cognitive domains were only measured with a single neuropsychological test, 
whereas a larger number of neuropsychological tests per cognitive domain may 
increase the reliability and external validity of estimates presented here. The findings 
presented here may not apply to other HIV-1 subtypes (e.g. HIV-1 subtype-B), as 




This exploratory study shows that the immune markers TYMP and NGAL may be 
associated with neurocognitive impairment in PLWH. This is the first study to our 
knowledge to investigate the associations of TYMP and NGAL in neurocognitive 
impairments in patients with HIV. The results from this study indicate that TYMP and 
NGAL potentially are interesting targets for future fundamental and clinical 
investigations in HIV-associated neurocognitive impairments.  
 
These markers may be involved in the underlying neuropathological mechanisms of 
HAND. Previous studies have shown an association between peripheral inflammation 
and reduced brain volumes. However, the association of peripheral inflammation 
with brain cortical thickness and surface area remains unclear. In the next chapter 
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(Chapter 4), I aim to establish whether inflammation and in particular, TYMP and 
NGAL were related to regional cortical brain alterations. Findings in the next chapter 
may help to explain the associations of these markers with cognitive domains 
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3.7. Supplementary: Chapter 3 




CCL2 is a chemoattractant chemokine. Clinical studies suggest CCL2 increases 
with age (Blasko et al., 2005) and is associated with faster cognitive decline in 
dementia (Westin et al., 2012). Blood and CSF CCL2 is related to 
neurocognitive impairment in HIV (Yuan et al., 2013) and Alzheimer’s diseases 
(Lee et al., 2018). In an in vitro blood-brain barrier (BBB) model, migration of 




Transforming growth factor (TGF)-β1is potent modulator of immune and glial 
cells. TGF-β1 exerts anti-inflammatory effects in the HIV-positive brain and 
play a neuroprotective function (Dhar et al., 2006). An inverse correlation 
between TGF-β1 and dementia in HIV has been presented (Perrella et al., 
2001).  
Interleukin (IL)-1β Interleukin (IL)-1β is a potent pro-inflammatory cytokine that is responsible 
for host defense and responses. IL-1β is increased by HIV infection and aging 
(Kreuzer et al., 1997; Scully et al., 2016; Wiercińska-Drapalo et al., 2004). A 
more recent study by Festa and colleagues convincingly suggest that IL-1β 
functions as a key neuroinflammatory constituent in the pathogenesis of HIV-
associated neurocognitive impairment (Festa et al., 2015). 
Interferon (IFN)-γ Interferon (IFN)-γ is an inflammatory marker that plays a crucial role in the 
host immunity against viral and bacterial pathogens (Roff et al., 2014). IFN-γ 
has demonstrated a steady increase in HIV with associations with HIV-
associated neurocognitive disorders (Schrier et al., 2015) and extended age 
(Lee et al., 2014). IFN-γ has recently been reported to contribute to BBB 
dysfunction through blocking signaling of the Platelet-derived growth factor 
receptor beta (PDGFRβ) in human brain pericytes. PDGFRβ signaling is crucial 






Neutrophil gelatinase-associated lipocalin (NGAL) is a neuroinflammatory 
mediator that has been identified to influence neuronal health in pre-clinical 
studies. Specifically, activated astrocytes are able to release NGAL and exert 
neuronal toxicity (Bi et al., 2013). Animal models have reported that NGAL is 
upregulated in the brain by induction of lipopolysaccharides as well as after 
psychological stressors (Ip et al., 2011; Mucha et al., 2011). In a rodent model 
of cerebral ischemia, it was reported that NGAL is significantly upregulated in 
the hippocampus. In the same study with cell cultures, it was found that NGAL 
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exerted neurotoxic effects on hippocampal neurons and promoted 
neuroinflammation through activation of microglia (Kim et al., 2017). A 
clinical study demonstrated that serum NGAL levels are increased in patients 
with mild cognitive impairment (Choi et al., 2011). However, studies on the 




Metalloproteinase (MMP)9 is responsible for remodeling of processes 
involved in inflammation, degrades extracellular matrix (ECM) proteins and 
activates cytokines and chemokines (Yabluchanskiy et al., 2013). MMP9 is 
increased in HIV infection via pro-inflammatory pathways (Missé et al., 2001). 
It is directly involved in BBB disruption (Takata et al., 2011) and increased 
levels in serum (Barr et al., 2010) can be used as an indication of BBB damage 





Vascular endothelial growth factor (VEGF) is an angiogenesis growth factor 
crucial for the growth of blood vessels and the development of the adult 
nervous system (Toi et al., 1995). Serum VEGF-A is significantly increased in 
PLWH (Sporer et al., 2004). It also functions in BBB breakdown in 
neuroinflammatory disease (Argaw et al., 2012) and may function as a marker 




Thymidine phosphorylase (TYMP) is an endothelial cell growth factor involved 
in angiogenesis. The combination of increased VEGF-A and TYMP significantly 
promote BBB breakdown in cell culture and animal models (Chapouly et al., 
2015). In a clinical investigation of primary circulating monocytes in PLWH 
with controlled viremia (below detection level) versus HIV patients on HAART 
who experience viremia, the TYMP gene expression was upregulated in 
patients experiencing viremia in comparison to those with below detection 
level (Wu et al., 2013). HIV may be a contributor to the increased TYMP levels, 
as reported by an investigation of Tuberculosis Meningitis (TBM) and co-
infected TBM/HIV brain tissue. TYMP gene expression was increased by 3-fold 
in co-infected TBM/HIV tissue in comparison to TBM only tissue samples 










Table 2. Sample characteristics of the two cohorts used in this study. 
 
 Cohort 1 (n=56) Cohort 2 (n=94)  




    p-value 
Age years, mean (SD) 30.9 (4.73) 37.74 (7.43) 37.51 (9.07) <.001* 
Sex, female N (%) 6 (10.7) 30 (69.9) 27 (52.9) <.001# 
Education, years (SD) 10.41 (1.25) 10.68 (1.39) 10.28 (1.55) N.S. 
Current CD4, mean (SD) 273.00 (148.41) 400 (241.46) - .006 
Viral load, mean (SD) 33799.89 (63991.46) 59486.86 
(148238.86) 
- N.S. 
Heavy drinkers N (%) 0 (0) 18 (41.86) 26 (51.0) <.001$ 
HAART N (%) 0 (0) 19 (44.18) 0 (0) - 
 
For the description statistics of study participant demographics, analysis of variance (ANOVA) was 
performed for continuous variables (with a Tukey post-hoc test for pair-wise comparisons in case of 
an overall effect between the three groups for age, sex and education). Unpaired t-test was 
performed to evaluate differences in CD4 count and viral load. Pearson chi squared tests for 
categorical variables (heavy drinkers). * Cohort 1 HIV-positive vs. Cohort 2 HIV- and HIV-positive, p < 
.001. #Cohort 1 HIV-positive vs. Cohort 2 HIV- and HIV-positive, p < .001. $Cohort 2 HIV- vs. HIV-
positive. 
A subgroup of participants included in the study was from a larger study (cohort 2) that investigated 
the effects of heavy drinking and cognitive performance in HIV participants. These included n=25 HIV- 
non/light drinkers (self-reported consumption of less than 3 standard (14gm alcohol) drinks per 
occasion during the 3 months prior to the assay), n=25 HIV-positive non/light drinkers, n=26 HIV- 
heavy drinkers (> 5 standard drinks per occasion over a 2-week period for 3 months prior to the 










HIV-positive non/light drinkers 
(Mean ± SD) 
HIV-positive heavy 
drinkers. 
(Mean ± SD) 
p-value 
TYMP 14.53 (11.79) 27.78 (28.24) p =.304 
VEGF 60.42 (33.00) 90.46 (68.48) p = .728 
MMP9 60.30 (29.25) 64.13 (30.99) p = .429 
CCL2 68.28 (34.89) 99.15 (55.74) p = .096 
NGAL 66.12 (26.72) 70.47 (24.16) p = .103 
TGF-B1 6.52 (5.03) 5.58 (3.94) p = .897 
Independent sample t-test was performed to evaluate immune markers in HIV-positive non/light 
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A spectrum of cognitive impairments known as HIV-associated neurocognitive 
disorders (HAND) are consequences of the effects of HIV-1 within the central 
nervous system (CNS). Regardless of treatment status, an aberrant chronic neuro-
immune regulation is a crucial contributor to the development of HAND. However, 
the nature to which inflammation affects brain structures critical for cognitive status 
remains unclear. The present study aimed to determine associations between 
peripheral immune markers with cortical thickness and surface area. Participants 
included 65 treatment-naïve people living with HIV (PLWH) and 26 HIV-negative 
controls. Thickness and surface area of all cortical regions were derived using 
automated parcellation of T1-weighted images acquired at 3T. Peripheral immune 
markers included C-C motif ligand 2 (CCL2), matrix metalloproteinase (MMP)9, 
neutrophil gelatinase-associated lipocalin (NGAL), thymidine phosphorylase (TYMP), 
transforming growth factor (TGF)-β1 and vascular endothelial growth factor (VEGF) 
were measured using enzyme-linked immunosorbent assays. Associations between 
these markers with thickness and surface area of cortical regions were evaluated. A 
mediation analysis examined whether associations of inflammatory markers with 
cognitive functioning were mediated by brain cortical thickness and surface area. 
After controlling for multiple comparisons, higher NGAL was associated with reduced 
thickness of the bilateral orbitofrontal cortex in PLWH. The association of NGAL with 
worse motor function was mediated by the cortical thickness of the bilateral 
orbitofrontal region in PLWH. Taken together, this study suggests that NGAL plays a 
potential role in the neuropathophysiology of neurocognitive impairments of HIV. 
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4.1. Introduction  
 
HIV infection of the central nervous system commonly results in a spectrum of 
neuropsychological deficits known as HIV-associated neurocognitive disorder (HAND) 
(Clifford and Ances, 2013). HAND is classified according to the severity of 
neurocognitive impairment with milder forms occurring in up to 50% of the HIV-
infected population regardless of treatment status (Heaton et al., 2010). 
Neuroimaging studies have indicated that structural brain abnormalities are 
common features of HAND (O’Connor et al., 2018). Historically, HIV-neuroimaging 
studies focused on white matter hyperintensities and subcortical atrophy (Aylward 
et al., 1993; Navia et al., 1986). However, with successful antiretroviral therapy 
(ART), recent findings have shifted our understanding of the cognitive phenotype of 
HIV-associated neurocognitive impairments and suggest a mixed subcortical-cortical 
pattern linked to subcortical damage (Paul, 2019; Sacktor, 2018; Sacktor and 
Robertson, 2014). Similarly, HIV-1 related effects may directly target subcortical 
structures. However, cortical structures may be indirectly affected via several 
(inflammatory) mechanisms and observed as changes in cortical thickness and 
surface area. This coincides with an interest in understanding the mechanisms of 
HIV-1 cortical dysfunction.  
 
Despite the growing body of evidence, existing HIV-1 studies largely investigated 
cortical volumes (Ances et al., 2012; Cohen et al., 2010; Janssen et al., 2015; 
Kallianpur et al., 2013), with limited investigations into thickness and surface area. In 
the pre-ART era, a magnetic resonance imaging (MRI) study indicated that cortical 
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thickness is affected, in acquired immunodeficiency syndrome (AIDS) participants 
having 15% thinner primary sensory, motor and premotor cortices (Thompson et al., 
2005). A reduction in the prefrontal and parietal tissue correlated with cognitive-
motor deficits (Thompson et al., 2005). Therefore, investigations of cortical thickness 
and surface area may be a useful tool to study the associations of biological 
anomalies e.g. an increased inflammatory environment, with changes in brain 
structures that are affected by the neuropathophysiology of HIV-1. 
 
Previous investigations on HIV-1 subtype B (HIV-1B) infection have shown that 
peripheral inflammatory (C-C chemokine ligand (CCL)2, interleukin (IL)-1β, IL-6, IL-16, 
IL-18, interferon gamma-induced protein (IP)-10, macrophage inflammatory protein 
(MIP)-1β, and stroma cell-derived (SDF)-α) and monocyte activation marker (soluble 
cluster of differentiation (sCD)14 and sCD163) levels were associated with reduced 
brain volumes in several regions (Gongvatana et al., 2014; Ragin et al., 2010). 
However, associations of peripheral immune markers with thickness and surface 
area were not previously assessed in HIV-1 infection. This may be useful as it may 
provide insight into inflammatory mechanisms responsible for structural brain 
changes and cognitive status. Peripheral inflammation was found to mediate the 
relationship of cortical thickness and cognitive performance with metabolic disorders 
(Corlier et al., 2018; Kaur et al., 2015). Further, inflammation was related to cortical 
thinning in older age and schizophrenia patients (Jacomb et al., 2018; McCarrey et 
al., 2014). Similarly, inflammation may influence cortical thickness and surface area 
in HIV-1 infection and may provide insight into indirect inflammatory mechanisms 
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responsible for structural changes and cognitive status in people living with HIV 
(PLWH).  
 
Studies of immune markers and brain alterations primarily included study 
participants with HIV-1B and it is known that the neurovirulence of HIV-1 may differ 
between various subtypes (Santerre et al., 2019; Tyor et al., 2013). Pre-clinical cell 
culture studies suggest that inflammatory responses are higher in HIV-1B infection 
than in HIV-1 subtype C (HIV-1C) infection (Campbell et al., 2007; Gandhi et al., 2009; 
Ruiz et al., 2019; Wong et al., 2010). Therefore, there is a need to investigate the 
nature to which inflammatory markers may influence brain cortical thickness and 
surface area of PLWH in geographical locations that are primarily HIV-1C infected. 
This may provide insights into the underlying mechanisms of HAND for these 
geographical regions.  
 
CSF markers may be a more accurate representation of neuroinflammation and the 
CNS pathophysiology that is associated with or lead to HAND. Considering that to a 
certain extent, 1) peripheral inflammation may provide an indication of 
inflammation within the CNS ((Capuron and Miller 2011) and 2) the ease and limited 
invasiveness of obtaining peripheral blood, this creates a practical option to 
investigate peripheral immune markers that are associated with structural brain 
alterations and the development of HAND. Therefore, the identification of such 
peripheral immune markers may provide insights of mechanisms that may be active 
within the CNS, potentially those related to the development of HAND. 
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In a previous study (Chapter 3), we found significantly higher levels of thymidine 
phosphorylase (TYMP) and neutrophil gelatinase-associated lipocalin (NGAL), and 
significantly lower levels of matrix metalloproteinase (MMP)9 in PLWH compared to 
HIV-negative controls, after controlling for age, sex, education, and alcohol use 
(Williams et al. 2019). TYMP and NGAL were associated with worse processing speed 
and motor function in PLWH (Williams et al. 2019). TYMP (Chapouly et al., 2015) and 
NGAL (Choi et al., 2011; Elneihoum et al., 1996; Morieri et al., 2018; Naudé et al., 
2013) are immune markers that may be involved in the neuropathophysiology of 
neurodegenerative diseases. TYMP gene expression is increased in circulating 
monocytes of PLWH (Wu et al., 2013) and may be increased in the HIV-infected brain 
(Kumar et al., 2012). Furthermore, preliminary evidence suggests that TYMP may 
have a functional role in BBB damage (Chapouly et al., 2015). NGAL promotes a pro-
inflammatory phenotype and apoptosis in microglia (Lee et al., 2007), astrocytosis 
(Lee et al., 2009) and sensitizes neurons to neurotoxicity (Bi et al., 2013; Naudé et 
al., 2012). Therefore, TYMP and NGAL show promise in furthering our understanding 
of the neuropathophysiology of HAND (Williams et al. 2019).The present study builds 
on these initial findings, and for this reason, we selected these cognitive domains 
(processing speed and motor function) for further investigation. We, therefore, 
hypothesized that these markers may be associated with reduced cortical thickness 
and surface area in the brain regions that are involved with these cognitive functions 
(processing speed and motor function). In addition to TYMP and NGAL, we 
investigated additional peripheral markers based on putative evidence of their 
associations with HIV-1 neuropathology in both pre-clinical and clinical studies. 
Therefore, the current study aim was to determine the association of peripheral 
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immune markers (CCL2, TGF-β1, MMP9, VEGF, TYMP and NGAL) with the cortical 
brain integrity, quantified using 3T MRI  
 
4.2. Methods  
 
4.2.1. Study participants 
 
A subset of participants that had undergone neuroimaging analysis from the overall 
cohort (Chapter 3) were included in this study. This included n = 65 HIV-positive and 
n = 26 HIV-negative participants, which were pooled from two independent studies. 
Cohort 1 (Joska et al. 2011) included 48 HIV-positive participants without comorbid 
alcohol or illicit substance use disorder. Cohort 2 included 17 HIV-positive and 26 
HIV-negative participants, 23 of whom (15 HIV-negative and 8 HIV-positive) met the 
diagnostic criteria for alcohol use disorder. A subset of participants was included in a 
prior study of peripheral immune dysregulation and neurocognitive performance 
(Williams et al. 2019). PLWH were recruited from primary health care clinics in Cape 
Town and the Western Cape region of South Africa. Participants were aged 18 
through 65 years with at least 7 years of formal education. PLWH were treatment-
naïve or had only recently started cART (< 1 month) before blood collection and 
neuroimaging analysis. The HIV-negative control participants were recruited from 
local voluntary counselling and testing clinics. Demographical variables were 
collected for all participants and the relevant laboratory measures (viral load and 
CD4 count) were collected for PLWH. HIV status was confirmed by two independent 
rapid tests and confirmed via ELISA analysis. Participation was voluntary and written 
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informed consent was obtained following a thorough explanation of the study 
procedures. Individuals received financial compensation for their time. This study 
was approved by the Human Research Ethics Committee of the Faculty of Health 
Sciences (University of Cape Town) (Sub-study HREC 213/2018 linked to primary 
studies: 003/2015, 023/ 2008 and 263/2007). Exclusionary criteria included: 1) 
severe psychiatric disorders or presented any other neurological disorders, 2) illicit 
substance abuse, 3) moderate to severe head injury (history of head injury with a 
loss of consciousness exceeding 30 minutes) or 4) HIV-positive participants with 
clinical signs of any other co-infections on history and clinical examination. The MINI 
v.6 (Sheehan et al. 1998) and Kreek–McHugh–Schluger–Kellogg (KMSK) (Kellogg et al. 
2003) were administered to screen for substance abuse in the past 12 months. 
Alcohol use was classified as non/light drinkers (self-reported consumption of 2 or 
fewer standard (<14gm alcohol) drinks per occasion in a day over a period of 3 
months prior to the assay) and heavy drinkers (> 5 standard drinks per occasion over 
a 2-week period over a period of 3 months prior to the marker assays).  
 
4.2.2. Neurocognitive measures  
 
Neurocognitive performance was assessed with a detailed battery as described 
previously (Joska et al., 2011; Williams et al., 2019). Briefly, the test battery included 
processing speed (WAIS-III Digit symbol, WAIS-III Symbol search, Colour Trails I, 
Stroop Colour) (Golden, 1975), verbal (Animal Fluency) (Acevedo et al., 2000), 
learning (the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-
Revised) (Benedict et al., 1998), memory (HVLT-R Delayed recall, BVMT-R Delayed 
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recall), motor functioning (Groove pegboard Dominant, Groove pegboard Non-
dominant) (Klove 1963) and executive functioning (Colour Trails2) (D’Elia et al., 1996) 
that were used to create 6 composite indices (processing speed, verbal, learning, 
memory, motor and executive functioning) as previously described (Joska et al., 
2011; Williams et al., 2019) 
 
4.2.3. Laboratory assessment of blood  
 
Blood samples were collected via venipuncture at a study visit within a period of 1 
month prior to the scan visit. Blood samples for each participant were separated, 
and plasma and serum samples were immediately frozen and stored at -80°C. HIV 
viral load was determined by the CAP/Roche Cobas Ampliprep (sampled post-2015) 
and the Abbott M2000SP and M2000RT (sampled prior to 2015) methods. The CD4 
count was determined by PanLeucogate (PLG) (Beckman Coulter FC500MPL) 
method. Peripheral immune markers were selected for investigation based on 
putative evidence of their associations with HIV-1 neuropathology in both pre-
clinical and clinical studies. These included C-C motif ligand 2 (MCP-1/CCL2) (Cohen 
et al., 2011; Eugenin, 2006), matrix metalloproteinase (MMP)9 (Barr et al., 2010; 
Xing et al., 2017), neutrophil gelatinase-associated (NGAL) (Williams et al., 2019), 
thymidine phosphorylase (TYMP) (Williams et al., 2019), transforming growth factor 
(TGF)-β1 (Dhar et al., 2006; Perrella et al., 2001), and vascular endothelial growth 
factor (VEGF) (Argaw et al., 2012; Nag et al., 2002; Sporer et al., 2004). Blood 
concentrations of CCL2, TGF-β1, MMP9, VEGF, TYMP and NGAL were measured 
using the enzyme-linked immunosorbent assay (ELISA) (R&D systems, DuoSet ELISA) 
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according to the manufacturer’s instructions. CCL2, VEGF, and TYMP were measured 
in serum. TGF-β1, NGAL and MMP9 were measured in plasma. Samples were diluted 
as follows CCL2: 1:2, TGF-β1: 1:30, MMP9: 1:150, VEGF: no dilution, TYMP: 1:10 and 
NGAL: 1:100. All samples were assayed in duplicate. The intra- and inter-assay 
coefficients of variation for all tests were within acceptable ranges of <8% and <10% 
respectively. 
 
4.2.4. Structural neuroimaging acquisition and processing  
 
Imaging was performed on a 3T Siemens Skyra with 32 channel head coil (Siemens 
AG, Erlangen Germany). The structural images were acquired using a T1-weighted 3-
dimensional magnetization-prepared rapid acquisition gradient echo (MPRAGE) 
sequence: TE[1]: 1.53ms, TE[2]: 3.21ms, TE[3]: 4.89ms, TE[4]: 6.57ms, fov: 256mm, 
flip angle = 20, 128 slices and voxel size: 1x1x15.mm. 
 
Quantification of cortical thickness and surface area with certain regions was 
performed using the Freesurfer software suite (v5.3) (Martinos Center, Harvard 
University, Boston, MA; http://surfer.nmr.mgh.harvard.edu). Technical post-
processing details have been described previously (Desikan et al., 2006; Fischl et al., 
2002). In brief, Freesurfer is a validated automated software program which 
transforms the MPRAGE scan of an individual into a template space with the skull 
stripped and the brain segmented. Brain regions were parcellated into subcortical 
and cortical regions of interest (ROI). For the primary aim, the analysed ROIs 
included the cortical lateral orbitofrontal, precentral, caudal anterior cingulate, 
 184 
paracentral, superior parietal, inferior parietal, supramarginal and precuneus. These 
cortical regions were chosen based on prior studies (Kallianpur et al., 2012; Netto et 
al., 2011; Sanford et al., 2017; Thompson et al., 2005). As an exploratory aim, the 
analysed ROIs included all cortical regions of the whole brain (Supplementary file). 
Two trained raters independently confirmed segmentation of these ROIs (MEW and 
ARA). Bilateral estimates were used for all analyses for each brain region.  
  
4.2.5. Statistical analysis  
 
All analyses were conducted using SPSS (version 25, IBM, USA). Data distribution for 
the markers MMP9, TYMP, VEGF, NGAL, CCL2 and TGFβ1 were found to be skewed, 
therefore the data was natural log-transformed, which resulted in acceptable 
skewness (<-1.2) and kurtosis (<1.7). For description statistics of study participant 
demographics, Wilcoxon t-test was performed for continuous variables and Pearsons 
chi-squared tests for categorical variables. 
 
 For the primary aim, an exploratory analysis was done with Pearson correlations to 
investigate the associations between the inflammatory markers and the cortical 
thickness/surface areas of specific ROIs in PLWH and HIV-negative participants 
respectively. Statistical significance for all analyses was set at p less than .05.  
 
Bonferroni correction accounted for the number of brain regions tested (α/n = .05/8 
= .00625) in the group comparisons (primary aim). Covariates that may affect marker 
levels included; sex (Krebs et al., 2016; Mathad et al., 2016), age (De Oliveira et al., 
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2015), comorbidities (Keating et al., 2017) and alcohol use (Meyerhoff, 2001). First, 
we evaluated the correlations between immune marker concentrations and 
thickness/surface area of cortical ROIs. Thereafter, for significant findings, separate 
regression models were conducted to examine the associations between cortical 
thickness/surface area and marker concentrations, after adjusting for the following 
covariates in individual models: demographics (age, sex and education), cohort 
(cohort, heavy drinkers) and HIV-positive disease parameters (nadir CD4 count, and 
viral load). A post-hoc analysis of covariance (ANCOVA) determined the interaction 
between HIV status and immune marker with cortical thickness/surface area as the 
dependent variable. 
 
As a secondary aim, a mediation analysis was conducted using the Baron and Kenny 
approach (Hayes, 2009). This was conducted to establish the mediating role of brain 
cortical thickness or surface area on the associations of inflammatory markers with 
cognitive functioning. Linear regression analysis was used to evaluate the 
associations between the independent variable (inflammatory marker) and the 
outcome variable (cognitive functioning). This direct association was referred to as 
relation c. The association between the independent variable (inflammatory marker) 
with the possible mediator (brain thickness/surface area) (referred to as association 
a) and the association between the possible mediator with the outcome variable 
(cognitive functioning) (referred to as relation b) was also evaluated. According to 
the guidelines of Baron and Kenny (Hayes, 2009), the associations of a, b and c needs 
to be significant in order to evaluate possible mediation by the mediator. Finally, the 
amount of change in the regression coefficient for the associate c, after adjustment 
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for the mediator was evaluated (referred to as c’). The mediation effect was 
calculated as the difference in the regression coefficient between c and c’ (referred 
to as ab).  
 
As an exploratory analysis, Pearsons correlations were conducted to investigate 
associations between the inflammatory markers and the cortical thickness/surface 
areas ROIs of the whole-brain (including those investigated in the primary aim) in 
PLWH and HIV-negative participants respectively. P values were considered 
statistically significant for all analyses at a value of less than .05 (Supplementary 




4.3.1. Sample characteristics 
 
The study sample included a total of 91 participants which comprised of 65 PLWH 
and 26 HIV-negative controls. PLWH had a mean age of 33.32 (6.66) years and 32.3% 
were female. The HIV-positive group had a median nadir CD4 count of 307 (169 - 
417) cells/μl and viral load of 3.95 (3.15 - 4.51) log copies/ml. PLWH were treatment-
naïve or had only recently started cART (< 1 month). PLWH had a higher mean age (p 
= .01) and a lower percentage of female participants (p = .025) when compared to 
HIV-negative controls. There were no significant differences for the 6 composite 
cognitive indices between HIV-positive and HIV-negative participants (p > .05). 
Sample characteristics are summarized in Table 1.  
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Table 1: Characteristic of HIV-positive and HIV-negative study participants 
 HIV– controls (n = 26) HIV+ (n = 65) p-value 
Age years mean (SD) 37.54 (7.66) 33.32 (6.66) .01 
Sex, female N (%) 15 (57.7) 21 (32.3) .025 
Education, years (SD) 10.88 (1.12) 10.38 (1.37) .12 
CD4 + nadir, median (IQR) - 307 (169- 417) - 
Viral load log copies/mL median (IQR) - 3.95 (3.15 - 4.51) - 
Heavy drinkers, N (%) 15 (57.7) 8 (12.3) < .001 
Cognitive domain    
Processing speed, mean (SD) 0.14 (0.50) 0.06 (0.53) 0.506 
Verbal, mean (SD) -0.15 (0.94) -0.01 (1.03) 0.556 
Learning, mean (SD) -0.01 (0.89) 0.16 (0.56) 0.402 
Memory, mean (SD)  -0.05 (0.84) 0.05 (0.90) 0.634 
Motor functioning, mean (SD)  0.01 (1.01) -0.15 (0.84) 0.334 
Executive functioning, mean (SD) -0.02 (1.09) 0.12 (1.10) 0.580 
Abbreviations: Interquartile range (IQR), Standard deviation (SD) 
 
4.3.2. Association of immune marker levels with the cortical thickness 
 
In PLWH, higher CCL2 levels were associated with larger thickness of the precentral 
gyrus (p = .019) and higher NGAL levels were associated with reduced thickness of 
the lateral orbitofrontal region (p = .004). After applying Bonferroni corrections of p 
= .05/8, higher NGAL levels remained associated with reduced thickness of the 
lateral orbitofrontal region (p = .004) (Table 2). To further evaluate if the outcome 
was specific for HIV status, an ANCOVA was performed post-hoc to determine the 
interaction between HIV status and NGAL levels, with the lateral orbital frontal 
cortex thickness as the dependent variable. The ANCOVA failed to detect evidence 
for an interaction (p > .05). The association between higher NGAL levels with the 
reduced lateral orbitofrontal thickness remained significant after controlling for 
demographic variables (age, sex and education) (p = .01), cohort (cohort, heavy 
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drinkers) (p = .002) and HIV-positive disease parameters (nadir CD4 count, and viral 
load) (p=.006) in separate models. Before and after applying Bonferroni corrections p 
= .05/8, no associations were found between any of the investigated immune 
markers and the respective regions of brain cortical thickness in HIV-negative 
participants (Table 3).  
 
Table 2: The associations of brain cortical thickness with peripheral immune markers 
in PLWH 
Bilateral brain ROIs TYMP VEGF MMP9 CCL2 NGAL TGFβ1 
Lateral orbitofrontal -.112 -.149 .033 .094 -.365a .072 
Precentral .182 -.208 -.132 .353b -.093 .093 
Caudal anterior cingulate -.195 .063 -.058 .050 -.202 -.045 
Paracentral .003 -.070 -.076 .194 -.078 .152 
Superior parietal -.067 .096 .003 .192 -.012 .037 
Inferior parietal -.149 .093 -.040 .164 -.182 -.154 
Supramarginal -.199 .108 -.109 .211 .065 -.016 
Precuneus -.088 .000 -.104 .184 -.162 .035 
Results displayed as standardized β (unadjusted). Results with significant p values are presented in 
bold, a p = .004, b p = .019 
 
Table 3: The associations of brain cortical thickness with peripheral immune markers 
in HIV-negative participants 
Bilateral brain ROIs TYMP VEGF MMP9 CCL2 NGAL TGFβ1 
Lateral orbitofrontal -.323 -.121 .089 -.078 -.158 -.025 
Precentral -.248 .011 .070 .017 -.240 .061 
Caudal anterior cingulate -.128 .007 .249 .037 -.033 .138 
Paracentral -.214 .013 .217 .001 -.014 -.182 
Superior parietal -.336 .058 .110 -.058 .120 -.219 
Inferior parietal -.339 -.205 -.339 .273 -.340 -.138 
Supramarginal -.443 -.125 .021 -.048 .066 -.189 
Precuneus -.369 .090 .202 -.051 .100 -.163 
Results displayed as standardized β (unadjusted). 
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The mediating role of lateral orbitofrontal thickness in the association of NGAL with 
processing speed was not determined because no significant association (p = .44) 
was found between the lateral orbitofrontal thickness and processing speed. Higher 
NGAL levels were associated with impaired motor functioning (c; β = .292, p = .02). 
This association was mediated by the thickness of the lateral orbitofrontal cortex (c’; 
β = .200, p = .12; ab; β = .09) (Figure 1).  
 
 
Figure 1: Schematic illustration of the mediation paths. Results displayed as 
standardized β. *p < .05, **p < .01 
 
4.3.4. Association of immune marker levels with the surface area 
 
In PLWH, higher TYMP levels were associated with the larger surface area of the 
supramarginal cortex (p = .01). In HIV-negative participants, higher NGAL levels were 
associated with a larger surface area of the lateral orbitofrontal (p = .032) and higher 





NGAL Motor function 
c = .292*
b = -.317*a = -.365**
ab = .092
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After applying Bonferroni corrections of p = .05/8, no significant associations were 
found between the investigated immune markers and the respective regions of brain 
cortical surface area for either group (Table 4 and Table 5). 
Table 4: The associations of brain surface area with peripheral immune markers in 
PLWH 
 
Bilateral brain ROIs TYMP VEGF MMP9 CCL2 NGAL TGFβ1 
Lateral orbitofrontal -.099 .019 -.063 -.175 .124 -.045 
Precentral -.126 -.112 .015 -.145 .175 .010 
Caudal anterior cingulate -.003 .036 .092 .241 .148 -.060 
Paracentral -.154 .062 -.005 -.063 .010 -.059 
Superior parietal .075 .003 -.089 .096 .099 .100 
Inferior parietal -.211 .106 -.089 .003 -.087 .253 
Supramarginal .391a .013 -.042 .210 .223 .156 
Precuneus .159 -.023 -.062 .111 .185 .035 
Results displayed as standardized β (unadjusted). a p = .01 
 
Table 5: The associations of brain surface area with peripheral immune markers in 
HIV-negative participants 
Bilateral brain ROIs TYMP VEGF MMP9 CCL2 NGAL TGFβ1 
Lateral orbitofrontal .177 .344 .242 .138 .420a -.089 
Precentral -.163 .225 -.050 -.149 .118 .059 
Caudal anterior cingulate -.021 .037 -.075 -.168 .023 -.220 
Paracentral -.407b -.091 -.183 .001 .062 -.310 
Superior parietal -.153 .294 .055 .121 .255 -.207 
Inferior parietal .073 .204 -.349 .303 .026 .253 
Supramarginal -.302 .071 -.303 .080 .131 .058 
Precuneus -.031 .315 -.067 .072 .234 -.178 
Results displayed as standardized β (unadjusted). a p = .032, b p = .044 
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4.3.5. Exploratory analysis: Association of Immune markers with the cortical 
thickness and surface area 
 
Higher NGAL levels were associated with reduced thickness in the highest number of 
ROIs (n=14), followed by TYMP (n=6). These associations were largely found in the 
regions of the frontal cortex in PLWH (Supplementary Table 1). The most significant 
findings (considered as p ≤ .004) observed were the associations of higher NGAL 
levels with the reduced thickness of the frontal pole, inferior temporal and lateral 
orbitofrontal (all p = .004) and higher TYMP levels with the reduced thickness of the 
frontal pole (p = .002) (Supplementary Table 1). These associations were not 
observed in HIV-negative participants (Supplementary Table 2). The most significant 
findings for surface area were higher TYMP levels and a larger surface area of the 
supramarginal (p = .01) and higher TGFβ1 levels with the larger surface area of the 
postcentral gyrus (p = .007) in PLWH (Supplementary Table 3). These associations 
were not found in the HIV-negative participants (Supplementary Table 4). 
 
4.4. Discussion  
 
The results from this study demonstrate that higher plasma NGAL levels may be 
associated with a reduced thickness of the bilateral orbitofrontal cortex and that 
that cortical thickness of the bilateral orbitofrontal may mediate the association of 
NGAL with worse motor function in PLWH. An exploratory analysis revealed that 
higher NGAL and TYMP levels had several associations with ROIs in the frontal cortex 
of PLWH.  
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To the best of our knowledge, this is the first study to describe the associations of 
circulating immune markers with brain structural abnormalities in South African 
patients that are geographically located to regions which are primarily infected with 
HIV-1C. Only two other existing studies with HIV-1B infected participants described 
associations of plasma cytokines with brain volumes (Gongvatana et al., 2014; Ragin 
et al., 2010).  
 
In the current study, we report an association of higher NGAL levels with reduced 
thickness of the lateral orbitofrontal cortex in PLWH. The reduced thickness of the 
lateral orbitofrontal region in HIV-1 infection has been reported in several studies 
(Kallianpur et al., 2012; Netto et al., 2011; Sanford et al., 2017). We further report an 
association between peripheral immune dysregulation, reduced cortical thickness 
and cognitive performance in HIV-1 infection. However, ANCOVA analyses did not 
show a significant interaction between NGAL and HIV status, with lateral 
orbitofrontal thickness as the dependent variable. Therefore, this finding may not be 
dependent on HIV-status. For the mediation analysis, we describe that the 
association of higher NGAL levels with worse motor function (Williams et al., 2019) 
was mediated by the reduced cortical thickness of the lateral orbitofrontal region in 
PLWH. Even though the orbitofrontal region is not formally considered to be 
involved in motor function, prior studies have found an association between 
prefrontal (Thompson et al. 2005) and orbitofrontal cortical thinning and worse 
motor function (Kallianpur et al. 2012). A previous study with treatment-naïve 
participants showed that the reduced thickness of the prefrontal cortex was 
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associated with cognitive/motor deficits in HIV-1 infection (Thompson et al., 2005). 
More specifically, our findings are in line with a study that reported an association 
between the reduced lateral orbitofrontal thickness and worse motor function in 
PLWH (Kallianpur et al., 2012). Further, two parcels in the frontal gyrus, pars orbitalis 
(8 and 7) have strong connectivity with the lateral orbitofrontal cortex and also with 
several movement-related areas, including the supplementary motor area, insula, 
midcingulate and supracallosal anterior cingulate, supramarginal left and right. 
These inferior frontal gyrus-pars orbitalis areas may relate the lateral orbitofrontal 
cortex to brain areas involved in movement initiation (Du et al. 2020). It remains 
unclear whether these associations reflect neuronal death due to HIV-related toxins 
or perhaps to a diaschisis effect resulting from compromised sub-cortical brain 
structures (Kallianpur et al., 2012). Based on our findings, there is a possibility that 
the lateral orbitofrontal region may be affected by immune responses in HIV-1 
infection, however, this warrants further investigation. 
 
Frontal cortical dysfunction may be particularly vulnerable to indirect immune-
related mechanisms. Findings from the exploratory analysis revealed that from all 
the investigated markers, NGAL and TYMP showed the majority of associations with 
the regions of cortical thickness in PLWH. These associations were largely found with 
reduced thickness in regions of the frontal cortex. This is of interest since previous 
studies have shown associations between reduced thickness in the frontal cortex 
with worse processing speed and motor function in HIV-1 infection (Kallianpur et al., 
2012; Netto et al., 2011; Sanford et al., 2017; Thompson et al., 2005), supporting the 
findings from the current study. A recent study has reported that peripheral 
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monocyte activation markers; sCD14 and sCD163 were associated with reduced 
volumes in regions of the frontal lobe in treated women with HIV (Kamkwalala et al. 
2020). Neuroinflammation is increased in the frontal cortical tissue of participants 
with HAND (Boven et al. 1999; Guha et al. 2018). Despite this being an exploratory 
analysis and not controlling for multiple comparisons, the association shown by 
NGAL and TYMP are in line with the association in specific domains shown in our 
previous study (Williams et al., 2019). Higher TYMP and NGAL levels were associated 
with worse neurocognitive performance in the domains of processing speed and 
motor function. The associations of these markers were largely found in the regions 
involved in these cognitive functions.  
 
The exact mechanism of NGAL and TYMP in the neuropathophysiology of HIV is not 
clearly understood. However, evidence from existing studies on the neurobiological 
functions of NGAL and TYMP in other neurological diseases can provide a 
hypothetical explanation for our findings. NGAL or lipocalin-2 (LCN2), is an acute-
phase protein that is secreted in response to a wide range of pathological stimuli 
(Chakraborty et al., 2012). NGAL reportedly promotes a pro-inflammatory phenotype 
and apoptosis in microglia (Lee et al., 2007), astrocytosis (Lee et al., 2009) and 
sensitize neurons to neurotoxicity (Bi et al., 2013; Naudé et al., 2012). NGAL was 
significantly higher in the frontal cortical tissue (including the orbitofrontal cortex) of 
patients with Alzheimer’s disease compared to non-demented controls (Dekens et 
al., 2017). In an HIV gp120 transgenic mouse model, it was shown that NGAL was 
one of the most upregulated immune factors in the brain of an HIV gp120 transgenic 
mouse model (Maung et al., 2014). Moreover, NGAL could contribute to neuronal 
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injury in gp120 transgenic mice (Maung et al., 2014). Therefore, NGAL may be 
present in the frontal cortex of PLWH and potentially have negative effects on 
neurons and immune cells of the CNS, resulting in structural cortical changes. 
Findings from the current study further support the potential role for NGAL in HIV-
associated neurocognitive impairments and this may be an important marker for 
future investigations.  
 
TYMP (or ECGF1) is an endothelial cell growth factor with a functional role in 
angiogenesis. The TYMP gene expression is increased in circulating monocytes of 
PLWH with viremia (Wu et al., 2013) and its protein expression may be increased in 
the CNS of people with HIV-1 (Kumar et al., 2012). Furthermore, TYMP was shown to 
contribute to blood-brain barrier breakdown in cell culture and animal models 
(Chapouly et al., 2015). Studies investigating the association of TYMP with HIV-
associated neurocognitive impairments remain limited and to our best knowledge, 
no other study has investigated these markers PLWH. Future studies should 
investigate the underlying mechanisms of both NGAL and TYMP in HIV-associated 
neurocognitive impairments. Specifically, investigations of human post-mortem 
brain tissues and gene expression will provide further insights into the expression 
levels of these immune markers in HIV infection. 
 
Higher CCL2 levels were associated with a larger thickness of the precentral gyrus. 
Even though this association did not survive multiple comparisons, this is a 
contradictory finding from previous studies linking higher CCL2 levels with lower 
volumes (Ragin et al. 2010a) and with worse neurocognitive performance (Woods et 
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al. 2006; Ancuta et al. 2008). However, higher peripheral CCL2 levels were also 
associated with higher volumes of the basal ganglia and amygdala volumes in HIV-
positive participants (Gongvatana et al. 2014). The basis for this positive association 
cannot be ascertained from this study. The positive relationship between peripheral 
CCL2 levels and brain structures may be due to hypertrophy resulting from fluid 
accumulation secondary to inflammation of these brain structures (Gongvatana et al. 
2014). 
 
Our results further indicate that TYMP, NGAL and TGF-β1 were associated with 
differences in cortical surface area, although these findings did not survive 
corrections for multiple comparisons. The associations and biological effects of 
immune markers on brain surface area are still largely unknown. Cortical surface 
area is believed to be determined by the number of ontogenetic columns that run 
perpendicular to the surface of the brain (Hogstrom et al. 2013). The radial unit 
hypothesis of cortical development stipulates that cells within the cortical column 
share a common origin and migrate from the subventricular zone to their location 
within the cortex (Rakic 1988). The tension-based morphogenesis hypothesis (Van 
Essen 1997) further suggest that abnormal mechanical tension along the axons may 
affect the cortical surface area. We speculate that TYMP, NGAL and TGF-β1 levels 
may be associated with neurobiological processes such as synaptogenesis, dendritic 
arborization and intracortical myelination that may continue to affect cortical 
surface area. Their associations with the brain surface area may depend on the 
underlying neuropathological environment. 
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Our study sample differed from previous studies, with regards to geographical region 
(HIV-1 subtype) and treatment status. All studies investigating cortical 
thickness/surface area were done in HIV-1 subtype B infection (Kallianpur et al., 
2012; Netto et al., 2011; Sanford et al., 2017; Thompson et al., 2005). It is known 
that the inflammatory phenotype may differ between HIV-1 subtypes (Gandhi et al., 
2009), therefore findings presented here may differ for HIV-1B infection. 
Interestingly, when comparing the effect of HIV-1B and HIV-1C on structural volume 
declines, HIV- 1B and HIV-1C were associated with similar structural volume 
differences compared to their relative controls. However, no significant differences 
were found in the structural volume decline when directly comparing HIV-1B and 
HIV-1C (Ortega et al., 2013). This underscores the need for further investigation into 
the direct and indirect mechanisms for geographical regions which are primarily HIV-
1C infected.  
 
We investigated a treatment-naïve cohort. Majority of previous studies investigating 
the effect of HIV-1 on cortical thickness was done in treatment-experienced 
participants (Kallianpur et al., 2012; Netto et al., 2011; Sanford et al., 2017), with 
limited studies investigating treatment-naïve participants (Thompson et al., 2005). It 
was shown that in both treatment-naïve and treatment-experienced HIV-1 positive 
participants, there is an association between a reduced frontal cortex and worse 
neurocognitive performance. Similarly, as shown in the current study, associations of 
immune markers were largely found in the regions of reduced frontal cortex.  
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Inflammation may persist in the brain of both treatment-naïve and treatment-
experienced participants as shown in studies with post-mortem human brain tissues. 
A study by Shapshak et al., reported an increase of pro-inflammatory cytokines in 
post mortem brain tissue of treatment-naïve cognitively impaired PLWH (Shapshak 
et al., 2004). Interestingly, it was found that when comparing brain tissue of HIV-
positive participants with and without HIV encephalitis, similar features of immune 
activation in the CNS was recorded, regardless of ART at the time of death (Tavazzi et 
al., 2014). Furthermore, brain alterations may persist despite viral suppression. In a 
longitudinal treatment study, at both baseline and follow-up, virally suppressed 
PLWH had greater white matter volume loss compared to HIV-negative controls 
(Cardenas et al., 2009). Similarly, in a 24-month longitudinal treatment study, 
volume decline of the basal ganglia was reported in young adults despite the 
initiation of ART within the first 4 weeks of infection (Kallianpur et al., 2019). This is 
suggestive of an ongoing structural brain dysfunction despite the introduction of 
ART, indicating persistent underlying neurobiological mechanisms that are involved 
in the neuropathophysiology of HIV.  
 
Several studies that investigated ART experienced participants with (Cohen et al. 
2011; Correia et al. 2013; Falasca et al. 2017; Imp et al. 2017) and without viral 
suppression (Ancuta et al. 2008; Kamat et al. 2012; Krebs et al. 2016; Xing et al. 
2017) reported an association between inflammation and HAND. Similarly, studies 
investigating cohorts with varying levels of CD4 count (Ancuta et al. 2008; Cohen et 
al. 2011; Kamat et al. 2012) showed associations between inflammation and HAND 
(Williams et al. 2020). Even though ART may reduce the viral load and subsequently 
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the level of inflammation in the CNS, low-grade neuroinflammation may still be 
present. Therefore, the effect of low-grade inflammation on brain structures and the 
development of HAND may be independent of ART. We hypothesize that findings 
presented in the current study may similarly be reflected in investigations of 
treatment-experienced participants.  
 
Several study limitations should be emphasized. First, this study included a limited 
number of study participants, so replication in a larger cohort is warranted. Second, 
some of the study participants were heavy alcohol users. Heavy episodic drinking 
affects brain cortical thickness and structure (Morris et al., 2019). To minimize these 
effects, we controlled for alcohol use in our statistical analysis. Further, we have 
previously shown that both 1) inflammatory marker levels and 2) neurocognitive 
performance was not significantly different between the heavy-drinkers and non-
heavy drinkers (all p values were greater than .1) (Williams et al., 2019). It is also 
relevant to note, the findings presented here may not apply to HIV-1B infection, as 
inflammatory levels may be influenced by the HIV-1 subtype (Gandhi et al., 2009). 
Further, when adjusting for multiple comparisons, an adjustment was only made for 
the number of brain regions tested. Therefore, these findings should be considered 
as preliminary and the interpretation of findings requires caution. Other potential 
confounding factors that were not screened out from this study, may in part, explain 




4.5. Conclusion  
 
This study shows that the immune marker NGAL was associated with the reduced 
thickness of the lateral orbitofrontal cortex and that the association of NGAL with 
worse motor function may be mediated by the thickness of the lateral orbitofrontal 
cortex. Further, NGAL and TYMP may be important markers of frontal cortex 
structural dysfunction in South African participants, which are predominantly HIV-1C 
infected. Therefore, in the context of regions geographically located to HIV-1C, NGAL 
and TYMP may play a role in the neurobiological mechanisms underlying the 
neuropathophysiology of HIV-1 associated neurocognitive impairment. NGAL and 
TYMP are promising markers for further investigations into their potential as anti-
inflammatory therapies for HIV-associated neurocognitive impairments. 
 
Here, I show that peripheral immune markers are associated with structural brain 
changes as well as HIV-associated neurocognitive impairment in South African 
participants. Several pre-clinical studies have suggested that inflammation may be 
higher in HIV-1B infection. However, this has not been investigated in clinical studies 
of PLWH. Recent evidence has reported that the HIV viral Tat protein differs 
between HIV-1 subtypes. These Tat differences may influence the differential 
inflammatory levels between HIV-1 subtypes. In the next chapter, I review the 
current literature of the differential effects of Tat sequence variation on the 
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As an exploratory aim, the analysed ROIs of the whole brain included the superior 
frontal, rostral and caudal middle frontal, pars opercularis, pars triangularis, pars 
orbitalis, lateral and medial orbitofrontal, precentral, paracentral, frontal pole, 
superior parietal, inferior parietal, supramarginal, postcentral, precuneus, superior, 
middle, and inferior temporal, banks of the superior temporal sulcus (STS), fusiform, 
transverse temporal, entorhinal, temporal pole, parahippocampal, occipital, lateral 





























Table 1: Association of Immune markers with the cortical thickness of all brain regions in HIV-positive 
participants 
Brain ROIs TYMP VEGF MMP9 CCL2 NGAL TGFβ1 
Temporal pole .097 -.313* -.013 -.201 -.109 -.201 
Frontal pole -.383** .072 -.124 -.006 -.362** .007 
Banks sts -.107 .059 .229 -.017 -.069 .272 
Superior temporal .081 .014 .227 .061 .060 .203 
Middle temporal -.331* -.159 -.154 -.337* -.433** -.167 
Precentral .182 -.208 -.132 .353* -.093 .093 
Postcentral -.150 .093 -.077 .175 .030 .289 
Supramarginal -.199 .108 -.109 .211 .065 -.016 
Superior parietal -.067 .096 .003 .192 -.012 .037 
Precuneus -.088 .000 -.104 .184 -.162 .035 
Cuneus -.122 .090 -.112 .125 .030 -.121 
Pericalcarine -.099 -.154 .14 .010 -.232 .007 
Lingual -.075 -.189 -.104 .035 -.246 -.039 
Superior frontal -.180 -.085 -.057 .179 -.264* -.034 
Rostral anterior cingulate -.074 -.068 -.19 .042 -.280* -.115 
Caudal anterior cingulate -.195 .063 -.058 .050 -.202 -.045 
Posterior cingulate -.024 .085 -.194 .041 -.162 .035 
Isthmus cingulate -.224 -.093 -.243 -.081 -.252* -.154 
Medial orbitofrontal -.155 .036 .046 .076 -.282* -.050 
Inferior temporal -.346** -.260* -.037 -.316* -.374** -.106 
Lateral occipital -.298* -.060 -.008 -.069 -.231 .048 
Inferior parietal -.149 .093 -.04 .164 -.182 -.154 
Caudal middle frontal -.037 -.252* -.185 .143 -.304* -.019 
Rostral middle frontal -.256* -.083 -.07 -.016 -.341** -.038 
Lateral orbitofrontal -.112 -.149 .033 .094 -.365** .072 
Pars orbitalis -.274* -.160 -.031 .032 -.338** .038 
Pars triangularis -.041 -.145 -.06 .051 -.261* -.090 
Pars opecularis -.119 -.256* -.059 .094 -.276* .064 
Insula -.05719 -.157 -.065 .164 -.256 -.151 
Transverse temporal .01369 -.038 -.084 .077 -.137 .061 
Entorhinal -.05009 -.070 .304* -.035 -.064 -.132 
Paracentral .003372 -.070 -.076 .194 -.078 .152 
Fusiform -.262* -.154 -.017 -.050 -.277* -.133 
Para hippocampal .138 -.227 -.182 -.065 -.155 -.240 


















Table 2: Association of Immune markers with the cortical thickness of all brain regions in HIV-negative 
participants 
Brain ROIs TYMP VEGF MMP9 CCL2 NGAL TGFβ1 
Temporal pole -.044 -.117 .100 -.272 .270 -.225 
Frontal pole -.294 -.046 .184 -.104 .023 -.169 
Banks sts -.683** -.093 -.025 .022 -.097 -.274 
Superior temporal .025 .026 -.466* .255 -.195 .531* 
Middle temporal -.221 -.079 .147 .163 .062 .124 
Precentral -.248 .011 .070 .017 -.240 .061 
Postcentral -.213 .428* .186 .229 .266 .211 
Supramarginal -.443 -.125 .021 -.048 .066 -.189 
Superior parietal -.336 .058 .110 -.058 .120 -.219 
Precuneus -.369 .090 .202 -.051 .100 -.163 
Cuneus .057 -.100 -.306 -.489* -.207 -.413 
Pericalcarine -.378 -.256 -.064 -.316 .000 -.468 
Lingual -.624** -.027 -.067 .011 .104 -.368 
Superior frontal .024 .003 .292 -.305 -.011 -.179 
Rostral anterior cingulate -.061 .126 .435* -.159 .096 -.145 
Caudal anterior cingulate -.128 .007 .249 .037 -.033 .138 
Posterior cingulate -.363 -.177 .105 .037 -.146 -.098 
Isthmus cingulate -.624** -.383 -.085 -.004 -.215 -.216 
Medial orbitofrontal -.283 -.188 .199 .118 -.096 -.023 
Inferior temporal -.088 .041 .351 -.016 .225 -.217 
Lateral occipital -.165 .085 -.283 .146 .100 -.149 
Inferior parietal -.339 -.205 -.339 .273 -.340 -.138 
Caudal middle frontal -.388 .101 .162 -.080 .064 -.290 
Rostral middle frontal -.306 .104 .175 -.139 .029 -.113 
Lateral orbitofrontal -.323 -.121 .089 -.078 -.158 -.025 
Pars orbitalis -.070 .123 .178 -.058 .175 .002 
Pars triangularis -.259 .116 .050 -.083 .055 -.027 
Pars opecularis -.237 .121 .077 -.226 -.006 -.220 
Insula -.234 -.152 .371 -.132 -.072 -.145 
Transverse temporal -.297 -.094 .091 .012 -.130 .048 
Entorhinal .083 -.112 -.149 .117 -.267 .600* 
Paracentral -.214 .013 .217 .001 -.014 -.182 
Fusiform -.262 -.044 .169 -.187 .058 -.083 
Para hippocampal -.169 .076 .006 -.232 -.083 .059 














Table 3: Association of Immune markers with the surface area of all brain regions in HIV-positive 
participants 
Brain ROIs TYMP VEGF MMP9 CCL2 NGAL TGFβ1 
Temporal pole .044 .165 -.076 .077 .142 -.112 
Frontal pole -.082 -.047 -.166 -.138 .066 -.084 
Banks sts -.005 .286* .071 .096 .164 .107 
Superior temporal .318* .030 .067 .023 .293 .038 
Middle temporal -.001 .229 .084 -.018 .130 .276* 
Precentral -.126 -.112 .015 -.145 .175 .010 
Postcentral -.150 .029 .036 -.096 .209 .385** 
Supramarginal .391** .013 -.042 .210 .223 .156 
Superior parietal .075 .003 -.089 .096 .099 .100 
Precuneus .159 -.023 -.062 .111 .185 .035 
Cuneus .189 -.074 -.169 .058 .138 .076 
Pericalcarine .008 -.189 -.118 -.010 .157 .073 
Lingual -.107 -.014 -.091 .140 .168 -.095 
Superior frontal -.140 .038 -.030 -.140 .135 .001 
Rostral anterior cingulate -.048 .029 .072 .119 .126 -.096 
Caudal anterior cingulate -.003 .036 .092 .241 .148 -.060 
Posterior cingulate .087 .047 .077 .142 .121 -.083 
Isthmus cingulate .131 .077 .144 .118 .303* .139 
Medial orbitofrontal -.065 -.010 -.017 -.121 .131 -.038 
Inferior temporal -.001 .131 .010 -.088 .061 .115 
Lateral occipital -.016 .243 -.009 .107 .244 -.060 
Inferior parietal -.211 .106 -.089 .003 -.087 .253 
Caudal middle frontal -.028 .089 .096 .027 .192 .053 
Rostral middle frontal .005 -.105 -.041 .061 .146 .015 
Lateral orbitofrontal -.099 .019 -.063 -.175 .124 -.045 
Pars orbitalis .048 -.032 -.118 -.084 .031 -.093 
Pars triangularis .120 .028 -.118 .204 .098 -.049 
Pars opecularis -.064 -.011 .045 -.066 .058 -.013 
Insula -.107 .030 .143 -.061 .168 .040 
Transverse temporal .090 -.040 .195 .037 .183 -.026 
Entorhinal .184 -.094 -.084 -.081 -.091 -.043 
Paracentral -.154 .062 -.005 -.063 .010 -.059 
Fusiform .059 -.081 -.118 -.077 .160 -.175 
Para hippocampal -.222 .164 .053 -.081 .059 .006 












Table 4: Association of Immune markers with the surface area of all brain regions in HIV-negative 
participants 
Brain ROIs TYMP VEGF MMP9 CCL2 NGAL TGFβ1 
Temporal pole -.141 .161 -.116 .407 .087 .161 
Frontal pole .228 -.084 -.354 .132 -.033 .265 
Banks sts -.221 .054 -.588* .441 -.027 .135 
Superior temporal -.274 .102 -.532 .537* -.060 .226 
Middle temporal -.196 .212 -.698** .144 .119 -.037 
Precentral -.163 .225 -.050 -.149 .118 .059 
Postcentral -.225 .291 -.211 .139 .148 .081 
Supramarginal -.302 .071 -.303 .080 .131 .058 
Superior parietal -.153 .294 .055 .121 .255 -.207 
Precuneus -.031 .315 -.067 .072 .234 -.178 
Cuneus .356 .345 -.302 -.371 .342 -.098 
Pericalcarine -.208 -.138 -.023 -.440 .109 -.365 
Lingual .208 .008 -.046 -.214 .222 -.159 
Superior frontal -.045 .149 -.317 .023 .128 -.095 
Rostral anterior cingulate -.024 .056 -.228 -.097 .133 -.054 
Caudal anterior cingulate -.021 .037 -.075 -.168 .023 -.220 
Posterior cingulate -.113 .128 -.246 -.051 .133 -.195 
Isthmus cingulate .364 .567** -.144 -.041 .354 .107 
Medial orbitofrontal .103 .017 -.176 -.170 -.148 .059 
Inferior temporal -.135 -.004 -.463* .226 -.088 .181 
Lateral occipital -.046 .306 -.328 .051 .202 .133 
Inferior parietal .073 .204 -.349 .303 .026 .253 
Caudal middle frontal -.061 .122 -.167 .015 .327 -.095 
Rostral middle frontal .124 .169 -.116 .124 .082 .017 
Lateral orbitofrontal .177 .344 .242 .138 .420* -.089 
Pars orbitalis -.006 .326 -.027 .005 .212 -.174 
Pars triangularis .292 .387 -.161 -.160 .196 .140 
Pars opecularis .303 .292 -.565** -.227 .200 .123 
Insula -.002 .205 .530* -.110 .248 -.285 
Transverse temporal .157 .307 -.275 -.012 .264 .013 
Entorhinal .192 .270 -.338 -.229 -.086 .372 
Paracentral -.407* -.091 -.183 .001 .062 -.310 
Fusiform -.160 .010 -.270 .124 -.103 .363 
Para hippocampal -.301 .054 -.128 .318 .110 .013 
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HIV-associated neurocognitive disorders (HAND) are a spectrum of neurological 
disorders due to the effects of HIV-1 in the central nervous system (CNS). The HIV-1 
subtypes; HIV-1 subtype B (HIV-1B) and HIV-1 subtype C (HIV-1C) are responsible for 
the highest prevalence of HAND and HIV infections respectively. The HIV 
transactivator of transcription (Tat) protein is a major contributor to the 
neuropathogenesis of HIV. The effects of the Tat protein on cells of the CNS is 
determined by the subtype-associated amino acid sequence variations. The extent to 
which the sequence variation between Tat-subtypes contribute to underlying 
mechanisms and neurological outcomes are not clear. In this review of the literature, 
we discuss how amino acid variations between HIV-1B Tat (Tat-B) and HIV-1C Tat 
(Tat-C) proteins contribute to the potential underlying neurobiological mechanisms 
of HAND. Tat-C is considered to be a more effective transactivator, whereas Tat-B 
may exert increased neurovirulence, including neuronal apoptosis, monocyte 
infiltration into the brain, (neuro)inflammation, oxidative stress and blood-brain 
barrier damage. These findings support the premise that Tat variants from different 







5.1. Introduction  
 
HIV-1 is well known for its effects on the immune system and the development of 
Acquired Immunodeficiency Syndrome (AIDS). However, the presence of HIV-1 in the 
central nervous system (CNS) is also responsible for a spectrum of neurological 
disorders known as HIV-associated neurocognitive disorders (HAND). HIV-associated 
neurocognitive impairment ranges in severity from asymptomatic neurocognitive 
impairment (ANI) to mild neurocognitive disorder (MND) to the most severe form, 
HIV-associated dementia (HAD) (Antinori et al., 2007). 
 
The neuropathogenesis of HAND is complex and is characterized by events such as 
oxidative stress, neuroinflammation, synapse pruning and neuronal death. The 
development of HAND is affected by several factors, which may include the HIV-1 
subtype (Constantino et al., 2011; Gandhi et al., 2009; Rao et al., 2008; Samikkannu 
et al., 2015). Further, the neurovirulence and neurological outcomes of HIV-1 
subtypes were shown to be affected by Trans-activator of transcription (Tat)-subtype 
variation (Gandhi et al., 2009; Rao et al., 2013). However, the extent to which Tat 
and HIV subtypes contribute to the neurovirulence and neurological outcomes 
remains largely unclear.  
 
HIV-1 is divided into four groups M, O, N and P. Group M is the "major" group 
responsible for the global human HIV epidemic. Further, Group M is subdivided into 
9 subtypes (A, B, C, D, F, G, H, J and K) as well as at least 51 circulating recombinant 
forms (CRFs) (de Arellano et al., 2010; Hemelaar, 2012). The HIV-1 subtype-B (HIV-
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1B) is present in America, Western Europe, and Australasia and represents about 
12% of all HIV infections (Taylor et al., 2008). In contrast, the dominant HIV-1 
subtype-C (HIV-1C) is present in countries of Southern Africa and India and 
represents about 50% of the world’s HIV infected population (Geretti, 2006). The 
current knowledge of HIV-1 neuropathogenesis is derived largely from studies on the 
HIV-1B subtype (Taylor et al., 2008). The onset and severity of HAND are affected by 
HIV subtype differences (Tyor et al., 2013), with HIV-1B and HIV-1C having different 
effects (Santerre et al., 2019). Whether genetic variations between HIV-1 subtypes 
affect HIV transmission, disease progression and neurological outcomes remain 
controversial.  
 
Pre-clinical studies suggest an increased neurovirulence for HIV-1B compared to HIV-
1C (Mishra et al., 2008; Rao et al., 2008). Initial investigations report a lower 
prevalence for HAND in countries where HIV-1C is the dominant subtype (Clifford et 
al., 2007) compared to countries where HIV-1B is dominant (Sacktor et al., 2001). 
More specifically, studies of HIV-1B reported HAND prevalence rates of 36%-52% 
(Heaton et al., 2011, 2010). In the pre-antiretroviral therapy (ART) era patients with 
HIV-1B were characterized by deficits in motor skills, cognitive speed, and verbal 
fluency, while in the post-ART era, deficits were more pronounced in memory 
(learning) and executive function (Heaton et al., 2011, 2010). Studies of HIV-1C 
reported HAND prevalence rates of 33%-53% (Ghate et al., 2015; Joska et al., 2011; 
Kamat et al., 2017; Mogambery et al., 2017). Patients were characterized by deficits 
in motor and information processing speed (Ghate et al., 2015; Kamat et al., 2017). 
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Evidence from more recent studies provide contradictory findings and suggest that 
there are no significant differences in the prevalence of HAND between HIV-1B and 
HIV-1C (Day et al., 2016; de Almeida et al., 2013). A recent study in China showed 
that the prevalence of HAND may be slightly higher in HIV-1B compared to HIV-1C 
(31,8% versus 23.9%) (Wu et al., 2017) but remain statistically insignificant. Recently, 
it has been shown that even though CSF/serum ratios of amyloid-β protein isoforms 
were significantly lower in HIV-1C than in HIV-1B, there were no significant 
differences in global deficit scores between HIV-1B and HIV-1C patients (de Almeida 
et al., 2019). Similarly, HIV-1B and HIV-1C were associated with similar structural 
volume declines compared to their relative controls. However, no significant 
differences were found in the structural volume decline when directly comparing 
HIV-1B and HIV-1C (Ortega et al., 2013).  
 
A challenge when comparing the neurocognitive outcomes between two different 
geographical regions [e.g. Europe and America (HIV-1B) and Southern African and 
India (HIV-1C)] is addressing differences in education as well as other socio-cultural 
dissimilarities. The interpretation of findings from such comparative studies, 
therefore, become more challenging. At this stage, it is difficult to clearly understand 
the role of the HIV-1 subtype on clinical outcomes. The limited number of clinical 
studies available underscores the need for further research in this field.  
 
The increased neurovirulence of HIV-1B may be attributed to the activity of HIV viral 
proteins, including; glycoprotein (gp) 120, Tat and Viral protein r (Vpr). This review 
will focus on the HIV Tat protein. Although other viral proteins such as Vpr and 
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gp120 have been shown to cause neurotoxicity (Jones et al., 2007; Rao et al., 2014), 
there is a strong research interest in understanding the neuropathological 
mechanisms induced by Tat because its secretion persists despite viral suppression 
(Johnson et al., 2013; Mediouni et al., 2012). A clearer understanding of the possible 
differences in the pathogenic potency of Tat variants from different HIV-1 subtypes 
may provide insight into the underlying characteristics of subtype-specific HAND. 
Due to limited studies on how Tat subtype differentially affects underlying 
mechanisms of HAND, here, we reviewed the differences by both Tat and HIV-1 
subtype. 
 
5.2. HIV Tat protein sequence and structure  
 
The HIV-1 subtype B Tat protein has approximately 101 amino acid residues which 
differ for each HIV strain and consists of two exons with six functional regions 
(Siddappa et al., 2006). The first exon contains residues 1-72 and second exon has 
residues 73-101. In Tat-B, region 1 (residues 1-21) is a Proline-rich region with a 
conserved Tryptophan (W20). Region 2 (residues 22-37) is a Cysteine-rich region, with 
seven well-conserved Cysteines at position 22, 25, 27, 30, 34, and 37. Region 3 
(residues 38-48) contains conserved residues at F38 and at 43LGISYG48. The 4th region 
(residues 49-57) contains basic residues and a conserved region 49RKKRRQRRRPP57. 
This is also known as the TAR binding domain or the cell-penetrating peptide (CPP). 
Region 5 (residues 58 to 72) is a Glutamine-rich region and considered as the region 
with the highest rate of sequence variation. Region 6 (residues 73 to 101) consists of 
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the C-terminal domain that contains the ESKKKVE motif known as the RGD domain 
and is encoded by the second exon (Figure 1). In HIV-1B and HIV-1D, a conserved 
RGD motif is present in this region (Siddappa et al., 2006; Smith et al., 2003).  
 
Tat sequences from most clinical HIV-1 isolates are 101 amino acids in length. 
Several clinical isolates also display Tat sequences with 86-106 amino acids (Jeang et 
al., 1999). Pre-clinical and in vitro studies largely make use of the 86 amino acid 
configuration. However, it is considered as a truncated protein compared to that 
found in clinical isolates. Several in vitro studies utilize the HIV-1B (BRU strain) 
(Barré-Sinoussi, Chermann et al., 1983; Rosen et al., 1986) or a closely related HXB2 
HIV-1B molecular clone (Rosen et al., 1986). Studies suggest that Tat sequences from 
clinical isolates preserve the full 101 amino acid form, which indicates the functional 
relevance of the second exon in an in vivo setting (Strazza et al., 2011).  
 
A sequence alignment (Figure 1) of the full-length Tat-B and Tat-C indicates several 
residue variants. Tat-C contains several polymorphisms which have been previously 
shown to be involved in neurological outcomes in both pre-clinical and clinical 
studies (Rao et al., 2013, 2008; Ruiz et al., 2019). As reviewed here, key 
polymorphisms include a Serine substitution at residue 31 (C31S), a Serine 
substitution at residue 57 (R57S) and a Glutamate substitution at residue 63 (Q63E). 
With these residue changes, initial biochemical studies speculated Tat-C to have a 
relatively higher-ordered structure and be less flexible than Tat-B (Siddappa et al., 
2006). However, recent findings from additional biochemical studies speculated the 
opposite with Tat-C having a more flexible structure which allows for greater 
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flexibility in binding and resulting in greater transactivation efficiency (Bachu et al., 
2012; Desfosses et al., 2005; Johri et al., 2015). Further, Tat protein structural studies 
are needed to support these findings.  
 
 
Figure 1: Schematic presentation of HIV Tat-B (subtype B, Isolate MN) and HIV Tat-C 
(subtype C, Isolate 92BR025) full amino acid sequence alignment including Exon 1 
and 2. Yellow highlighted residues present sequence variance. Purple highlighted 
residues represent key sequence polymorphisms with a reported effect on 
neurological outcomes. Functional regions of Tat: region I (residues 1 to 21) is an 
acidic/Pro-rich region; region II (residues 22 to 37), a Cysteine-rich region; region III 
(residues 38 to 48) containing conserved “core” region; region IV is arginine-rich 
(residues 49–57); region V (residues 58–72) a Glutamine-rich region and region VI 
(residues 73–101) is encoded by exon 2 and known as the RGD region.  
 
Tat functions by binding to a 59‐bp stem‐loop RNA structure, known as the 
transactivation response element (TAR). The TAR is located at the 5' end of nascent 
HIV‐1 transcripts. Tat, therefore, acts as an RNA specific viral transcription factor via 
its interaction with the TAR RNA element (Desfosses et al., 2005). The effective 
binding of Tat to TAR allows HIV to achieve a high-level transcription. Specifically, 
sequence variation between Tat-B and Tat-C has been shown to affect the 
transactivation capacity, immune modulation, neuronal damage, and pathways 
related to neuronal damage. 
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5.3. Transcriptional capacity   
 
It is known that Tat brings about a strong transactivation response from a long 
terminal repeat (LTR) promoter through binding to TAR. The binding affinity between 
Tat and TAR determines the transcriptional capacity, which may be affected by 
residue polymorphisms present in Tat variants from different HIV-1 subtypes. 
Studies showed a greater transactivation capacity for Tat-B (Siddappa et al., 2006), 
whereas others have found a greater transactivation capacity for Tat-C (Bachu et al., 
2012; Desfosses et al., 2005). Several aspects contribute to the level of Tat 
transactivation which includes the stability of the Tat-TAR complex, number of LTR 
NF‐κB binding sites, and its subsequent immune regulation.  
 
Tat-C has a more flexible structure, which allows for more effective binding to 
partners, compared to Tat-B. Therefore, Tat-C-TAR forms a more stable complex 
with a higher binding affinity (Johri et al., 2015). In addition, it has been reasoned 
that HIV-1C LTR has a greater number of NF‐κB binding sites and subsequently allows 
for greater LTR activation (Bachu et al., 2012). HIV-1 subtype-specific mutations are 
present in regulatory regions within the LTR and this results in HIV-1C presenting 
three NF-κB binding sequences and HIV-1B presenting two NF-κB binding sequences 
(de Arellano et al., 2010). This may have contributed to the fact that when HIV-1 
variants and CRFs were investigated for their transcription activities, HIV-1C LTR had 
the highest basal and phorbol myristate acetate induced transcription activities 
related to the HXB2 subtype B promoter (de Arellano et al., 2010). Compared to Tat-
B, Tat-C had stronger transactivation potentials, and a higher affinity for the Tat RNA 
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element in a Tat-TAR electrophoretic mobility shift assay (de Arellano et al., 2010; 
Desfosses et al., 2005).  
   
The transcriptional capacity of Tat is linked to specific residue polymorphisms 
between Tat-B and Tat-C. A Glutamic acid mutation (Q63E) present in Tat-C was 
shown to contribute to greater transcriptional activation in human CD4 T-Cells 
(Kurosu et al., 2002). Another well studied polymorphism C31S is present in Tat-C. 
The Cysteine at position 31 is not considered as critical for LTR activation, but it may 
be more critical for inducing monocyte chemotaxis (Ranga et al., 2004) as discussed 
in the latter section of this review. Interestingly, HIV-1B is considered to have a 
greater neurovirulence, but a less potent transactivator. This may suggest that in 
addition to HIV transactivation, several other mechanisms may contribute to the 
development of HAND.   
5.4. Neuronal cell damage 
 
The Tat protein is a key viral protein in the development of HAND. Tat-mediated 
neuronal cell damage occurs through various mechanisms which include but not 
limited to the dysfunction and activation of the kynurenine pathway (KP), 
glutamatergic system, and the upregulation of key synaptic plasticity genes in 
neuroblastoma cells. The level of neuronal damage may also be influenced by Tat 
protein sequence variation.   
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It has been shown that Tat-induced neurotoxicity may be influenced by specific 
protein signatures present in Tat-B. The level of neurotoxicity may be due to the 
presence of the dicysteine motif (C30C31) within the Tat-B protein than attributed to 
the HIV subtype (Table 1). Tat-C with an intact dicysteine motif proved to be more 
neurotoxic to human neuronal cultures compared to Tat-C lacking this motif (Rao et 
al., 2013). Therefore, Tat-B with its key protein signatures may exert its neurotoxic 
effects by contributing to several potential underlying mechanisms and pathways of 
neuronal damage. 
 
5.4.1. Tat dysregulates the Kynurenine Pathway (KP) 
 
The KP is responsible for catabolizing tryptophan to quinolinic acid (QUIN) using 
several enzymatic reactions. Activation of indoleamine-2,3-dioxygenase (IDO) (rate-
limiting enzyme of the kynurenine pathway) leads to increased tryptophan 
catabolism and the generation of neurotoxins such as kynurenine (KYN) (Samikkannu 
et al., 2009). This process is important in energy production, protein production, 
protein synthesis, neurotoxicity, and immune tolerance. Several studies have 
reported an association between QUIN and severity of HAND (Heyes et al., 2001; 
Valle et al., 2004).  
 
KP activation may be present in the brain, even with the introduction of combination 
antiretroviral therapy (cART) (Drewes et al., 2015). QUIN/Tryptophan ratios are early 
predictors of neurological diseases in untreated SIV-infected macaques and were 
considered to outperform all other KP metabolites in predicting neurological disease 
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(Drewes et al., 2015). In cART treated macaque models, KP metabolites did not 
restore to control levels in the striatum even though levels were normalized in the 
CSF of most animals (Drewes et al., 2015). These suggest that cerebral KP activation 
may only be partially resolved with cART (Drewes et al., 2015). QUIN production may 
be specific to stimulation by HIV viral proteins, including Tat.   
 
Macrophages treated with Tat (subtype not reported) for 72 hours yielded 
significantly higher levels of QUIN compared to negative controls (Smith et al., 2001). 
The levels of QUIN produced was above or equal to that related to neuropathological 
damage in vitro (Kerr et al., 1998, 1995). Increased IDO mRNA expression was also 
found in Tat treated macrophages in a dose-dependent manner (Smith et al., 2001). 
This level of expression may also be affected by the HIV Tat variants from different 
HIV-1 subtypes. In HIV-1B treated astrocytes, IDO enzyme activity, as well as KYN 
concentration, were significantly upregulated compared to HIV-1C treated cells 
(Samikkannu et al., 2009). At this stage, it remains unclear as to which amino acid 
polymorphism within the Tat protein may influence differential activation of the KP. 
However, introducing a C30S mutation in Tat-C results in a potentially ineffective 
upregulation of IDO mRNA expression from Tat treated monocytes (Campbell et al., 
2007).  
 
5.4.2. Tat disrupts calcium ion regulation in the glutamatergic system 
 
The dysfunction of the glutamatergic system and N-methyl-D-aspartate receptors 
(NMDAR) are key neuropathological contributors to neuronal damage. The presence 
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of HIV-1 in the CNS induces the recruitment of infected cells (monocytes) into the 
brain (González-Scarano and Martín-García, 2005) (Figure 2). Neurotoxic and viral 
products present in the brain overexcites the NMDAR which may lead to neuronal 
damage. Overexcitation of NMDAR has been linked to several neurodegenerative 
disorders (Lin et al., 2014). HIV-1 and in particular the HIV-1 Tat protein can induce 
neuronal apoptosis by over-excitation of NMDAR (Haughey et al., 2001; Hu, 2015; 
O’Donnell, 2006).  
 
Glutamate is an excitatory neurotransmitter and plays an important function in 
learning and memory. However, excessive glutamate causes excitotoxicity by 
increasing calcium ion influx, which leads to neuronal dysfunction and cell-death 
(Vázquez-Santiago et al., 2014). Similar findings were observed in vivo, whereby Tat-
B induced hippocampal neural degeneration and was associated with learning and 
memory impairment in an animal model of HAND (Fitting et al., 2008; Harricharan et 
al., 2015).  
 
In Tat-B and Tat-C treated human neuroblastoma cells, glutamate was significantly 
increased in Tat-B treated cells and glutamine was significantly increased in Tat-C 
treated cells (Samikkannu et al., 2015). Increased glutamate subsequently reduces 
glutamine and this results in an increased level of nitric oxide synthase (NOS) (Prast 
and Philippu, 2001). NOS has been linked to several cellular dysfunctions in the CNS 
(Prast and Philippu, 2001), including neurotoxicity (Samikkannu et al., 2015). The HIV 
Tat protein has also directly been linked to inducing NOS production in human 
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astrocytes (Liu et al., 2002) and increased NOS levels have previously been 
associated with HAD in people living with HIV (PLWH (Pocernich et al., 2005).  
 
Moreover, the HIV Tat may act as an agonist of the NMDAR and can induce neuronal 
excitotoxicity (Li et al., 2008). In an in vivo experiment, Tat-B ventricular infusion in 
C57BL/6J mice leads to synapse loss by altering the GluN2B subunit containing 
NMDAR signaling (Raybuck et al., 2017). The polymorphisms in the HIV Tat sequence, 
particularly the C31S mutation is suggested to have no effect of the binding of Tat to 
the NMDAR but may rather be more critical for activation of NMDA (Li et al., 2008). 
It had been shown that once Tat is bound to the cell membrane by the Arginine-rich 
domain, C31 would bind with C744 on the NR1 subunit forming a disulfide bond (Li et 
al., 2008). This results in a free thiol group on C798 which may cause persistent 
activation of the NMDA. This may explain why Tat-B treated neuronal cultures may 
have greater neurotoxicity compared to Tat-C (Li et al., 2008). Tat may also indirectly 
activate the NMDAR by activation of the low-density lipoprotein receptor-related 
protein (LRP). Tat-B interacts with the LRP leading to activation of Src-kinase, which 
in turn leads to increased NMDA-evoked (Ca2+) responses (Krogh et al., 2014), but it 
is not known whether there are subtype-specific differences in LRP activation.  
 
In addition to the dysregulation of NMDA, abnormal intracellular calcium (Ca2+ ) 
influx can be induced by dysfunction of the L-type voltage-gated calcium channels (L-
channels). Several pre-clinical studies suggest that the HIV Tat protein increases Ca2+ 
through over-activation of L-channels (Bansal et al., 2000; Brailoiu et al., 2008). 
There are also associations between Tat-induced Ca2+ dysregulation and neuronal 
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dysfunction (Nath et al., 2000b, 2000a). Tat-B (dicysteine motif) appears to be more 
effective than Tat-C in activating L-channels, and this may account for the 
differences in neurotoxicity (Campbell et al., 2007; Wong et al., 2010).  
 
Tat protein is also responsible for disrupting calcium-regulating systems in the 
endoplasmic reticulum (ER) and mitochondria in neurons. The ER and mitochondria 
are important storage organelles for calcium and vital in maintaining Ca2+ 
homeostasis. Increased mitochondrial injury has been associated with worse 
neurocognitive function in PLWH (Var et al., 2016). In mouse striatal neuron cultures, 
Tat-B protein induced instability in the mitochondrial inner membrane resulting in 
excessive Ca2+ and synaptic injury (Fitting et al., 2014). Moreover, due to the 
dicysteine motif in Tat-B, Tat-B significantly depolarizes the mitochondrial 
membrane in human neuronal cultures, whereas in Tat-C, there is little or no 
depolarization of mitochondrial membranes (Mishra et al., 2008). 
 
5.4.3. Tat alters synaptic plasticity and neuron morphology 
 
Tat-B and Tat-C differentially impact synaptic plasticity. An investigation of the 
expression of 84 key human synaptic plasticity genes of Tat treated neuroblastoma 
cells (SK-N-MC) yielded differential results. Tat-B treated cells upregulated 69/84 
synaptic plasticity genes and 36 genes were upregulated more than ≥3 fold 
(Samikkannu et al., 2015). Whereas in the case of Tat-C, 46/84 synaptic plasticity 
genes were upregulated with 25 genes being upregulated more than ≥3 fold 
compared to control cells. Even though a direct comparison of the gene expression 
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levels induced between Tat-B and Tat-C has not been made, the Tat-B protein 
induced a greater fold change in several gene expression levels than Tat-C. These 
included genes of synaptic plasticity, immediate-early response, late response, long-
term potentiation, long-term depression, cell adhesion, cAMP response element-
binding protein (CREB) factors, neuronal receptors, postsynaptic density and others. 
This further correlates with Tat-B treated cells displaying a greater decrease in spine 
density compared to Tat-C treated cells (Samikkannu et al., 2015). This study 
suggests that Tat-B substantiates neuronal toxicity and dysregulates synaptic 
plasticity genes in SK-N-MC, which may contribute to the severe neuropathogenesis 
linked to HAND.  
 
It was also shown that Tat-B reduced synaptic proteins and neuronal dendritic spines 
in a mouse model of HAND (Fitting et al., 2010; Hammond et al., 2018; Lu et al., 
2011). Synaptodendritic injury may be related to the presence of the dicysteine 
motif present in Tat-B proteins. When human hippocampal neuronal cell cultures 
were exposed to either Tat-C or Tat-B for 24 hours, early reduction in F-actin puncta 
was more in Tat-B than in Tat-C. The activity of Tat-B on synaptodendritic damage 
was associated with the dicysteine motif. Reduction in F-actin puncta is a key feature 
of synaptodendritic injury, and this suggests that the dicysteine motif of Tat-B may 
be critical for synaptodendritic damage (Bertrand et al., 2013).  
 
The Tat protein may indirectly induce neuronal damage. Monocyte-derived 
macrophages (MDM) were infected with either HIV-1B or HIV-1C. As a method of 
evaluating indirect macrophage-mediated neurotoxicity, conditioned medium (i.e. 
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cell culture medium taken from HIV infected cells) from infected MDMs were used to 
treat human and rat primary neuronal cell cultures. A greater level of neuronal 
toxicity was found in cultures exposed to HIV-1B conditioned medium compared to 
cultures exposed to HIV-1C conditioned medium (Constantino et al., 2011). HIV-1 
isolates used in this study were derived from peripheral blood mononuclear cells of 
HIV infected patients. The lower levels of neurotoxicity by HIV-1C was due to the 
slower replication kinetics of HIV-1C in MDMs. This may be attributed to the viral 
genotype, specifically Tat and not the viral load. In a study conducted by Rao and 
colleagues, it was shown that in MDMs infected with an equal viral load, HIV-1B 
infected MDMs recruited more monocytes than HIV-1C infected MDMs (Rao et al., 
2008). Furthermore, monocyte recruitment was HIV-1 Tat and CCL2 dependent. The 
results from this study, therefore, show that the differential effects of HIV-1B and 
HIV-1C on mechanisms of neurotoxicity may be attributed to the viral genotype, 
specifically Tat (Rao et al., 2008). 
 
Previous research has shown that subtype-specific differences between HIV-1C and 
HIV-1B may influence HIV-1 fitness (replicative capacity). Higher replicative capacity 
of HIV-1B isolates compared to HIV-1C isolates were mediated by the gp120 coding 
region of the env gene and an increased binding/fusion of the CD4/CCR5 on host 
cells (Marozsan et al., 2005). Further, it has been reported that HIV-1B and HIV-1C 
differ in the sequence of the Gag polyprotein. HIV-1B viruses contain a LYPX motif 
whereas HIV-1C viruses lack the LY dipeptide in the late domain II of the Gag 
polyprotein (Ajasin et al., 2019; Kiguoya et al., 2017). The presence of the LYPX motif 
in HIV-1B influences increased virion release in the presence of CCL2 due to greater 
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access to ALIX (an adapter protein which enhances viral particle production). In the 
case of HIV-1C, the absence of the LYPX domain results in HIV-1C being unable to 
utilize ALIX and subsequently results in the lower replicative capacity of HIV-1C 
(Ajasin et al., 2019). Future studies should investigate whether Tat protein signatures 
may influence HIV-1 replicative capacity.  
 
An additional protein signature present in Tat-B may influence neuroinflammatory 
levels, which can subsequently affect the morphology and integrity of neurons and 
astrocytes. In primary human neuron-astrocyte co-cultures that were incubated with 
media containing equivalent amounts of Tat variant, the Tat-B (R57) and mutated Tat-
C (S57R) presented with the shorter, thinner and more beaded appearance of 
neurons compared to Tat S57, which are suggestive of neuronal damage (Ruiz et al., 
2019). Axonal/dendritic integrity was more significantly compromised in co-cultures 
treated with conditioned microglial media with Tat-R57 compared to Tat-S57 variants 
and these are further suggestive of synaptic compromise in HAND (Ruiz et al., 2019; 
Takeuchi et al., 2005). These suggest that the R57S mutation that is largely found in 
Tat-C may influence the lower levels of inflammation and subsequent neuronal 
damage (Table 1). In addition to these mechanisms, Tat and specifically Tat protein 





5.5. Monocyte activation and recruitment 
 
Monocyte activation is one of the initiating steps in the neuropathology of HAND 
(González-Scarano and Martín-García, 2005). Monocyte activated phenotypes result 
in the increased recruitment of peripheral cells into the CNS, contributing to the 
neuropathology of HAND (González-Scarano and Martín-García, 2005). Limited 
studies exist for the effect of HIV subtype and Tat variation on the level of monocyte 
activation itself. However, HIV Tat proteins can activate microglia and this activated 
state presents with a release of inflammatory chemokines and cytokines (Gandhi et 
al., 2009) (Figure 2).  
 
The HIV Tat protein is responsible for several chemotactic events within the 
neuropathophysiology of HAND. The Tat protein has been correlated with increased 
CCL2 levels in human astrocytes (Khiati et al., 2010), and increased monocyte 
transmigration across a BBB model (Weiss et al., 1999). This is supported in 
C578BL/6 mice that were injected with Tat1-72 into the right hippocampus, which 
resulted in significantly higher CCL2 levels compared to control animals. The changes 
were also associated with substantial infiltration of monocytes into the brain (Pu et 
al., 2003). Increased levels of chemotactic immune marker CCL2 have been 
implicated in the migration of HIV-positive cells across the BBB (Eugenin, 2006) and 
worse neurocognitive performance in PLWH (Ancuta et al., 2008; Kamat et al., 2010; 
Woods et al., 2006).  
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The level of monocyte chemotaxis may also be attributed to the specific HIV subtype 
and the signature in the HIV Tat protein. MDMs infected with HIV-1B recruited 64% 
more monocytes than HIV-1C infected MDMs (Rao et al., 2008). Monocyte 
recruitment was HIV-1 Tat and CCL2 dependent. This suggests that the increased 
level of monocyte recruitment of HIV-1B may, therefore, be influenced by the Tat 
protein and its relevant protein sequence. This has been linked specifically to the 
dicysteine motif present in Tat-B proteins. When comparing MDMs infected with 
HIV-1C (Tat) with an intact dicysteine motifs and MDMs infected with HIV-1C (Tat) 
lacking the dicysteine motif, the presence of the motif accounted for the increased 
monocyte chemotaxis (Rao et al., 2013). The C31S mutation found in Tat-C renders it 
defective for monocyte chemotactic activity without a loss in the transactivation 
property (Ranga et al., 2004). Therefore, Tat-B may be more effective in increasing 
the transmigration of infected monocytes in the brain, increasing inflammatory 
markers, neurotoxic and viral products, which essentially may be a reason for the 
increase neurovirulence of HIV-1B compared to HIV-1C. 
 
5.6. (Neuro)inflammation: Cytokines and Chemokines  
 
Cytokines and chemokines are small proteins which function in cell signaling 
(Leonard and Lin, 2000). A dysregulated cytokine and inflammatory profile are major 
contributors to the developments of HAND (Burdo et al., 2013; Lyons et al., 2011; 
Yuan et al., 2013). Dysregulated levels of cytokines/chemokines in the peripheral 
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blood, CSF and brain have been associated with HAND (Burdo et al., 2013; Lyons et 
al., 2011; Shapshak et al., 2004; Yuan et al., 2013). 
 
Primary CNS cells [human astrocytes (HA) and neuronal cells (SK-N-MC)] treated with 
HIV-1B produced higher levels of IL-33/ST2L compared to HIV-1C treated cells 
(Yndart et al., 2015). IL-33 is an inflammatory marker with an association to myocyte 
enhancer factor 2C (MEF2C) expression, which is a transcription factor that regulates 
synaptic function. In HIV-B, increase IL-33 is also associated with an increase in 
apoptosis, nucleotide-binding oligomerization domain containing 2 (NOD2) and 
solute carrier family 11 (SLC11A1). These are markers related to dysregulated 
synaptic function and apoptosis and are common hallmarks of HAND (Yndart et al., 
2015). More particularly, the change in the inflammatory response may be related to 
the HIV Tat protein and its relative protein sequence.  
 
In pre-clinical investigations, Tat-B treated monocytes induced a significant 
upregulation of proinflammatory cytokines IL-6 and TNF-α compared to Tat-C 
treated monocytes (Gandhi et al., 2009). IL-6 and TNF-α are common pro-
inflammatory markers that are key regulators of the inflammatory environment and 
can contribute to the development of HAND when chronically increased (Harezlak et 
al., 2011). In primary human neuronal cell cultures, induction of neuronal apoptosis 
was maximized when cells were exposed to a combination of TNF-α and Tat, 
compared to exposing cells to either TNF-α or Tat separately (Shi et al., 1998). TNF-α 




Furthermore, in human and rat Tat1-86 treated neuronal cultures, neuronal apoptosis 
was induced by TNF-α and activation of Non-N-methyl-D-aspartate receptors by an 
NF-κB-independent mechanism (New et al., 1998). When treating CHME3 cells with 
Tat-B and Tat-C, contradictory findings to the above reported that Tat-C had greater 
potential in inducing higher levels TNF-α and IL-6 at the mRNA level (Johri et al., 
2015). However, a major shortcoming of this study is that the CHME3 cell line has 
been recently shown to be derived from CHME5 which is a rat derived cell line 
(Garcia-Mesa et al., 2017). Species differences in chemokine/cytokine subnetworks 
in neurons (Du et al., 2017) may help explain why the findings may differ from many 
other studies of human neuronal cell cultures (Campbell et al., 2007; Ruiz et al., 
2019; Wong et al., 2010). In another study, injecting Tat-C into the hippocampus 
increased IL-1β expression but not TNF-α in rats (Makhathini et al., 2018). 
Interpretation of these contradictory findings may be challenging due to the lack of 
supportive evidence of the Tat variant, as inflammatory responses may be related 
particularly to their Tat sequence (Campbell et al., 2007; Ruiz et al., 2019). 
 
Anti-inflammatory molecules and IL-4 and IL-10 were found to be higher in Tat-C 
treated monocytes compared to Tat-B treated monocytes (Gandhi et al., 2009). This 
is contradictory to previous findings, whereby Tat-C induced lower levels of IL-10 in 
monocytes compared to Tat-B (Wong et al., 2010). This discrepancy can be 
attributed to the different Tat-C proteins used in these studies. Tat-C proteins lacking 
the dicysteine motif (C31S) could not induce an intracellular calcium flux through L-
type channels and this resulted in lower levels of IL-10 (Wong et al., 2010). 
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Therefore, the decrease in IL-10 production by Tat-C has been suggested to be partly 
due to the lack of L-type calcium channel activation in this subtype (Campbell et al., 
2007; Wong et al., 2010). Due to the lack of Tat-C’s ability to induce a calcium influx, 
it is less effective in upregulating the markers TNF-α, IL-6, CCL2, and IDO in 
comparison to that of Tat-B (Campbell et al., 2007) (Table 1).  
 
The natural polymorphism found in Tat-C (R57S) may be an additional influencer of 
the lowered inflammatory response. This polymorphism may be responsible for the 
reduced uptake of Tat by bystander cells and subsequently reduced 
neuroinflammation (Ruiz et al., 2019). In the study by (Ruiz et al., 2019), Tat proteins 
were mutated to investigate its effects on the inflammatory response. Tat-B 
containing the R57 yielded higher levels of inflammatory gene transcripts of IL-6, IL-8, 
IL-1β, and CXCL1 compared to Tat-B with an R57S (found in Tat-C) substitution. 
Conversely, the same was noted in mutated Tat-C S57R (found in Tat-B) variants that 
yielded higher levels of these inflammatory markers compared to Tat-C (R57S). This 
emphasizes the importance of this polymorphism in Tat uptake and 
neuroinflammation. Also, only wild type Tat-B (R57) and Tat-C (S57R) mutant were 
able to stimulate TNF-α production in treated cells, compared to Tat-B (R57S) mutant 
and wild type Tat-C (S57) (Ruiz et al., 2019). Genetic variation can modulate the 
ability of HIV-1 Tat to systematically disseminate (neuro)inflammation (Ruiz et al., 
2019). Tat variants from different HIV-1 subtypes may therefore affect inflammatory 
responses. 
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5.7. Tat and amyloid-beta production 
 
HIV patients may present intraneuronal amyloid beta 1-42 (Aβ1-42) accumulation or 
perivascular diffuse Aβ1-42 depositions, whereas extracellular amyloid plaques are 
predominant features in Alzheimer’s disease (András and Toborek, 2013; Ortega and 
Ances, 2014). Under pathological conditions, Aβ1-42 is generated from amyloid 
precursor protein (APP) and catalysed by two proteases, β-secretase and γ-secretase 
a process known as amyloidogenesis. It was recently shown that in 65 PLWH from 
Brazil, CSF/serum ratios of Aβ40, Aβ42, and Aβ-total were lower in the HIV-1C group 
than in the HIV-1B group (de Almeida et al., 2019). Growing evidence suggests that 
Tat upregulates Aβ1-42 production and Tat-B specifically has been marked as the 
major contributor to increased Aβ1-42 deposition in HIV patients (Aksenov et al., 
2010; Hategan et al., 2017).  
 
In a study conducted on cultured hippocampal neurons, it was shown that Tat-B 
induced Aβ1-42 generation, whereas this effect was not found for Tat-C (Aksenov et 
al., 2010) (Table 1). In another study with a human primary glioblastoma cell line and 
a transgenic mouse model of Alzheimer’s disease, it was shown that Tat in 
extracellular space can directly stimulate Aβ1-42 generation by binding and recruiting 
APP into lipid rafts, a site where β- and γ-secretase activity is high (Kim et al., 2013). 
Tat at the extracellular space may gain entry into the cell cytoplasm through a 
process facilitated by heparan sulfate proteoglycans and LRPs (Krogh et al., 2014; Liu 
et al., 2000; Tyagi et al., 2001). The LRP is a large endocytic and signaling receptor 
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that is widely expressed in tissues, including neuronal cells involved in the uptake 
and degradation of various physiological ligands including APP and Aβ. Binding of Tat 
to LRP competitively inhibits the uptake and clearance of Aβ (Kim et al., 2013).  
 
The R57S mutation in Tat-C significantly reduces its cellular uptake (Ruiz et al., 2019), 
which may account for reduced Aβ1-42 generation, compared to Tat-B (R57). Tat can 
disrupt Aβ1-42 clearance, interfering with neprilysin, a major Aβ-degrading enzyme in 
the brain (Shirotani et al., 2001). Tat-B was shown to directly inhibit neprilysin 
cleaving activity by 80% and the Cysteine-rich domain of the Tat protein is essential 
for binding to the neprilysin active site, as peptides without Cysteine residues fail to 
bind to neprilysin (Daily et al., 2006; Rempel and Pulliam, 2005).  
 
In primary cultured rat hippocampal neurons, it was demonstrated that internalized 
Tat is rapidly engulfed into the endosome which fuses with the lysosome to form 
endolysosome. Tat engulfment enlarges and increases endolysosome pH (Chen et 
al., 2013; Hui et al., 2012). Both these events have been linked to the disruption of 
Aβ metabolism in Alzheimer’s disease (Cataldo et al., 2004, 2000). Comparative 
evidence on whether Tat-B and Tat-C endosome engulfment and endolysosome 
processing are subtype-specific is lacking. However, Tat-B may be more efficient in 
cellular uptake compared to Tat-C (Ruiz et al., 2019) and therefore may possess 
enhanced endolysosome distraction. The majority of our current understanding of 
the effects of Tat on Aβ production is largely based on in vitro experimentation. 
Thus, further investigations with human post-mortem brain tissues are needed to 
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evaluate Aβ localisation and levels of different Aβ species in the brains of HIV-1B and 
HIV-1C patients. 
 
5.8. Blood-brain barrier damage 
 
The blood-brain barrier (BBB) is a diffusion barrier that functions in regulating the 
microenvironments for protecting the neural tissues from infectious agents and 
toxins within the circulating system (Atluri et al., 2015). BBB dysfunction is a 
common hallmark of HAND (Saylor et al., 2016). The HIV viral Tat protein contributes 
to BBB disruption by several mechanisms including; Tat-mediated apoptosis of 
human brain microvascular endothelial cells (hBMVECs), alteration of multiple 
signaling pathways related to BBB disruption (McRae, 2016), increasing oxidative 
stress, increasing the production of metalloproteinases (MMPs) and altering 
expression of tight junction proteins (Banerjee et al., 2010; McRae, 2016). 
Collectively, these Tat-mediated mechanisms contribute to the increased BBB 
damage in HIV neuropathogenesis.  
 
Tat-mediated apoptosis of hBMVECs is a product of activating signaling pathways of 
BBB disruption and oxidative stress. Treatment of hBMVECs with recombinant Tat 
(subtype not mentioned) resulted in the activation of vascular endothelial growth 
factor receptor-2 (VEGFR-2) and FMS-related tyrosine kinase 4 (FTK-4) (Kim et al., 
2003). Activation of VEGFR-2 and FTK-4 resulted in the dysregulated release of NOS 
and subsequent cellular apoptosis (Kim et al., 2003). Another study suggested that in 
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Tat (101 amino acid configuration) treated hBMVECs, apoptosis was a result of ER 
stress and mitochondrial dysfunction (Ma et al., 2016). Further, Tat alters multiple 
signaling pathways related to BBB disruption that includes interaction and activation 
of Mitogen-activated protein kinase (MEK) ½, Phosphoinositide 3-kinases (PI-3K), NF-
кB, CREB, Ras, caveolin-1, COX-2 and Rho (McRae, 2016).  
 
Studies investigating the differential effects of Tat variants from different HIV-1 
subtypes on Tat-mediated apoptosis of hBMVECs remains scarce. Current findings 
are largely based on Tat-B mediated apoptosis of hBMVECs. Further investigations of 
the effect of Tat-C mediated apoptosis of hBMVECs may provide insight into the 
neuropathogenesis of HAND within the context of HIV-1C infection. However, 
current literature suggests that Tat-B and Tat-C differ in their ability to produce 
reactive oxygen species (ROS).  
 
ROS are highly reactive, toxic oxygen moieties which can lead to oxidation of 
proteins and DNA, peroxidation of lipids, and ultimately cell death (Ivanov et al., 
2016). It is known that HIV infection and the Tat protein can activate several key 
pathways, induce ROS production, alter redox regulation which collectively 
contributes to apoptosis and peroxidative damage (Aukrust et al., 2003). HAD has 
been associated with markers for oxidative stress in the brain and CSF of HIV 
patients (Pocernich et al., 2005).  
 
A tripeptide knows as glutathione (GSH) alters the redox balance and also leads to 
the production of ROS and subsequently functions in the development of HAND. 
 248 
(Samikkannu et al., 2014). Depending on the Tat variant, Tat proteins exert 
differential effects on monocyte (MC)-derived immature dendritic cells (IDC) and 
neuroblastoma cells (SK-N-MC) by redox activation. Tat-B treated cells significantly 
increases the production of ROS, down-regulates gene expression and protein 
modification of glutathione synthetase (GSS), glutathione peroxidase 1 (GPx1), 
superoxide dismutase 1 (SOD1) and catalase (CAT), compared to Tat-C treated cells 
(Samikkannu et al., 2014). This further suggests that Tat-B induces oxidative stress 
and exacerbated immuno-neuropathogenesis compared to Tat-C (Samikkannu et al., 
2014). Even though Tat-C may exert damage to a lesser degree, Tat-C induces 
NADPH oxidase (NOX)2 and NOX4 expression and intracellular ROS levels in Tat-C 
treated hBMVECs (Mishra and Singh, 2014). However, studies performing a direct 
comparison of the effects of these subtypes remains limited. In combination, the 
presence of Tat, ROS and inflammatory markers are contributors to the level of BBB 
dysfunction (Price et al., 2005). 
 
In combination with oxidative stress induced by Tat, Tat may also upregulate 
inflammatory markers, complement components and MMPs. MMPs have shown 
evidence for its association with BBB damage (Xu et al., 2012) as well as 
neurocognitive impairment in PLWH (Li et al., 2013). In a study investigating the 
recombinant Tat-C, (CRF)02_AG (West and Central Africa) and Tat-B on hBMVECs, 
(CRF)02_AG reported minimal effects, whereas Tat-B induced transcriptional 
upregulation of 90 genes in hBMVECs. These included pro-inflammatory 
chemokines, complement components C3, C7, complement factor B and MMP-3, 
MMP-10, and MMP-12 (Woollard et al., 2014). These findings suggest that Tat 
 249 
proteins from these subtypes may differentially affect molecular and cellular 
functioning in hBMVECs and may affect BBB dysfunction. Tat may also alter the 
expression of key proteins which maintain the integrity of the BBB (i.e. tight 
junctions).  
 
Tat alters the expression of tight junction proteins, with reductions in zona occuldens 
(ZO)-1, ZO-2, occludin, claudin, and increases in junctional adhesion molecule (JAM)-
2 (Banerjee et al., 2010; McRae, 2016). In hBMVECs, redox-sensitive kinase (PYK2) 
activation leads to increased tyrosine phosphorylation of VE-cadherin and β-catenin, 
which results in a disruption of junctional assembly of hBMVECs, and ultimately 
increased endothelial permeability (Mishra and Singh, 2014). Tat-C induces 
disruption of VE-cadherin mediated by miRNA- 101 in hBMVECs (Mishra and Singh, 
2013). Furthermore, Tat-B can produce an aggravated disruption of BBB integrity and 
greater altered expression of tight junction, ZO-1 and JAM-2, compared to Tat-C 
(Gandhi et al., 2010). These may explain the reason for a greater neurovirulence of 
Tat-B compared to Tat-C (Mishra et al., 2008).  
 
Tat-B may also influence the functionality of important drug transporters such as P-
glycoprotein (P-gp) and multi-drug resistance protein (MRP)-1, which are present on 
endothelial cells. Efflux function, expression and promoter activity of P-gp and MRP-
1 is upregulated by Tat-B (Hayashi et al., 2006, 2005; Zhong et al., 2010). However, it 
is not clear as to how subtype variation and particularly Tat sequence variation may 
affect P-gp and MRP-1. This should be investigated in future studies as this may 




Figure 2: Differential effects of Tat-B and Tat-C in the neuropathophysiology of 
HAND. (1) Infected monocytes are able to cross the BBB which later differentiate 
into macrophages. (2-3) Infected macrophages within the brain can infect and 
activate microglia and further activate astrocytes. (4) These infected macrophages 
release viral Tat proteins that may directly further activate neuroimmune cells 
including microglia and astrocytes. (5) Tat-B induces a higher level of oxidative stress, 
KP metabolites, Aβ and glutamate which essentially affects neuronal integrity. (6) 
Tat-B induces a higher inflammatory response compared to Tat-C. (7) Tat-B may be 
responsible for higher CCL2 levels, greater BBB damage and essentially higher 
monocyte transmigration across the BBB. This was largely found to be attributed to 
the dicysteine motif present in Tat-B. (8) In combination, Tat-B may exert its 
neurotoxic effects to a greater degree than Tat-C and subsequently a greater level of 





Table 1: Amino acid signatures associated with differential effects of HIV-1 Tat-B and Tat-C proteins  
Subtype/ 
sequence 
Effect Reference Subtype/ 
sequence 
Effect Reference 
1. Transcriptional capacity   
Tat-B Lower transactivation capacity  (Bachu et al., 2012; 
de Arellano et al., 
2010; Desfosses et 
al., 2005) 
Tat-C Higher transactivation capacity  (Bachu et al., 2012; de 
Arellano et al., 2010; 
Desfosses et al., 2005) 
Tat-B C30C31 Not critical for transactivation (Ranga et al., 2004) Tat-C C30S No significant effect on the 
transactivation capacity 
Ranga et al. 2004) 
Tat-B Q63 Lower transactivation capacity (Kurosu et al., 2002) Tat-C Q63E Higher transactivation  capacity (Kurosu et al., 2002) 
2. Neuronal damage 
 
Tat-B 
Higher glutamate levels in treated 
neuroblastoma cells 
(Samikkannu et al., 
2015) 
Tat-C Higher glutamine levels in treated 
neuroblastoma cells 
(Samikkannu et al., 2015) 
Upregulation of (69/84) synaptic 
plasticity genes in treated 
neuroblastoma cells 
(Samikkannu et al., 
2015) 
Upregulation of (46/84) synaptic 
plasticity genes in treated neuroblastoma 
cells 
(Samikkannu et al., 2015) 
Tat-B C30C31 Higher neurotoxicity to human 
neuronal cells 
(Li et al., 2008; Rao 
et al., 2013) 
Tat-C C30S Lower neurotoxicity to human neuronal 
cells 
(Rao et al., 2013) 
Higher activation of the NMDA (Li et al., 2008) 
 
Does not affect NMDAR binding but 
attenuates NMDA activation and 
neurotoxicity in HEK-NMDAR cells 
(Li et al., 2008) 
Higher activation of L-type 
channels 
(Campbell et al., 
2007; Wong et al., 
2010) 
 
Lower activation of L-type channels (Campbell et al., 2007; 
Wong et al., 2010) 
Little or no depolarization of 
mitochondrial membranes in neurons 
 
(Mishra et al., 2008). 
Greater depolarization of 
mitochondrial membranes in 
neurons  
(Mishra et al., 
2008). 
No significant synaptodendritic injury in 
hippocampal neuronal cells 
(Bertrand et al., 2013) 
Critical for synaptodendritic injury 
in hippocampal neuronal cells 
(Bertrand et al., 
2013) 
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Higher IDO mRNA expression in 
monocytes  
(Campbell et al., 
2007) 
Less effective at upregulating IDO mRNA 
expression in monocytes 
 
(Campbell et al., 2007) 
 
Tat-B R57 Higher inflammatory-induced 
dysfunction in  human neuron-
astrocyte cultures  
(Ruiz et al., 2019) Tat-C R57S Lower inflammatory-induced dysfunction 
in  human neuron-astrocyte cultures 
(Ruiz et al., 2019) 
3. Monocyte activation and recruitment  
Tat-B C30C31 Higher monocyte chemotaxis  (Ranga et al., 2004; 
Rao et al., 2013, 
2008) 
Tat-C C30S Defective for monocyte chemotaxis  (Ranga et al., 2004) 
4. (Neuro)inflammation: Cytokines and Chemokines  
 
Tat-B 
Higher inflammation (IL-6, TNF-α) 
in monocytes 
(Gandhi et al., 2009) Tat-C Lower inflammation (IL-6, TNF-α) in 
monocytes 
(Gandhi et al., 2009) 
Tat-B C30C31 Higher inflammation (TNF- α, IL-6, 
IL-10 and CCL2) in monocytes 
 
 
(Campbell et al., 
2007; Wong et al., 
2010)  
Tat-C C30S Does not induce a calcium influx which 
results in lower levels of IL-10 in 
monocytes 
(Wong et al., 2010) 
Less effective in upregulating markers 
TNF- α, IL-6 and CCL2 in monocytes 
(Campbell et al., 2007) 
Higher levels of IL-4 in monocytes (Gandhi et al., 2009) 
Tat-B R57 Higher expression of 
inflammatory gene transcripts (IL-
6, IL-8, IL-1β, and CXCL1) 
(Ruiz et al., 2019) Tat-C R57S Reduced uptake of Tat by bystander cells 
and subsequently reduced 
neuroinflammation (IL-6, IL-8, IL-1β, and 
CXCL1) 
(Ruiz et al., 2019) 
Stimulate TNF-α production in 
treated cells 
(Ruiz et al., 2019) Unable to stimulate TNF-α production in 
treated cells 
(Ruiz et al., 2019) 
5. Tat and amyloid-beta production  
 
Tat-B 
Higher induction of Aβ1-42 
production in hippocampal 
neurons  
 
(Aksenov et al., 
2010) 
Tat-C Less effective in inducing Aβ1-42 
production in hippocampal neurons 
 
(Aksenov et al., 2010) 
 
Tat-B C30C31 Higher binding to the neprilysin 
active site  
(Daily et al., 2006; 
Rempel and Pulliam, 
2005) 
Tat-C C30S Tat lacking the dicysteine motif fail in 
binding neprilysin  
(Daily et al., 2006; 
Rempel and Pulliam, 
2005) 
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6. Blood-brain barrier damage 
Tat-B Higher ROS production in MC-
derived IDC and SK-N-MC  
(Samikkannu et al., 
2014) 
Tat-C Less effective in upregulating ROS in IDC 
and SK-N-MC 
(Samikkannu et al., 2014) 
Higher expression of genes 
related to pro-inflammatory 
chemokines, complement 
components C3, C7, complement 
factor B and MMP-3, MMP-10, 
and MMP-12 in hBMVECs  
(Woollard et al., 
2014) 
Less effective in upregulating genes of 
BBB integrity in hBMVECs 
(Woollard et al., 2014) 
Altered expression of tight 
junction, ZO-1 and JAM-2 in 
hBMVECs 
(Gandhi et al., 2010) Less effective in altering the expression 
of tight junction, ZO-1, and JAM-2 
(Gandhi et al., 2010) 
Where Tat-B/Tat-C are indicated, these are studies that did not include sequence data and only reported the effect of Tat-B/Tat-C on underlying mechanisms  
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5.9. Key observations  
 
The HIV Tat protein is a major viral determinant in the development of HAND. Tat-B 
and Tat-C differ biologically, and this affects the neuropathophysiology and clinical 
outcomes of HAND. The extent to which Tat sequence variation affects 
neurovirulence and neurological outcomes requires further investigation. This is 
particularly evident with pre-clinical studies reporting contradictory findings to that 
reported in clinical studies.  
 
Firstly, it is noted that this area of research remains scarcely investigated with a 
limited number of clinical studies being investigated within the last ten years. The 
current knowledge of Tat-mediated neuropathogenesis is largely derived from Tat-
B/HIV-1B, with a limited amount of studies investigating Tat-C. The lack of clinical 
studies in this area underscores the need for further research. Therefore, future 
investigations into Tat-C and the effect of Tat sequence variation may further explain 
the effect of Tat on clinical outcomes. Due to the limited number of studies 
investigating Tat-B and Tat-C variation, for this review, we have also included studies 
on the variation of HIV-1B and HIV-1C and their contribution to neurological 
outcomes. However, it should be noted that neurological outcomes from these 
studies cannot be solely attributed to the Tat protein, as several other viral proteins 
differ by subtype and subsequently may have also affected neurological outcomes 
(Samikkannu et al., 2011). 
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Secondly, several studies did not report the HIV Tat variant and HIV-1 subtype in 
their relevant investigations. It is assumed that Tat-B is the universal strain for the 
neuropathogenesis of HAND. Future studies should specify the Tat variant and HIV-1 
subtype investigated, as many of the neuropathological effects are influenced by 
specific residues within the Tat protein and not specifically by the HIV-1 subtype.  
 
Thirdly, this review identified several key protein sequence differences which may 
account for the altered neuropathogenesis. This includes a Serine substitution at 
residue 31 (C31S), a Serine substitution at residue 57 (R57S) and a Glutamate 
substitution at residue 63 (Q63E). These polymorphisms present in Tat-C accounts for 
the more potent transactivation capacity and a lower level of monocyte recruitment, 
neuroinflammation, and neuronal damage. Future studies should aim in investigating 
these signatures across larger cohorts to support its relevant role in HAND. 
Furthermore, key questions remain with as to how these cross-subtype 
polymorphisms contribute to 1) monocyte activation 2) monocyte recruitment 3) 
neuroinflammation and 4) BBB dysfunction. 
 
Fourthly, amino acid sequences of other viral proteins (i.e. gp120) differ between 
HIV-subtypes (Gnanakaran et al., 2007; Rao et al., 2014). Future studies should 
sequence additional viral proteins (gp120, Nef, Vpr, and p24) and determine to 
which extent protein signatures from these proteins are involved in 
neuropathological processes of HAND. An understanding of the differences in the 
pathogenesis of these subtypes and protein signatures may provide insight into the 
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development of HAND and potential avenues for improved therapeutic 
development. 
 
5.10. Conclusions  
 
HIV-1B and HIV-1C present with several key biological differences which may affect 
the development of HAND. The extent to which Tat sequence variation contributes 
to underlying mechanisms and neurological outcomes remain unclear. Here we 
reviewed and synthesized the current literature in the aim of elucidating the effect 
of Tat variation in the neuropathogenesis of HAND. Despite limited studies and the 
lack of Tat sequence data, we report from fundamental research studies, key 
signatures that may be involved in the underlying mechanisms of HAND. These 
include sequence polymorphisms C31S, R57S and Q63E present in Tat-C. Based on 
these polymorphisms, studies collectively indicated that Tat-C may be a more 
effective transactivator. Tat-B may have a greater effect on neuronal damage by 
neuronal pathways, increasing monocyte recruitment, (neuro)inflammation, 
oxidative stress and BBB dysfunction. This review highlights important protein 
signatures that may be crucial in the underlying mechanism for HAND.  
 
Based on the findings from this prospective review, in the next chapter, I report data 
for the influence of Tat sequence variation on inflammatory levels. In particular, how 
Tat sequence variation at positions 31 and 57 may influence immune markers in HIV-
1C infection.     
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The HIV transactivator of transcription (Tat) protein is an important viral protein and 
has a functional role in the neuropathophysiology of HIV-associated neurocognitive 
disorders (HAND). Previous pre-clinical studies have identified the C30S and R57S 
mutations of Tat as major contributors to the reduced immune activity and 
neurovirulence in HIV-1 subtype-C (HIV-1C) infection. However, the number of 
available studies investigating the association between immune marker levels and 
Tat sequence variation in HIV-1C infection remains limited. This exploratory study 
investigated the association between several peripheral immune markers and Tat 
sequence variation. Peripheral Immune markers were selected on putative evidence 
of their link to key neuro-immune function. Immune markers were measured using 
enzyme-linked immunosorbent assays (ELISA). Thirty-six HIV-1 subtype-C infected 
participants were included with all participants investigated for the C31/C31S 
mutation and thirty-five participants investigated for the R57/R57S mutation. 
Peripheral immune marker levels did not differ across the C31S and C31 groups. 
Peripheral thymidine phosphorylase levels (TYMP) were lower in the R57S group than 
in the R57 group (p = .05). Although this study did not have sufficient power to rule 
out false negatives, this exploratory study provides evidence that the Tat sequence 
variant which is largely present in Tat-C (R57S) may account for the lower TYMP levels 
in HIV-1C infection. Future studies should investigate these signatures across larger 






HIV-associated neurocognitive disorder (HAND) is a common feature of HIV-1 
infection of the central nervous system (CNS). The neuropathogenesis of HAND is 
multidimensional and is affected by several factors including the HIV-1 subtype (Rao 
et al., 2013, 2008). HIV-1 is characterized by genotypical variation which is 
distributed across different geographical regions. HIV-1 subtype-C (HIV-1C) is 
responsible for the highest prevalence of HIV infection and is geographically 
associated with Southern Africa and India (Geretti, 2006). HIV-1 subtype-B (HIV-1B) 
is related to a higher reported prevalence of HAND and is the dominant subtype in 
areas of America and Europe (Taylor et al., 2008). 
 
A major viral determinant of neurological outcomes in HIV infection is attributed to 
the HIV Transcription of transactivation (Tat) protein (Gandhi et al., 2009; Rao et al., 
2013). HIV-1 Infected monocytes are able to migrate across the blood-brain barrier 
(BBB), and subsequently infect and activate cells of the CNS (González-Scarano and 
Martín-García, 2005). This leads to the secretion of the HIV Tat protein from 
microglia and macrophages. Amongst other mechanisms, Tat can stimulate the 
release of inflammatory markers (Chen et al., 2017). The chronic release of 
inflammatory markers affects neuronal health. Previous studies have shown 
associations between an aberrant immune regulation and HAND (Cohen et al., 2011; 
Falasca et al., 2017). Further, HIV-1 subtype/Tat sequence variation may directly 
influence the levels of inflammatory markers (Gandhi et al., 2009).       
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Recent studies have found that Tat protein sequence mutations at position 31 
(Campbell et al., 2007; Rao et al., 2013; Ruiz et al., 2019; Wong et al., 2010) and 57 
(Ruiz et al., 2019) had an association with the levels of inflammation, neurovirulence, 
and neurocognitive performance (Williams et al., 2020). HIV-1C and HIV-1B differ in 
their Tat sequence. Tat-B generally has a Cysteine at position 31 (C31) and an 
Arginine at position 57 (R57), whereas Tat-C generally has a Serine mutation at 
position 31 (S31) [prevalence of 74%-99% (Rao et al., 2008)] and 57 (S57 ) [prevalence 
of 82% (Ruiz et al., 2019)]. Therefore, Tat-C largely presents with the important 
mutations C31S and R57S.  
 
It is not clear to what extent Tat protein sequence variation may influence 
inflammatory levels in HIV-1C infection. Further, no study has directly examined 
immune marker levels among individuals based on the presence or absence of the 
C31S and R57S variant in individuals with HIV-1C infection. Therefore, this study aimed 
to determine the effect of Tat sequence variation (C31S and R57S) on selected 




6.2.1. Study Participants 
 
This study included a sub-sample of a previously published dataset (Joska et al., 
2011). All participants with genotyping data from the primary study (Joska et al., 
2011) were included in this study. A total of 36 HIV-1C infected participants were 
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included in this study. All participants had measures for the C31/C31S mutation, and 
35 participants had measures for the R57/R57S mutation. One participant had a R57K 
mutation and was therefore excluded from the study.  
 
People living with HIV (PLWH) were previously recruited from primary health care 
clinics in Cape Town and the Western Cape region of South Africa. PLWH completed 
at least one study visit, which included a detailed sociodemographic, medical and 
neuropsychological assessment as well as the relevant laboratory measures 
(including genotyping, viral load and CD4 count). HIV serostatus was confirmed by 
two independent rapid tests and confirmed via ELISA analysis. Participants included 
in this study ranged from 18 through 65 years in age. PLWH were treatment naïve or 
had only recently started cART (< 1 month) before blood collection. This was to 
investigate the levels of Tat without the potential confound of A Cases were 
excluded from this study if they had 1) severe psychiatric disorder or presented any 
other neurological disorder, 2) substance abuse (other than alcohol) and 3) 
moderate to severe head injury. Written informed consent was obtained following a 
thorough explanation of the study procedures and individuals received financial 
compensation for their time. This study was approved by the Human Research Ethics 
Committee of the Faculty of Health Sciences (University of Cape Town) (Sub-study 




6.2.2. Laboratory Assessment of Blood 
 
Blood samples were prepared as described in a previous study (Chapter 3) (Williams 
et al., 2019). All immune markers were measured using Enzyme-linked 
Immunosorbent Assays (ELISA) (R&D systems, DuoSet ELISA) according to the 
manufacturer’s instructions. For this study, the immune markers matrix 
metalloproteinase (MMP)9, neutrophil gelatinase-associated lipocalin (NGAL), 
transforming growth factor (TGF)-β1 and thymidine phosphorylase (TYMP) were 
selected for investigation. These markers were selected for investigation based on 
their 1) positive outcomes in the primary study (Williams et al., 2019) as well as their 
2) potential involvement in the pathophysiology of Tat-mediated neuropathogenesis 
and HAND, as reviewed from the scientific literature (Choi et al., 2011; Dhar et al., 
2006; Kumar et al., 2012; Wu et al., 2013; Xing et al., 2017). TYMP was measured in 
serum. MMP9, NGAL, and TGF-β1 were measured in plasma. Samples were diluted 
as follows MMP9: 1:150, NGAL: 1:100, TGF-β1: 1:30 and TYMP: 1:10. All samples 
were assayed in duplicate. The intra- and inter-assay coefficients of variation for all 
tests were within acceptable ranges of < 8% and < 10% respectively. 
 
6.2.3. HIV-subtyping  
 
Tat exon 1 region (HXB2 position 5831–6045) was amplified by polymerase chain 
reaction (PCR) using the Promega GoTaq Flexi Kit (Promega, Madison, WI). The 
primer pair Tat-1_OF (5′-AAAGCCACCTYTGCCTAG) / Tat-1_OR (5′-
CTCATTGCCACTGTCTTCTGC), and Tat-1_IF (5′-GTAGARGATMGATGGAACRA) / Tat-
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1_IR (5′-CYCTAATTCTTTYAAYTAACC) were used for pre-nested and nested PCR, 
respectively. Amplification conditions were held at 94°C for 2 min, followed by 40 
cycles of denaturing (94°C; 30s), annealing (55°C; 30s), extension (68°C; 1 min) and a 
final extension step for 10 min at 68°C. The PCR product was stored at 4 °C until 
visualized by agarose gel electrophoresis 
 
Purification of PCR products was performed with the Nucleospin® Gel and PCR clean-
up kit, according to manufacturer instructions (Machery-Nagel GmbH & Co.KG, 
Germany). All PCR products were sequenced by BigDye Terminator v.3.1 Cycle 
Sequencing Ready Reaction Kit (ThermoFisher Scientific) and analysed on the ABI 
Prism 3130xl automated DNA sequencer (Applied Biosystems, Foster City, CA). 
Sequences were analysed and the overlapping DNA fragments were assembled using 
Sequencer version 5.2.4 (Gene Codes Corporation, Ann Arbor, MI). Nucleotide 
sequences were translated into amino acid sequences and the C30C31 motif or C31S 
mutation and R57 or R57S mutation was recorded. The Tat exon 1 subtype was 
determined using online subtyping tools Jumping profile of Hidden Marko Model 
(jphmm.gobics.de) and REGA HIV-1 
(www.bioafrica.net/subtypetool/html/subtyinghiv.html) 
 
6.2.4. Statistical analysis  
 
All analyses were conducted using SPSS (version 25, IBM, USA). P-values were 
considered statistically significant for all analyses at a value of less than .05. Data 
distribution for markers NGAL and TGF- β1 were found to be skewed, therefore the 
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data was log-transformed prior to statistical analyses. MMP9 and TYMP 
demonstrated normal data distribution with acceptable skewness and kurtosis. 
Pearson’s chi-squared tests were used to test group differences for sex between Tat 
variants. The Wilcoxon signed-rank test was used to determine differences in the 
study characteristics and levels of plasma/serum markers between Tat variants C31 
versus C31S and R57 versus R57S respectively. 
6.3. Results  
 
6.3.1. Sample characteristics  
 
The pilot study population included a total of 36 PLWH, which included 36 
participants investigated for the C31/C31S mutation and 35 participants investigated 
for the R57/R57S mutation. For the C31/C31S mutations, 28 participants had the C31S 
and 8 had the C31. For the R57/R57S mutations, 31 participants had the R57S and 4 had 










Table 1: Characteristics of PLWH 
 31 (n=36) p-value 57 (n=35) p-
value 
Amino Acid  C S  R S  
n 8 (22.2%) 28 (77.8%)  4 (11.4%) 31 (88.6%)  
Sex (male) n, 
%  
8 (100%) 24 (85.7%) .26 4 (100 %) 27 (87.0%) .44 
Age, mean 
(SD) 
30.25 (5.52) 30.29 
(4.91) 
.99 329.50 (4.20) 30.55 (4.91) .72 
Viral load Log 
copies/mL, 
median (IQR) 
3.41 (3.11 - 
4.56) 
4.09 (3.13 - 
4.69) 
.61 4.05 (3.20 - 
4.76) 










.11 337.5 (237 - 
497.75) 
222.5 (148 - 
381.5) 
.58 
Abbreviations: Interquartile range (IQR), Standard deviation (SD) 
 
6.3.2. Peripheral Immune marker levels and Tat C31/C31S variation 
 
C31/C31S data were available for 36 participants. Marker levels were similar between 
all C31/C31S variations and no significant differences were found. The largest 
difference in immune marker levels was found for MMP9 (p = .26). The C31S group 
reported lower MMP9 levels, however, this was insignificant (p = .26). NGAL, TYMP 
and TGF-β1 levels were also insignificant between C31/C31S variations (p > .05) 




Figure 1: Differences in peripheral immune marker levels between Tat-C C31 and 
C31S. The bars indicate mean protein concentrations in the different study groups 
and are expressed as mean±standard error of the mean (SEM). 
 
6.3.3. Peripheral Immune marker levels and Tat R57/R57S variation 
 
R57/R57S data were available for 35 PLWH. The R57S group reported lower TYMP 
levels in PLWH (p = .05). NGAL, TGF-β1 and MMP9 levels were insignificant between 
R57/R57S variations (p > .05) (Figure 2). 
 
C31 (n=8) C31S (n=28) C31 (n=8) C31S (n=28)
C31 (n=8) C31S (n=28) C31 (n=8) C31S (n=28)
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Figure 2: Differences in peripheral immune marker levels between Tat-C R57 and 
R57S. The bars indicate mean protein concentrations in the different study groups 




The main findings from this pilot study were that 1) there were no significant 
differences in immune marker levels between C31S and C31 and 2) lower TYMP levels 
were found in R57S compared to R57 (p = .05).   
 
The C31S Tat mutation which is largely found in HIV-1C infection (present in 74%-99% 
of HIV-1C infections) is arguably the most widely studied in Tat-mediated 
neuropathogenesis (Campbell et al., 2007; Li et al., 2008; Ranga et al., 2004; Rao et 
al., 2013). Here, it is seen that there were no significant differences in immune 
marker levels between C31S and C31. Previously, pre-clinical studies have shown that 
monocyte cultures treated with Tat C31S resulted in lower levels of TNF-α, IL-6, IL-10 
R57S (n=31)  R57 (n=4) R57S (n=31)  R57 (n=4)
R57S (n=31)  R57 (n=4) R57S (n=31)  R57 (n=4)
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and MCP-1 compared to Tat C30C31 (Campbell et al., 2007; Wong et al., 2010). The 
limited number of study participants in the current study may explain the lack of 
statistical power for comparisons between C31S and C31. We have also investigated 
different immune markers compared to previous studies, and this, too, could explain 
the differences in findings.  
 
Recently, another important mutation (R57S) present in Tat-C has been suggested to 
influence immune marker levels and neurovirulence (Ruiz et al., 2019). The current 
study reported lower TYMP levels for R57S compared to R57 (p = .05). These findings 
are in line with a recent pre-clinical study which suggested that the R57S mutation 
(largely found in Tat-C) may be responsible for lower immune marker levels (Ruiz et 
al., 2019). Further, in a previous study done in our group (Williams et al., 2019), 
TYMP was significantly increased in South African PLWH (HIV-1C). The R57 is largely 
present in Tat-B and it is possible that this marker may be higher in HIV-1B infection 
compared to HIV-1C infection (Williams et al., 2019). Further, TYMP was associated 
with worse psychomotor processing speed in HIV-1C infection (Williams et al., 2019). 
However, the exact mechanism for TYMP is not yet known. TYMP gene expression is 
increased in primary monocytes in PLWH (Chapouly et al., 2015) and TYMP levels in 
the brain may be further increased by the presence of HIV (Kumar et al., 2012). 
Moreover, It was proposed that TYMP has a functional role in BBB dysfunction 
(Chapouly et al., 2015). TYMP should be investigated for its potential role in a Tat-
mediated pathway of HAND. 
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This study is limited by a sample size that is insufficiently large to exclude false-
negative findings. However, this exploratory study does provide evidence for the 
association between Tat variation and clinical immune marker levels. Future studies 
should investigate these sequence variants in larger cohorts as well as in HIV-1B 





Despite the limited number of participants, this pilot study provides evidence for the 
relationship between the R57S variant and lower peripheral TYMP levels in HIV-1C 
infection. Future studies should investigate these Tat sequence variations in larger 
cohorts. The next final chapter summarizes and provides overall conclusions for all of 
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7.1. Summary of findings 
 
In this thesis, I investigated the associations of peripheral inflammation (immune 
markers) with brain structural alteration and neurocognitive impairment. Further, I 
investigated the significance of Tat protein sequence variation on immune marker 
levels. These research questions were addressed in five manuscripts. The key 
findings of the thesis were as follows:  
 
1) Based on a systematic search of the current literature, it was concluded that 
PLWH have altered immune marker levels, including elevated markers of 
monocyte activation (neopterin, sCD14, sCD163) and inflammation (CCL2, IL-
8, IL-18, IP-10, IFN-α, sTNFR-II and TNF-α). These elevated levels persist in 
PLWH despite viral suppression. Further, the majority of studies found 
associations of HAND with immune markers, including those linked to 
monocyte activation (sCD14 and sCD163) and inflammation (IL-18 and IP-10) 
(Chapter 2-manuscript 1) 
2) In an exploratory investigation in a South African cohort of 99 PLWH and 51 
HIV-negative participants, TYMP and NGAL levels were significantly higher, 
while MMP9 levels were significantly lower in PLWH compared to HIV-
negative controls. Further, my results showed that in PLWH, worse 
psychomotor processing speed was associated with higher TYMP and NGAL 
levels and worse motor function was associated with higher NGAL levels in 
PLWH. This is the first study to my knowledge to investigate the associations 
of TYMP and NGAL with neurocognitive performance PLWH (Chapter 3-
manuscript 2). 
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3) In a subset of South African PLWH (Chapter 3), I examined the associations of 
peripheral immune markers with cortical thickness/surface area in 65 PLWH 
and 26 HIV-negative controls. Results indicate that higher NGAL levels were 
associated with the reduced thickness of the lateral orbitofrontal cortex. The 
association of NGAL with worse motor function was mediated by the cortical 
thickness of the lateral orbitofrontal cortex (Chapter 4-manuscript 3). 
4) In a prospective review, I summarized the differences between Tat-B and Tat-
C to elucidate the effect of Tat sequence variation on the underlying 
neuropathophysiology of HAND. Key sequence signatures C31S, R57S and Q63E 
are largely present in Tat-C. With these protein signatures, Tat-C is 
considered to be a more effective transactivator, whereas Tat-B may exert 
increased neurovirulence, including neuronal apoptosis, monocyte infiltration 
into the brain, (neuro)inflammation, oxidative stress and blood-brain barrier 
damage. (Chapter 5-manuscript 4) 
5) In an exploratory study, I investigated the association between peripheral 
immune markers and Tat sequence variants C30S and R57S in HIV-1C infection. 
Peripheral immune marker levels did not differ across the C31S and C31 
groups. However, peripheral thymidine phosphorylase levels (TYMP) were 
lower in the R57S group than in the R57 group (Chapter 6-manuscript 5).   
 
7.2. Final recommendations  
 
The overall conclusion from this thesis supports the premise that inflammation 
contributes to the development of HAND and that Tat sequence variation may 
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influence inflammatory levels in PLWH. The major conclusions from this thesis can 
be divided into three major components.  
 
Firstly, from a systematic search of the existing literature, I found that peripheral 
inflammation persists despite the introduction and successful use of ART. This 
suggests that other strategies besides simply suppressing the viral load, are 
necessary to address the ongoing peripheral inflammation in PLWH. Long-term 
treatment studies suggest that there is an ongoing immune activation in PLWH, and 
this may explain the persistent development of milder forms of HAND in the ART era. 
It is also noted that heterogeneity is evident in the current studies investigating the 
association of general peripheral immune markers and HAND. Therefore, greater 
uniformity in all studies investigating general markers and cognitive performance will 
allow for improved comparability of findings into the future. HIV Tat sequence 
variation may also be a contributor to the heterogeneity of inflammatory marker 
levels and cognitive impairments in the general HIV population.  
 
Secondly, in an evaluation of blood immune markers in a South African treatment 
naïve cohort, two immune markers; TYMP and NGAL may be promising targets for 
future investigation in samples of treatment-experienced participants. To my best 
knowledge, this study is the first to investigate the associations between TYMP and 
NGAL with HIV-associated neurocognitive impairments. This thesis reported the 
association of these markers with domain-based HIV-associated neurocognitive 
impairments as well as alteration of the frontal cortex in South African PLWH. 
Further, since inflammation is reportedly lower in HIV-1C infection, these markers 
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may possibly have a greater functional role in HIV-1B infection. Future studies should 
investigate the role of these markers in the underlying mechanisms of HAND. With 
this investigation done in treatment-naïve participants, findings of these markers 
may represent HIV-related effects only and not findings which may be confounded 
by the use of ART. The effect of inflammation on brain structures and HIV-associated 
neurocognitive impairment may be independent of ART, and we hypothesize that 
findings presented in the current study may similarly be reflected in investigation of 
treatment-experienced participants. However, further investigation is warranted. 
Therefore, these markers may be important in HIV-1C infection and should be 
investigated in 1) larger cohorts, 2) HIV-1B infected and 3) treatment-experienced 
participants.  
 
Thirdly, in a review of the existing literature, it was shown that Tat sequence 
variation influences the neurovirulence of HIV-1. Two sequence variants (C31S and 
R57S) in particular, were implicated in the differential effects of neuronal apoptosis, 
monocyte recruitment and BBB damage. The more recent R57S Tat variant was 
considered important in neuroinflammation. Similarly, in the investigated cohort, 
lower TYMP levels were found in the R57S group than in the R57 group. Despite the 
limited sample size, I reported evidence that Tat sequence variation may influence 
inflammatory levels. These signatures may also influence other immune markers not 
investigated in my pilot study. This may be a plausibility for the different immune 
marker levels in HIV-1B and HIV-1C infection. These signatures need to be 
investigated across larger cohorts as well as in HIV-1B infection. Studies of HIV-1C in 
general, as well as comparative studies between HIV-1C and HIV-1B, remains 
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scarcely investigated, with limited studies within the last ten years. The lack of 
studies in this area underscores the need for further research. Amino acid sequences 
of other viral proteins (i.e. gp120) also differ between HIV-subtypes (Gnanakaran et 
al., 2007; Rao et al., 2014). Future studies should sequence additional viral proteins 
(gp120, Nef, Vpr, and p24) and determine to which extent protein signatures from 
these proteins are involved in neuropathological processes (immune responses) of 
HAND. An understanding of the differences in the pathogenesis of these subtypes 
and protein signatures may provide insights into the development of HAND and 
potential avenues for improved therapeutic development.  
 
7.3. Limitations  
 
 
This study has several limitations which deserve emphasis. Firstly, in a systematic 
review of the literature, heterogeneity of the included studies was evident, which 
made the interpretation of findings much more challenging. A meta-analysis was not 
conducted due to the heterogeneity of the studies pooled for analysis (Chapter 2).  
 
Secondly, a limitation of the empirical chapters (Chapters 3, 4 and 6) were the 
limited sample sizes. Therefore, findings are to be replicated in larger prospective 
and ART-experienced cohorts. A larger sample size is needed to understand the 
association between immune markers and neurocognitive performance, brain 
imaging and Tat sequence variation.  
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Thirdly, a subset of the included participants were heavy drinkers which may have 
influenced the results. It has been shown that heavy drinking may affect 
neurocognitive performance, immune system (Meyerhoff, 2001) and brain cortical 
structure (Morris et al., 2019). However, I adjusted for various covariates in 
statistical analysis. It was also reported that there were no significant differences in 
1) immune marker profiles and 2) neurocognitive performance for the HIV-positive 
non/light drinkers vs. HIV-positive heavy drinkers.  
 
Fourthly, a small subset of participants started ART (<30 days) before blood 
collection, neurocognitive testing and neuroimaging. ART is also a contributor to 
dysregulated inflammatory levels in PLWH (Shah et al., 2016). However, long-term 
treatment studies reported that in most cases, the first neuro-immune responses are 
noted at durations greater than 3 months (Hattab et al., 2014; Krebs et al., 2016; 
Richert et al., 2017).  
 
Finally, findings presented here may not apply to other HIV-1 subtypes (e.g. HIV-1B), 
as inflammatory markers may be affected by the HIV subtype (Gandhi et al., 2009). 
Since inflammation is reportedly higher in HIV-1B infection, the peripheral immune 
markers identified in this study may be higher in HIV-1B infected participants.  
 
7.4. Conclusion  
 
The key findings from this thesis indicate that peripheral monocyte activation and 
inflammation plays a key role in HAND despite viral suppression, as shown in a 
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systematic search of the literature. Further, in a South African context which is 
primarily HIV-1C infected, TYMP and NGAL may be important markers in the 
neuropathophysiology of HAND. Finally, Tat protein sequence variation may 
influence certain immune marker levels and subsequently the phenotype of HAND. 
Taken together, the findings presented here further the understanding of the 
associations of inflammation with HAND, particularly in the South African context 
where HIV-1C predominates. Future studies should investigate these identified 
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